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ABSTRACT
This dissertation sought to explore the relatively understudied area of racial
disparities in adherence to cardiovascular medication regimens among the elderly. Black
and Hispanic seniors are well documented to have lower rates of adherence to their
prescribed cardiovascular medications, relative to their white counterparts. This
disproportionately lower adherence places these minority groups at higher risk for worse
cardiovascular prognosis and premature cardiovascular death. The Medicare Program,
which covers healthcare predominantly for elderly Americans, offers an interesting
laboratory to study these disparities and their response to policy changes. Using
nationally representative data from the Medical Expenditure Panel Survey on white,
black, and Hispanic Medicare seniors, this dissertation was an endeavor to: 1) evaluate
the impact on these disparities of the introduction of Medicare Part D, the prescription
drug benefit, in 2006, 2) explore the heterogeneity of these disparities at various locations
in the adherence distribution, signifying population subgroups with potentially distinct
behavioral patterns, and 3) systematically estimate the extent to which the inequality in
the determinants of adherence, such as socioeconomic status, insurance coverage, access
to care, and experience with providers, contributes to the particularly significant and
consequential black-white adherence differential. To pursue these aims, this dissertation
used some of the recent advances in econometric techniques for the study of inequality,
including the rank-and-replace procedure to adjust for health status in non-linear models,
unconditional quantile regression, and distribution-wide Oaxaca-Blinder decomposition,
respectively. The Institute of Medicine’s framework on racial healthcare disparities
constituted the primary basis for defining and empirically estimating adherence
disparities. These investigations contribute threefold to the literature: substantively,
conceptually, and empirically. The substantive findings can improve our understanding of
what works and what does not work for disparity reduction, bring our attention to
disparities among subpopulations potentially deserving priority intervention, and
systematically quantify the roles of clinical, social, and health-system factors in
perpetuating adherence disparities. The various conceptualizations of adherence
disparities employed in this dissertation, along with the state-of-the-art empirical
approaches to implement them offer much needed examples to guide future research on
disparities in general and medication-related disparities in particular.
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CHAPTER 1.

INTRODUCTION

“Ill fares the land, to hastening ills a prey,
Where wealth accumulates, and men decay”
Oliver Goldsmith,
Anglo-Irish writer (1730-1774)
Racial Disparities in Cardiovascular Disease
Cardiovascular diseases are the leading cause of death.1 They are also the most
costly conditions.2 Black Americans have 2-3 times higher likelihood of death due to
cardiovascular disease at any given age.3,4 This disparity in cardiovascular death accounts
for the largest share (34%) of the racial all-cause mortality differential in the United
States, with the disparity in death due to uncontrolled hypertension making up most of
that share.5 In the CARDIA study, Bibbins-Domingo et al found adult blacks to be 20
times more likely than their white counterparts to develop heart failure before the age of
50, pursuant to a striking disparity in uncontrolled blood pressure that persisted over
more than 10 years of follow-up.6 Based on an analysis of the National Health and
Nutrition Examination Survey, Fiscella et al estimated that bringing the blood pressure
level among blacks to that among whites could save more than 7,000 lives annually from
death due to heart disease or stroke.7 Hispanics as well are more likely to fall short of
treatment goals, including having persistently elevated blood pressure8,9 and cholesterol
levels.10,11 Among the social and behavioral factors that might explain the racial
disparities in cardiovascular disease,8,12-14 the lower levels of adherence to cardiovascular
medications among minorities is a repeatedly identified suspect that is amenable to
intervention.7,8,12,15
Medication Adherence
Medication adherence is “the extent to which a patient’s behavior, relevant to
medication and lifestyle recommendations, coincides with medical or health advice.”16,17
Adherence as a process encompasses three components: initiation, implementation, and
persistence.18 Regimen initiation refers to patients filling their newly prescribed
medications,19,20 thereby initiating the adherence process. If the patient starts taking
his/her medications but to varying degrees (in terms of the amount or frequency), then
this is a problem with the implementation phase of the process or the actual “execution”
of the regimen relative to what has been prescribed.21 The third phase of the adherence
process, persistence, describes the degree of conformity of the actual duration to the
recommended duration of therapy.16,22 Patient adherence to prescribed medications, that
are indicated, safe, and effective, plays a key role in the realization of therapeutic goals,
such as healthier blood pressure, blood glucose, and cholesterol, and positive overall
health outcomes, such as reduction in morbidity, and mortality.23 In 2005, the cost of

1

poor medication adherence in the United States was estimated to be $500 billion in
medication-related hospitalizations.24 In cardiovascular diseases, 40% of patients are
estimated to be poorly adherent (having less than 80% medication possession) to their
cardiovascular medications.25 Poor adherence to cardiovascular medications is associated
with 25% higher risk for cardiovascular events, including coronary heart disease (CHD),
stroke, and sudden cardiac death, and 60% higher risk for all-cause mortality.25 Poor
adherence to beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and statins
among CHD patients is associated with 10-40% higher odds of hospitalization and 1532% higher odds of coronary revascularization. Overall, 9% of the risk for major
cardiovascular events is directly attributable to poor adherence.25 Elderly patients, given
their multiple chronic conditions, polypharmacy, and functional decline, are at especially
high risk for the adverse effects of poor adherence.26,27
Racial Disparities in Adherence among the Elderly
Among the elderly, blacks and Hispanics with uncomplicated hypertension were
about 45% less likely to be adherent to their antihypertensive medications, including
alpha- and beta-blockers, ACE inhibitors, angiotensin II receptor blockers (ARBs),
Calcium channel blockers (CCBs), diuretics and vasodilators.28 Zhang et al examined
adherence to ACE inhibitors/ARBs and diuretics among seniors with heart failure, and
found blacks, Hispanics, and Native Americans to be about 40% less likely to achieve
adherence than whites.29 Zhang et al also reported that black and Hispanic seniors
surviving acute myocardial infarction (AMI) were 20-30% less likely to adhere to betablocker, ACE inhibitor, or statin therapy for 6 months or a year post-infarction.30 In an
analysis across race and gender of AMI survivors, Lauffenburger et al reported that black
and Hispanic women were least likely (having about 30-36% lower odds), compared with
white men, to be adherent to these post-AMI preventive therapies.31 In a meta-analysis of
published studies, Lewey et al estimated that generally patients of non-white race were at
about 50% higher odds of non-adherence to statins than whites.32 Racial disparities in
adherence persist even in settings with equal access to prescription drugs.11,33 Despite
their significant role in placing minorities at a higher risk for adverse cardiovascular
outcomes, adherence disparities have received very little attention in the literature.
Medicare: the Policy Context
The Medicare program offers an interesting laboratory to study adherence
disparities among the elderly and how these disparities respond to policy changes.
Medicare covers the cost of healthcare for more than 50 million elderly and disabled
Americans, with the elderly population (65 years and older) accounting for about 85% of
the Medicare population.34 Medicare is the largest single payer for healthcare in the
United States and spending on Medicare makes up about 16% of the federal budget,
making it a very rich policy arena.34 One major policy change in Medicare, perhaps the
largest since inception in 1965, was the introduction of the Medicare prescription drug
benefit, Part D by the Medicare Modernization Act of 2003.35 Prior to 2003, a
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“conspicuous failure in the US health policy”36 was the lack of a prescription drug benefit
for Medicare seniors, making the United States the only industrialized country to have
such a deficiency.36 Before Part D, 90% of Medicare elderly beneficiaries were taking
prescription medications for their conditions, and 27% of them had no source of
prescription drug coverage.37 Prevalence of drug uninsurance reached 34% among poor
seniors.37 Rates of foregoing prescription drugs because of cost, i.e. cost-related nonadherence (CRN), was about 26% in the overall Medicare population, 37% among those
with no coverage, 35% among the low-income, and 35% among those with complex
chronic diseases.37 Seniors with multiple chronic conditions had a striking 52%
likelihood of CRN, with similar rates among patients with congestive heart failure and
diabetes.37 Except for individuals with Medicaid and other public coverage (e.g. Veteran
Affairs and Indian Health Services), covered beneficiaries had patchy, discontinuous and
variable levels of drug coverage (through previous employers, HMOs, Medigap and other
private plans, and States’ Pharmaceutical Assistance Programs) with various caps and
deductibles that made beneficiaries, especially those who were sicker, seek to change
plans during the year after reaching their catastrophic limits.36,37 Studies that examined
the effect of the lack or restriction of drug coverage on seniors have shown detrimental
effects of these limits on their health, especially among the low-income and those in poor
health and multiple comorbidity (to the extent that limits and caps placed in some drug
plans may have resulted in irreversible health problems that led to nursing home
admissions).36
The introduction of Part D aimed to expand access to prescription drugs by
reducing the financial out-of-pocket burden associated with them and to improve the
quality of medication use by requiring drug plans to offer medication therapy
management (MTM) services to their eligible Medicare enrollees.38,39 Rates of CRN,
which motivated the introduction of Part D,36,40 decreased among Medicare enrollees
following Part D implementation in 2006.41-43 Part D also increased drug use and reduced
out-of-pocket expenditure.44,45 Among patients with cardiovascular diseases, Part D
improved medication adherence in hypertension, hyperlipidemias, and heart failure.46
Some have suggested that this improvement has led to a significant (about 4%) reduction
in hospitalizations for acute myocardial infarction (MI), angina, and congestive heart
failure (CHF).47 The Part D coverage gap, the “donut hole”, however, was associated
with some reduction in adherence to cardiovascular medications.48-51 While optimal
design and delivery of MTM services and the eligibility threshold are still active areas of
research,52 early evaluations of MTM among beneficiaries in 2010 show the versatility of
MTM for improving the quality of medication use process and its outcomes, including
medication adherence in clinically complex patients.53
In addition to its general goals and provisions, Medicare Part D also further
supported the low-income population, among whom racial/ethnic minorities are
overrepresented, by creating the low-income subsidy (LIS). The LIS effectively
eliminated cost-sharing for beneficiaries with limited assets and income below 150% of
the federal poverty line (assets < $25,010 and income <$21,855 for a couple in 2010).54
Dually eligible beneficiaries and those receiving Supplemental Security Income were
automatically signed up for the LIS.55 Recent evidence suggests that the LIS brought
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medication-related metrics, including adherence, duration of therapy, and overall
exposure to prescription drugs, among LIS-recipients closer to those among the more
advantaged non-LIS beneficiaries.56-58
Although the goals and effects of Part D introduction underscore a potential for
reduction of medication-related disparities, studies of minority experience with Part D
raise some alarming signs. In comparison with whites, minorities have had greater
difficulty navigating the Part D program, due in part to health literacy and socioeconomic
disadvantage,59 and were more unaware of and confused by their Part D benefits.60 Very
scant literature has formally examined the impact of Part D on drug-related disparities. In
one pre-post study of elderly beneficiaries,61 Part D was associated with a larger decrease
in out-of-pocket expenditure and unmet drug needs among black non-dually eligible
beneficiaries, and a larger decrease in unmet drug needs only among Hispanic dualeligibles, relative to their white counterparts. In a difference-in-differences evaluation,62
Part D was associated with a reduction of white-Hispanic disparities in expenditure and
use of prescription drugs, but an increase in the white-black disparity in total drug
expenditure. Minorities were also less likely to meet Part D utilization-based eligibility
criteria for MTM services,63,64 depriving scores of minority patients from a benefit that is
well-equipped to help them with their complex medication-related issues, including
adherence behavior.
Research Aims
This dissertation sought to examine the racial disparities in adherence to
cardiovascular medications in the Medicare elderly population. Using nationally
representative data from the Medical Expenditure Panel Survey (MEPS), the following
three aims were pursued:
Aim 1: To estimate the impact of Part D introduction on the racial disparities in
adherence to cardiovascular medications
By investigating the impact of Part D, we sought to answer two interrelated
questions: 1) whether adherence behavior among blacks and Hispanics was further
increased or reduced as a result of Part D coverage, and 2) to what extent the potential of
Part D to reduce adherence disparities has been realized. Such an impact evaluation can
inform future policy endeavors, by reinforcing our knowledge of what works and what
does not work for disparities reduction, including further recognition of the potential of a
policy change to exert unintended effects on both the absolute outcomes, adherence
among minorities in this dissertation, as well as, from a social justice perspective, the
state of adherence disparities among seniors.
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Aim 2: To identify population subgroups along the distribution of adherence where
disparities were most amplified
Although the traditional approach to studying adherence disparities at the mean
probability of achieving 80% medication possession is informative, it risks overlooking
significant disparities that might exist at other locations in the distribution. These
locations signify population subgroups with potentially distinct patterns of adherence
behavior, and they get indiscriminately lumped together when adherence is measured as a
binary classification of patients above and below 80% medication possession.
Investigating the extent of disparities along the distribution of adherence can thus bring to
our attention disparities that might be deserving of tailored, and potentially priority,
interventions.
Aim 3: To identify the potential drivers of the black-white disparity in adherence
After quantifying the extent of disparities across the distribution of adherence,
identifying where they were most significant, and after evaluating how Part D changed
the policy and coverage landscape for Medicare seniors, this dissertation turned to the
question of what might be driving those persistent disparities. As it unfolded in studies
for the first two aims, the black-white disparity in cardiovascular medication adherence
was the largest and potentially the most consequential, given the higher burden of
cardiovascular disease among blacks and their persistent social disadvantage.65 Despite a
large literature on adherence behavior among blacks, conducting a systematic,
comparative analysis of how the determinants of adherence disparately work to produce
the observed patterns of adherence among blacks and whites remains a critical gap in the
literature. For Aim 3, this dissertation built on the methods and findings under Aim 2 to
investigate the potential sources of black-white differences in adherence across the
distribution, in an attempt to reveal the determinants of adherence most responsible for
the observed black-white differential, as well as the population subgroups among whom
these determinants were significant.
In the course of investigating these research questions, which were previously
unstudied, disparities were conceptually defined according to the Institute of Medicine’s
framework on studying racial healthcare disparities.66,67 Extending this framework to the
study of disparities in adherence behavior is a much needed theoretical contribution. This
dissertation also makes use of recent advances in state-of-the-art econometric methods to
study inequality, including the rank-and-replace procedure to adjust for health status in
non-linear models,68,69 unconditional quantiles regression,70 and Oaxaca-Blinder
decomposition across outcome quantiles.71 Further, this dissertation introduces specific
methodology with validation to measure adherence in MEPS, filling an important gap in
the literature on prescription drug research. Finally, the substantive findings from this
dissertation regarding adherence disparities carry implications for disparity reduction
efforts under Medicare Part D.
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CHAPTER 2. IMPACT OF MEDICARE PART D ON RACIAL DISPARITIES
IN ADHERENCE TO CARDIOVASCULAR MEDICATIONS AMONG THE
ELDERLY
Background
Patient adherence to evidence-based cardiovascular medications is imperative for
attaining intermediate therapeutic goals, such as blood pressure and low-density
lipoprotein levels, and for the subsequent realization of favorable health outcomes.23,72-74
Poor adherence can have especially detrimental consequences among older adults, given
their multiple comorbidities, polypharmacy, and declining cognitive function.75-77
Further, across racial/ethnic groups, differentially worse adherence to cardiovascular
medications, such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and
statins, have been repeatedly observed, even after adjustment for socioeconomic status
and insurance coverage.28-32,78-85 Worse adherence among blacks and Hispanics, is a key
predisposing factor for falling short of treatment goals, including having persistently
elevated blood pressure8,9 and cholesterol levels.10,11 In the landmark CARDIA study,
blacks were 20 times more likely to develop heart failure before the age of 50, than
whites, with a persistent disparity in uncontrolled blood pressure as a key antecedent.6
Not surprisingly, the disparity in cardiovascular mortality is the major contributor to the
disparity in life expectancy in the United States,86 with blacks 2-3 times more likely than
whites to die from heart diseases at any given age.4
Medicare Part D, signed into law in 2003 and implemented in 2006, aimed to 1)
expand access to prescription drugs by reducing the financial out-of-pocket burden
associated with them, and 2) improve the quality of medication use by requiring drug
plans to offer medication therapy management (MTM) services to their eligible Medicare
enrollees.38,39 Cost-related non-adherence, which motivated the introduction of Part
D,36,40 decreased among Medicare enrollees following Part D implementation in 2006,
though not among the most vulnerable, e.g. those with low-income or poor health.41-43
Part D also increased drug use and reduced out-of-pocket expenditure.44,45 Among
patients with cardiovascular diseases, Part D improved medication adherence in
hypertension, hyperlipidemias, and heart failure.46 Some have suggested that this
improvement has led to a significant (about 4%) reduction in hospitalizations for acute
myocardial infarction (MI), angina, and congestive heart failure (CHF).47 The Part D
coverage gap, the “donut hole”, however, was associated with some reduction in
adherence to cardiovascular medications.48-51 While optimal design and delivery of MTM
services and the eligibility threshold are still active areas of research,52 early evaluations
of MTM among beneficiaries in 2010 show the versatility of MTM for improving the
quality of medication use process and its outcomes, including medication adherence in
clinically complex patients.53
In addition to its general goals and provisions, Medicare Part D also aimed to
further support the low-income population, among whom racial/ethnic minorities are
overrepresented, by creating the low-income subsidy (LIS). The LIS effectively
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eliminated cost-sharing for beneficiaries below 150% of the federal poverty line,
automatically including those who are dually eligible for Medicare and Medicaid as well
as those receiving Supplemental Security Income.55 Recent evidence indicates that LIS
recipients are doing better on medication use quality metrics, including medication
adherence in a number of chronic conditions.56-58
Taken together, the goals and impact of Part D coverage on the general Medicare
and LIS populations suggest that it may have reduced the racial/ethnic disparities in
medication adherence. Testing this hypothesis in a formal impact evaluation is still an
open empirical question. This evaluation is further motivated by the increasing
vulnerability among minorities who may not be receiving as much benefit from Part D as
their white majority counterparts. This concern is supported by studies showing that,
compared to whites, minorities have had more difficulties navigating the Part D program,
due in part to health literacy and socioeconomic disadvantage,59 and have been more
unaware of and confused by their Part D benefits.60 Further, given the greater burden of
cardiovascular diseases among minorities, particularly blacks, any potential unintended
consequences of Part D benefit designs and delivery structure may have especially
negative consequences for these already burdened minority beneficiaries. Very scant
literature has formally examined the impact of Part D on drug-related disparities,
generally, and to the best of our knowledge, none has focused specifically on the impact
of Part D on adherence disparities. In one pre-post study of elderly beneficiaries,61 Part D
was associated with a larger decrease in out-of-pocket expenditure and unmet drug needs
among black non-dually eligible beneficiaries, and a larger decrease in unmet drug needs
only among Hispanic dual-eligibles, relative to their white counterparts. In a differencein-difference evaluation by Mahmoudi and Jensen,62 Part D was associated with a
reduction of white-Hispanic disparities in expenditure and use of prescription drugs, but
increased white-black disparity in total drug expenditure.
The goal of this study was to investigate, using nationally representative data,
how Part D introduction affected the time course of adherence disparities in the Medicare
population, controlling for the secular trends that would have prevailed in the absence of
Part D. By investigating the impact of Part D, we sought to answer two interrelated
questions: 1) whether adherence behavior among blacks and Hispanics was further
increased or reduced as a result of Part D coverage, and 2) to what extent the potential of
Part D to reduce adherence disparities has been realized. Such an impact evaluation can
inform future policy endeavors, by reinforcing our knowledge of what works and what
does not work for disparities reduction, including further recognition of the potential of a
policy change to exert unintended effects on both the absolute outcomes, adherence
among minorities in our case, as well as, from a social justice perspective, the state of
disparities.

7

Methods
Data and Population
We analyzed the annual data files, linked to the Medical Conditions files and
Prescribed Medicines event files, of the Household Component of the Medical
Expenditure Panel Survey (MEPS-HC; MEPS for short) from 2002 to 2010. MEPS is an
annual, nationally representative survey of healthcare access, use, and expenditure by the
US civilian non-institutionalized population, with oversampling of minorities,
administered by the US Agency for Healthcare Research and Quality (AHRQ). Each year
MEPS panel participants are sampled from the previous year’s respondents to the
National Health Interview Survey. Each panel is then interviewed for five rounds over
two and a half years, providing data for two calendar years. MEPS annual files (known as
Full Year Consolidated Data Files) combine data from the two panels that overlap in the
particular year a file covers: rounds 3, 4, and 5 of the previous year’s panel and rounds 1,
2, and 3 of the current year’s panel. By combining data from the overlapping panels,
these annual files provide nearly double the sample size of individual panels and cover
the entire calendar year for each respondent. Although all MEPS data are reported by
respondents during computer-assisted personal interviewing, further detailed health
service use data, including on prescription drugs, are collected from a sample of
providers with respondents’ permission. Specifically of relevance to this study, the
quality of MEPS prescription drug data, as well as Medicare Part D enrollment has been
shown to be comparable to that of claims data.87,88 Additionally, MEPS provides very
rich data on respondents’ sociodemographics, health and chronic conditions, as well as
experience with providers and the healthcare system, allowing a thorough study of
adherence as shaped by these determinants.
The study sample included respondents who were: 1) continuously included in all
MEPS survey rounds for a calendar year. This excludes respondents who went “out of
scope” because of death, institutionalization, or other reasons. 2) Medicare beneficiaries
65 years and older (the "treated" group) as of January 1st of survey year, and nonMedicare but otherwise insured individuals 60-64 years old (near-elderly, the control
group) as of December 31st of survey year. This latter date serves to exclude individuals
who may become eligible for Medicare during survey year. The near-elderly were used as
the control group, since they are presumably closest in characteristics to the elderly and,
for the most part, have seen minimal policy changes in their drug coverage in the study
period.47 3) Self-reported being non-Hispanic white (henceforth “white”), non-Hispanic
black (henceforth “black”), or Hispanic. We could not include other racial/ethnic groups
or further distinguish Hispanic subgroups due to their small sample sizes. 4) Had at least
one of the following six conditions: hypertension, hyperlipidemia, angina, congestive
heart failure, myocardial infarction, and stroke. Clinical Classification Codes and 3-digit
ICD-9 codes in MEPS were used to identify respondents with these conditions in MEPS
Medical Conditions Files. Appendix Table A-1 lists all the conditions and their
associated codes. 5) Had at least one refill during the survey year of a maintenance
cardiovascular drug of the following therapeutic classes: ACE Inhibitors, Angiotensin II
Receptor Blockers (ARBs), HMG-CoA Reductase Inhibitors (Statins), Beta-blockers,
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Calcium Channel Blockers, Diuretics, or combination products of these medications.
Appendix Table A-2 lists the specific medications included and their Multum Lexicon®
class information.
Since the study population represents only a small portion of MEPS respondents
each year, it was necessary to pool the annual files to ensure adequate sample size for the
analyses we conducted. Survey design variables in annual files 2002 and following years
provide a correctly specified common variance structure to calculate the appropriate
standard errors with pooling.89 For our impact evaluation, we considered MEPS years
from 2002-2005 to cover the pre-Part D period, whereas data from 2007-2010 covered
the post period. We excluded 2006 from the post period since it was a transition year for
both individuals and health plans under Part D, and thus, if used in the post-Part D
period, it is likely that Part D effects might be under-estimated.39,47 We test this
hypothesis in a sensitivity analysis.
Measurement of Adherence
Using drug refill records for each included respondent, we measured adherence to
each medication class as the proportion of days covered (PDC) by refills for any
medication from that class, expressed as a percentage and capped at 100%. ACE
inhibitors and ARBs were considered a single class for this purpose. Also, component
medications of combination products were counted towards their respective classes. A
follow-up period specific to each drug class was calculated for each respondent, starting
from an index date corresponding to the first day of the interview round in which the first
refill (of that class) occurred. The end date was the last day of survey year, December
31st. While the majority of index refills (60-65%) for any class occurred in rounds 3/1
(resulting in January 1 as the index date), some respondents did not have refills for one or
more classes until rounds 4/2 or 5/3; in this case, the index date was set to the start date of
the specific round in which the refill occurred. More than 91% of index refills had
occurred in the first two rounds of a calendar year. In addition to calculating classspecific PDCs, we calculated an average PDC to summarize adherence to all drug classes
an individual was taking. We then classified respondents as adherent if they had PDC of
at least 80% over the follow-up period. The main outcome variable was the overall binary
adherence classification. Class-specific adherence classifications were examined in
secondary analyses.
Although all MEPS years in our analysis have extensive data on prescription
refills, including dispensed quantity, strength, dosage form, and therapeutic
class/subclass, data on days of supply were not available in years prior to 2010. We used
2010 data to characterize the patterns of observed days’ supply as they relate to dispensed
quantities of drug refills. In so doing, we identified the most frequent number of supply
days furnished by each level of dispensed quantity. Next, we derived a scheme to
smoothly approximate the distribution of refill supply days for use in prior years of
MEPS (where actual days of supply data are not available). For comparison, we also
more coarsely approximated days of supply by discretizing the distribution of dispensed
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quantities on the basis of some rough “rules of thumb” (e.g. dispensed quantities ≤ 45
pills give 30 days of supply, quantities >45 but ≤ 75 pills cover 60 days, and quantities
>75 provide 90 days of supply). Then, in 2010 data, we measured adherence, both as a
continuous PDC and as a dichotomous classification as explained above, using the actual
and the approximated days’ supply distributions.
To assess the validity of our derivations, we used Lin’s concordance
coefficient90,91 to compare the approximate continuous distributions of supply days and
estimated PDC to their actual counterparts. We also used Kappa and C-statistics to
compare dichotomous adherence classifications produced using approximate PDC
distributions against those produced using the actual PDC distribution. Finally, using the
most valid method for approximating refill days of supply from dispensed quantities, we
calculated days of supply for refills in years prior to 2010. The validity of computing
refill days of supply in earlier years using the pattern of days’ supply vis-à-vis dispensed
quantities in 2010 hinges on the potentially plausible assumption (based on discussions
with two cardiologists with more than 20 years of practice experience) that the dosing
frequency of a given strength of a specific cardiovascular drug has been stable over 20022010 in a specific patient population (for example: for the same patient population, if a
30-pill refill of 40-mg simvastatin covers 30 days in 2010, on average, this would have
also been true in 2002).
Conceptualizing Adherence Disparities
In most empirical research on healthcare disparities, authors have typically
estimated the disparity as the difference in outcome levels across racial/ethnic groups,
after adjusting for the entire set of covariates, including socioeconomic status (SES) and
other measures of race-related disadvantage.67 Typically, the magnitude of disparity is
viewed as the coefficient of the race indicator variable in a multivariable linear model or
the odds ratio in a logistic regression. Although not expressly stated, the normative
judgment underlying this approach to estimating disparities posits that racial disparities
are the differences due to race-related factors other than the control variables already
accounted for. This is because, in a multivariable model that adjusts for measured racial
disadvantage, such as income and education, the race variable only captures variation in
the remaining manifestations of racism that are not accounted for, such as
discrimination.69 McGuire and colleagues termed this disparity the residual direct effect
(RDE) of race.92 This traditional approach to estimating disparities ignores the
contributions of other inextricable features of racial disadvantage, such as low SES,
potentially leading to false conclusions regarding the existence of disparities.67,92 When
race is viewed as a complex, multidimensional lived experience involving both material
and psychosocial disadvantage, racial disparities in health outcomes must include all
differences due to every relevant dimension of racial inequality.65,93 This argument also
applies to ethnic disparities. In the interest of parsimony, and since race captures most
aspects of ethnicity and the two categorizations are not meaningful to disentangle in a
society with inequitable race relations,65,94 we use the term “race” here to refer to race
and ethnicity together.
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In its 2002 landmark report, “Unequal Treatment,” the Institute of Medicine
(IOM) provided a framework to define racial disparities in healthcare, distinguishing
disparities, which insinuate inequity and injustice, from benign differences in healthcare
that might be more legitimate.66,92 According to the IOM, racial healthcare disparities
correspond to the racial differences in healthcare that are justified neither by the clinical
appropriateness and health status needs, nor by the preferences and attitudes towards
medical care, assuming that those preferences were formulated under “full and accurate
understanding of treatment options.”66 Healthcare disparities arise through two broad
mechanisms:66 1) The operative legal, and regulatory environment in which healthcare
systems function, including policies and practice patterns, insurance coverage, SES, and
other differential factors that constrain healthcare use disproportionately for minorities,92
and 2) discrimination at the patient-provider level, which may take the form of prejudice,
stereotyping, or statistical discrimination under clinical uncertainty.95
To illustrate differences vs. disparities: if, for instance, Hispanics are on average
younger and thus healthier, the age-related difference in healthcare use between them and
whites should not be counted towards a disparity. On the other hand, if the health status
among blacks is worse than whites, but they are not receiving healthcare commensurate
with their health needs because of inequitable factors, then this difference in healthcare
use is indeed a disparity. In essence, the IOM framework attempts to isolate the
contributions of the current structural and fundamental impediments to achieving equity
in the health system, which are extrinsic to individuals and potentially ameliorable
through appropriate interventions. While it is true that the differentials in health status
and chronic disease burden have been shaped by historical racism, selectively adjusting
for health status allows examining differences between two clinically comparable groups
that, in the absence of racialized social factors such as poverty, stress, and limited access
to resources, would have exhibited similar rates of healthcare utilization and healthrelated behaviors. Not only does the IOM framing of disparities and their potential
sources provide an organizing heuristic to guide empirical research on disparities,
particularly by being explicit about value judgments, it also acknowledges the
contributions of multiple relevant dimensions of racial disadvantage to healthcare
disparities
In this study, we applied the IOM framework to examine disparities in medication
adherence and the impact of Medicare Part D on these disparities. Adherence behavior is
shaped by complex interactions of multiple factors, pertinent to the patient, the condition,
the drug regimen, the provider and the health system, as well as the social and economic
environments.17,77 MEPS offers a wide array of variables that we used to characterize
these determinants. We made a priori classifications for each predictor/determinant of
adherence as potentially contributing to disparities, on the basis of how it correlates with
race and socioeconomic disadvantage. Specifically, as we show in Figure 2-1, which is
similar in spirit to the IOM framework,66 the racial difference in adherence can be
decomposed into disparities and “non-disparities.”
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Figure 2-1. Conceptualizing adherence disparities in the light of the IOM
framework
* Measured in MEPS Self-Administered Questionnaire (SAQ)
† Proxy for language in clinical encounter
‡ We do not adjust for drug copay since it is on the causal pathway between Part D and
adherence. Adjusting for copay biases down Part D effects.
§ Discrimination in the clinical encounter is roughly captured by the experience with
provider variables, to the left.
| | Measured by the D’Hoore’s version of the Charlson comorbidity index96 using MEPS
3-digit ICD-9 codes, excluding respondent-specific cardiovascular conditions. Conditions
included in the index are not further adjusted for.
# Defined using depression ICD-9 codes 296 and 311.
HMO: Health Maintenance Organization; IOM: Institute of Medicine; RDE: Residual
Direct Effect.
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Adherence disparities arise due to disparate SES across racial groups, racial
discrimination, as well as racial differences in the experience with the healthcare system,
including having a usual source of care, health/drug insurance, language in the clinical
encounter (proxied by the interview language), satisfaction with care, and the quality of
patient-provider relationship. Differences in adherence that arose due to differences in
health status were not counted towards the disparity. As explained above, although health
differentials have been shaped by historical disadvantage, our goal was to compare
adherence behavior across racial groups of comparable health status so as to produce
disparity estimates that incorporate how the social and health-system factors in their
current form perpetuate these disparities. Following the IOM, we also do not count
differences in adherence due to preferences/beliefs, instantiated in MEPS by respondents’
attitudes towards risk, insurance, and medical care, towards disparities.
We discuss below the statistical details of how we empirically implemented our
Figure 2-1-conceptualization of disparities. Each of the conceptual stipulations we make
as to what constitutes a disparity in adherence and what does not is a hypothesis that can
be formally tested. To evaluate how our conclusions about disparities might change
depending on classification of particular factors, we conducted a series of sensitivity
analyses that ranged from counting only demographic differences towards disparities, to
fully adjusting disparity estimates for all covariates in hand (i.e. estimating RDE
disparities).
Statistical Analysis
We used a difference-in-differences (DID) design (Figure 2-2) to evaluate the
impact of Part D introduction on the racial disparities in adherence to cardiovascular
medications. DID is a quasi-experimental evaluation strategy that uses the mean outcome
in the control group observed after the treatment as an estimate of the counterfactual
outcome that would have been observed in the treated group, in the absence of treatment.
The key identifying assumption for a valid DID analysis is that the treated and
control groups exhibit parallel trends in the mean outcome in the absence of treatment
(policy implementation). With such a valid control group, the DID estimate of the
treatment effect thus equals what’s left after taking the difference across time and across
groups in the mean outcome, which serves to eliminate the secular time trend that is
common to both groups and unrelated to the treatment, as well as the systematic
differences due to time-invariant group characteristics (e.g. adherence is systematically
higher among the near-elderly than among the elderly), respectively.97 In regression
analysis, DID estimation is done using a set of binary indicator variables for groups, time
period, and their interaction term. To estimate the impact on disparities, we added race
indicator variables and their interaction terms with group and time indicators to the basic
DID setup, as shown in Equation 2-1. We apply the DID framework to pooled crosssectional MEPS data on Medicare seniors and the near-elderly before and after Part D.
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Figure 2-2. Difference-in-Difference (DID) evaluation of Part D effect on racial
disparities in adherence
Change in Disparities in Medicare (Tx Group)
= Δb – Δa
Change in Disparities in the near-elderly (Ctrl Group)
= Δd – Δc
DID Effect of Part D on Disparities
= (Δb – Δa) – (Δd – Δc).
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Using logistic regression, we model adherence, as a dichotomous outcome
variables (at or above 80% PDC cutoff) as a function of the DID setup as well as the
aforementioned predictors of adherence. In notation,
K
-1

γ1
+ γෝ2 .Medicare + γෞ.Medicare×Post
PrሾPDC≥80%ȁxሿ =g (αො +  Xk .βk + ෞ.Post
12
k=1

+ γෝ3 .Black + γෝ4 .Hispanic + γෞ
.Black×Post + γෞ
.Hispanic×Post
13
14
+ γෞ
.Black×Medicare + γෞ
.Hispanic×Medicare
23
24
.Black×Medicare×Post + γෞ
.Hispanic×Medicare×Post) (Eq. 2-1)
+ γෞ
123
124
Where, g-1 is the inverse of the logistic function that relates that the outcome (on
the probability scale) to the covariates. Pr[] is the population average probability of
adherence, conditional on covariates. X represents the individual characteristics that
predict adherence behavior, including demographics, health, SES, insurance, and
experience with the healthcare system, as listed in Figure 2-1. We also included the
interactions of SES and race indicators. Post, Medicare, Black, and Hispanic, are binary
indicator variables, each equals one for the post-Part D period (2007-2010), being a
Medicare senior, self-identifying as black, or Hispanic, respectively, and zero otherwise.
The interaction terms serve to capture the heterogeneity of average adherence across the
three dimensions of comparison: time, treated/control groups, and race. The coefficients
and γෞ
, provide an estimate of the effect of Part
of the two triple interaction terms,γෞ
123
124
D on adherence, comparing minorities to whites, i.e. the effects of Part D on the racial
disparities in adherence.
To implement our IOM conceptualization of adherence disparities within this DID
framework, we defined adherence disparities as the differences in mean adherence across
clinically comparable racial groups that arise due to inequitable social and health-system
factors, including SES, insurance coverage, access to primary care, and discrimination in
the clinical encounter (Figure 2-1). To make racial groups clinically comparable, we
selectively adjusted our race-specific outcomes predictions for perceived health status,
comorbidity, and clinical need (including the use of other prescription drugs). We also
adjusted for beliefs/preferences (including geographic location), per the IOM definition.
For brevity, we collectively label the factors that are potential sources of disparities (the
left two thirds of Figure 2-1) by the letter S, for SES and denote factors we adjust for by
H, for health (right side of Figure 2-1), reflecting that SES and health are at the heart of
the two groups of factors we conceptually distinguish.68
For empirical implementation, we followed Cook, McGuire, and colleagues68,69,92
in using a rank-and-replace procedure to estimate disparities. Briefly, we first estimated
our multivariable logistic DID model as above (Equation 2-1), controlling for all the
aforementioned covariates. The adequacy of model fit was tested using a modified
Hosmer-Lemeshow test for complex survey data.98 Next, we generated a composite score
of H factors for each individual in the dataset by calculating the linear combination of
each individuals’ observed value of each H variable multiplied by the pertinent

 Ⱦ ; simply, it is the
coefficient in the multivariable model, i.e. the H-score ൌ σൌͳ
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sum of the Xβ products for all K H variables, for each individual i. Next, we ranked
individuals in each racial group by their H-score, generating a percentile rank for each
individual within their race-specific H distribution. Then, to match minority and white
distributions of H variables, we replaced the value of each H variable for each minority
individual by the value of that variable in the white individual with the corresponding Hbased percentile rank. Replacing minority with white distributions this way preserves the
joint associations among H variables and is superior to other methods for ranking and
replacement.69 This replacement creates a counterfactual minority group that still
preserves its observed distributions of social and health-system exposures (the S
variables), while now possessing the white distributions of health, clinical need, and
preferences (H variables). Then, we predicted average marginal adherence levels in
counterfactual minority and factual white groups using our estimated DID model
(Equation 2-2). Finally, we computed racial disparities as the differences in predicted
average adherence between each counterfactual minority group (blacks, Hispanics) and
the reference (factual) white group. In simple notation, the disparity Δ is given by
∆=AdherenceFactual Whites -AdherenceCounterfactual Minority
∆=ሺͺͲΨȁR=W, S=W, H=W)
(Eq. 2-2)
- ሺͺͲΨȁR=M, S=M, H=W)
Where, R is race, M minority, W white, and S and H take on the same designation
as above. To calculate the DID effect of Part D on the disparities, we used predictive
margins99 to compute Δ before and after Part D in the treated and control groups and took
the double difference across time and groups (see notes of Figure 2-2).
Finally, since there were high rates of missing data for the (categorical) variables
on beliefs and experience with providers (highest rate 4.4%, leading to up to 25% sample
reduction if only complete cases were included), we used multiple imputation using
chained equations (MICE) to impute the missing data for each of these variables.100
Following recent recommendations in the imputation literature,100,101 we imputed the
variables with missing data in 5 imputation datasets, adjusting for survey design in the
imputation model. Using Stata –MI- set of commands, we carried out our analyses,
including ranking-and-replacement and estimating predictive margins, across all
imputation datasets and produced a single set of point estimates and standard errors that
took into account the uncertainty due to imputation. All analyses accounted for MEPS
complex survey design using Taylor series linearization in STATA® 13 (StataCorp;
College Station, TX).
Analogous to the main analysis, we also conducted a series of sensitivity and
subgroup analyses to assess robustness of our findings to the conceptual and empirical
decisions made, and to assess potential heterogeneity of Part D effects across policyrelevant groups. First, we assessed the robustness of our DID-based predictions to a
series of empirical adjustments, using the rank-and-replace procedure, for demographics,
health, concurrent drug therapy, and beliefs/preferences. These various adjustments
reflect different value judgments regarding how differences in each of these factors
originated and how they contribute to producing adherence disparities. We also estimated
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Part D impact on RDE disparities directly from our multivariable DID model. Second, we
graphically assessed the plausibility of the parallel trend assumption necessary for the
validity of DID estimation. We further considered how our DID estimates would change
if we included 2006 data in post-Part D year, and if we restricted the treated group to a
population more comparable to the near-elderly controls (i.e. Medicare elderly 65-70
years old).102 Third, we analyzed the effect of Part D on disparities in adherence to each
of the five cardiovascular medication classes we considered, in addition to evaluating
effects by gender and dual-eligibility status.
Results
Sample Characteristics
The main study sample included 14,221 and 3,456 MEPS respondents, nationally
representative of 19.7 and 5.3 million Medicare seniors and non-Medicare near-elderly
individuals, respectively. Thus, our total sample size was 17,677 respondents,
representing a total of 25 million individuals nationwide. As shown in Table 2-1, over
the entire study period (2002-05, 2007-2010), Medicare seniors and the near-elderly had
comparable adherence behaviors, with overall adherence rates hovering around 40%.
Black seniors in Medicare had the lowest overall adherence rate (36.59%). In comparison
with the near-elderly controls, Medicare seniors were more likely to be females and less
likely to be married. They also had worse health status, more physical/cognitive
limitations and comorbidities, and a higher burden of cardiovascular disease, particularly
the advanced stages of coronary heart disease, congestive heart failure, myocardial
infarction, and stroke. They were also less likely to be current smokers, obese, or to
exercise. Seniors were also more likely to be poor or low-income, and less likely to have
completed high school or college education. As expected, seniors were less likely to have
private or employer-sponsored insurance coverage, but concurrently used more
medications, visited physicians more often, and were more likely to have had
hospitalizations during survey year. Seniors’ experience with providers was comparable
to that of their near-elderly counterparts, but they tended to more positively rate their
satisfaction with the healthcare system.
In both treated and control groups, blacks and Hispanics were more likely than
whites to have no spouse/significant other, and to live in urban areas. Across regions,
blacks were heavily concentrated in the South while Hispanics also concentrated in the
West. Both groups were less likely to live in the Midwest. Minorities had worse health
status and comorbidity, as well as a higher burden of hypertension and diabetes.
However, they had either lower or comparable prevalence rates of other conditions, such
as hyperlipidemia, cardiovascular complications (CHD and AMI), and depression.
Minorities were also less likely to exercise and to be obese. Relative to whites, smoking
was higher among blacks while lower among Hispanics. Invariably, minorities had lower
education and income, and expectedly were more likely to receive Medicaid coverage
and less likely to have private or employer-sponsored insurance. Blacks were more likely
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Table 2-1.

Characteristics of treated and control groups by race

Characteristics

Medicare Elderly (65 years or older)
White
Black
Hispanic
Overall

Sample Size

10,311

2,300

1,610

14,221

2,519

547

390

3,456

Weighted
Population

16,722,679

1,767,117

1,164,105

19,653,901

4,469,185

498,497

284,937

5,252,619

White

Near-Elderly Controls
Black
Hispanic

Overall

% (unless otherwise noted)
Adherence to CV Medications
Overall

39.93

36.59

38.51

39.54

40.61

41.13

41.53

40.71

ACEIs/ARBs

47.02

43.55

47.81

46.75

47.67

47.78

49.17

47.78

Statins

44.08

45

43.49

44.11

43.74

41.15

48.74

43.8

Beta-Blockers
Ca Channel
Blockers
Diuretics

48.42

43.58

48.8

48.04

47.34

45.35

45.68

47.02

41.36

40.68

37.53

41

41.07

48.78

56.84

43.24

48.01

43.92

43.52

47.32

49.82

46.05

53.09

49.51

74.69
±6.36

73.54
±6.25

73.63
±5.91

74.53
±6.34

61.97
±1.38

62.05
±1.42

61.74
±1.35

61.96
±1.38

57.85

63.37

60.8

58.52

51.17

53.67

57.98

51.78

Married
Urban
Residence
Census Region
Northeast

57.38

34.05

46.84

54.66

77.25

47.35

62.34

73.6

77.67

86.25

92.73

79.33

78.33

91.55

92.47

80.36

21.05

18.73

14.89

20.47

20.2

21.16

23.04

20.45

Midwest

25.42

17.25

6.02

23.54

26.65

17.44

9.48

24.84

South

35.21

56.75

43.35

37.63

35.51

53.47

31.2

36.98

Demographics
Age
(Mean±SD)
Female Gender
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Table 2-1.

(Continued)

Characteristics
West

Medicare Elderly (65 years or older)
White
Black
Hispanic
Overall
18.32

White

Near-Elderly Controls
Black
Hispanic

Overall

7.28

35.75

18.36

17.64

7.93

36.28

17.73

Self-Reported Health
Excellent

14.54

9.23

7.54

13.65

16.6

6.34

7.49

15.13

Very Good

29.52

21.82

16.83

28.08

35.79

26.08

18.07

33.9

Good

33.41

33.66

31.96

33.35

31.26

34.55

31.89

31.61

Fair

16.62

26.66

32.69

18.48

11.31

24.64

27.85

13.47

8.63

10.99

6.45

5.04

8.39

14.7

5.88

63.61

65.45

62.51

39.09

48.87

43.07

40.23

14.86

15.15

9.93

3.6

6.41

10.21

4.22

5.9
Poor
Any Physical
62.19
Limitation *
Any Cognitive
9.05
Limitation *
Conditions (over survey year)

Charlson Comorbidity Score
1st/2nd Quartiles

57.06

47.07

44.27

55.41

64.63

54.1

45.52

62.6

rd

31.91

38.25

40.96

33.02

28.56

33.49

43.66

29.85

th

3 Quartile
4 Quartile
Comorbidity
Count, †
Median(IQR)
Hypertension

11.02

14.68

14.77

11.57

6.81

12.41

10.82

7.56

6(3,8)

4(2,6)

5(3,7)

5(3,8)

4(3,7)

4(2,6)

4(2,6)

4(2,7)

81.96

92.89

90.23

83.43

77.13

94.55

91.38

79.55

Hyperlipidemia

59.82

48.15

51.53

58.28

64.34

47.45

56.64

62.32

Angina/CHD

17.25

11.71

16.09

16.68

9.54

7.36

8.53

9.27

CHF

4.66

5.12

2.89

4.59

1.86

2.14

0.41

1.81
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(Continued)

Characteristics

Medicare Elderly (65 years or older)
White
Black
Hispanic
Overall

White

Near-Elderly Controls
Black
Hispanic

Overall

AMI

6.88

5.12

5.15

6.62

3.96

4.17

3.39

3.95

Stroke

5.49

5.94

5.3

5.51

2.28

2.62

4.75

2.45

Depression

11.78

5.61

11.87

11.23

13.02

7.11

13.49

12.48

Diabetes

22.08

35.49

40.7

24.39

20.89

32.38

39.58

22.99

Asthma

9.03

11.03

10.53

9.3

11.79

14.06

12.4

12.04

Emphysema

7.27

3.95

3.07

6.72

4.08

2.79

1.39

3.81

Arthritis

61.04

63.98

58.83

61.17

48.99

55.6

47.72

49.55

14.27

16.39

14.54

16.04

12.6

18.6

15.85

8.26

7.56

9.61

12.68

7.94

8.89

12.03

3.92

6.4

3.84

2.59

1.77

7.07

2.75

8.35

10.52

5.6

8.38

14.49

19.76

9.72

14.73

46.85

38.56

40.62

45.74

57.07

43.59

45.14

55.14

27.86

40.26

32.69

29.26

39.85

50.07

44.38

41.06

Beliefs & Behaviors
More likely to
14.44
take risks
Can overcome
9.89
illness without
medical care
Does not need
3.65
health insurance
Behaviors
Current Smoker
Moderate/
Vigorous
Exercise
Obese
(BMI≥30)
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(Continued)

Medicare Elderly (65 years or older)
White
Black
Hispanic
Overall
Socioeconomic Status
Characteristics

White

Near-Elderly Controls
Black
Hispanic

Overall

Income: ‡
Poor/Near-Poor

13.39

31.57

32.54

16.16

6.83

20.94

25.88

9.2

Low-Income

18.34

26.36

24.75

19.44

6

14.6

13.89

7.24

25.8

27.52

30.67

26.33

27.45

28.13

26.54

47.94

67.62

27.46

10.77

32.33

55.23

15.23

38.02

22.2

47.95

43.19

44.63

29.76

42.6

0.06

51.21

3.28

0.22

0.59

41.25

2.48

1.01

57.81

4.52

1.02

1.32

52.12

3.82

28.06

16.14

32.82

82.77

68.48

54.76

79.9

25.44

37.36

9.16

3.89

20.92

31.64

7.01

24.22

14.14

39.37

62.28

44.09

25.39

58.55

9.13

6.87

9.13

31.2

31.18

36.32

31.47

40.02

39.35

47.74

35.19

42.14

46.24

31.4
Middle-Income
Education: Less
22.5
than High
School
High School
50.8
Diploma
Language:
0.28
Interview Not
in English
No English at
1.18
Home
Insurance (over survey year)
Employer34.48
Sponsored
5.47
Medicaid
Private- Non
42.73
HMO
9.29
Private- HMO

Healthcare Use (over survey year)
No. of concurrent CV Medications §
0-1

39.63

36.28
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Characteristics

Medicare Elderly (65 years or older)
White
Black
Hispanic
Overall

White

Near-Elderly Controls
Black
Hispanic

Overall

2-3

53.74

54.51

54.25

53.84

46.97

56.37

49.91

48.02

≥4

6.63

9.21

5.74

6.81

5.29

8.44

7.95

5.74

No. of other concurrent medications
0-1

11.49

14.94

13.62

11.92

15.31

15.83

18.72

15.54

2-4

48.13

47.02

49.89

48.14

53.96

49.22

46.09

53.08

30.73

34.95

35.2

31.38

1(1,2)

1(1,1)

1(1,1)

1(1,2)

17.07
(9.62,32.69)

13.93
(6.27,25.58)

12.18
(3.32,25.45)

16.53
(9.01,31.81)

96.79

96.99

92.71

96.59

12.91

15.78

12.75

13.17

40.38
38.04
36.49
39.94
≥5
No. of
Pharmacies
1(1,2)
1(1,1)
1(1,1)
1(1,2)
Used,
Median(IQR)
Average Copay
for CV Drugs
19.92
13.36
9.62
18.59
(8.60,43.41) (4.00,31.48) (2.67,27.66) (7.63,41.72)
($2010),
Median(IQR)
Had a Usual
97.59
96.55
96.4
97.42
Source of Care
Had ≥1 Any
19.78
20.88
16.45
19.68
Inpatient Stay
Quintiles of ambulatory physician visits (range)

Q 1 (0-2)

15.35

22.59

20.4

16.3

23.78

27.85

27.79

24.38

Q 2 (3-4)

17.78

21.75

19.19

18.22

23.44

23.92

20.01

23.3

Q 3 (5-7)

20.52

22.63

22.71

20.84

21.35

17.72

22.8

21.08

Q 4 (8-12)

22.73

18.31

20.02

22.17

18.21

19.07

14.55

18.09

Q 5 (≥13)

23.62

14.72

17.68

22.47

13.22

11.44

14.85

13.14
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(Continued)

Medicare Elderly (65 years or older)
White
Black
Hispanic
Overall
Experience with Providers
Characteristics

65.13
Always Listens
Always
60.91
Explains Care
Always
67.59
Respects
Satisfaction with Healthcare
Dissatisfied7.59
Neutral
29.47
Satisfied

Very Satisfied

62.95

White

Near-Elderly Controls
Black
Hispanic

Overall

74.42

70.81

66.3

62.11

69.97

67.29

63.14

71.38

66.12

62.16

62.45

72.23

61.69

63.34

75.92

72.53

68.63

65.8

75.99

65.08

66.73

10.86

10.03

8.03

8.03

11.55

14.33

8.71

29.14

23.24

29.07

34.21

28.5

31.8

33.54

60

66.73

62.91

57.76

59.95

53.86

57.75

Boldface estimates are statistically significant at the 5% level and represent pairwise comparisons relative to reference groups:
overall proportions among Medicare elderly were compared to the near-elderly controls, and minorities were compared to their
white counterparts (within treated/control groups).
* Physical limitations included functional or sensory limitations, or limitation in the Instrumental Activities of Daily Living or
in the Activities of Daily Living. Cognitive limitations included confusion, dementia, problems making decisions, or needing
supervision for own safety.
† Excluded respondent-specific cardiovascular conditions. Charlson Score based on D’Hoore’s version suing 3-digit ICD-9
codes.96
‡ Poor/Near-Poor: <125% FPL; Low-Income: ≥125 to <200 %FPL; Middle-Income ≥200 to <400% FPL; High Income
(reference): ≥400% FPL.
§ Same-pill combination products were counted as one drug
CV: Cardiovascular; ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers; SD: Standard
Deviation; IQR: Interquartile Range; CHD: Coronary Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial
Infarction; BMI: Body Mass Index; FPL: Federal Poverty Line; HMO: Health Maintenance Organization.
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to concurrently take multiple cardiovascular medications than whites, although they were
not seeing physicians as much (in Medicare). Interestingly, both blacks and Hispanics
tended to rate their relationship with providers more positively than whites.
Adherence Measurement and Validation
In validating our approach to derive refill days of supply from dispensed
quantities, we compared continuous PDC and dichotomous adherence calculated using
the derived distribution of supply days to those calculated using the actual days of supply
data in the 2010 sub-sample of our study sample. As shown in Table 2-2, we found the
PDC measurements based on derived days of supply to be in substantial agreement with
PDC measurements based on actual days of supply. Agreement was highest when a
refined approach was followed to derive days of supply from dispensed quantities
(Discretization 3 in Table 2-2; Lin’s concordance coefficient 0.97, κ-statistic 0.94). This
level of agreement was also consistent across drug classes, and at all stages of PDC
measurement. Using the “Discretization 3” scheme, we calculated PDCs for our entire
sample.
Multivariable DID Logistic Regressions
To substantiate our DID analysis, we graphically assessed the adjusted trends in
adherence disparities across treated and control groups from 2002 to 2010. Since
Medicare seniors and the near-elderly were different in important ways, particularly
health and socioeconomic status, examining trends adjusted for covariates was a more
appropriate approach to assess the common trend assumption central to the validity of
DID analysis. Figure 2-3 provides visual evidence to suggest that adherence disparities
in both groups were on similar trajectories until around 2005 when, interestingly,
adherence trends started to change among both seniors and their near-elderly
counterparts, even before the formal implementation of Part D in 2006.
In the main sample and subgroups, we estimated multivariable logistic models of
adherence as a function of the DID interactions, as well as the full set of covariates. The
magnitude of the DID coefficients, specifically the triple interactions of race, Medicare
coverage, and post-Part D, remained relatively stable to sequential adjustment for
covariates. This observation is illustrated in Appendix Figure A-1. Coefficient estimates
expressed in terms of odds ratios for all models, are listed Appendix Table A-3 and A-4.
All models had non-significant P values in Hosmer-Lemeshow modified Goodness-of-Fit
tests, indicating adequate fit for the data.
Ranking-and-Replacing H Distributions in the Main Analysis
Using the rank-and-replace procedure, we adjusted the marginal adherence
predictions (specifically, average probabilities of adherence) based on our estimated
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Table 2-2.
1,282)

Derivation of refill days of supply and validation of adherence measurement in the 2010 sub-sample (n=

Deriving refill days of supply from dispensed
quantities of pills

Agreement between the original PDC distribution based on actual
days of supply vs. PDC distributions derived via discretization of
dispensed quantities of refills
Continuous PDC

Scheme
Discretization 1

Discretization 2
Discretization 3

Dispensed
Quantity

Corresponding
Days of Supply

≤45
>45 but ≤75
>75
≤75

30
60
90
30

>75
0-7
8
9-14
15-16
20-44
45
46-75
76-119
120
>120

90
Same
16
Same
30
Same
90
30
90
30
90

Binary Adherence Classification

Pearson
Correlation

Lin's
Concordance

Observed
κ
Agreement Statistic

CStatistic

0.94

0.94

94.07%

0.88

0.94

0.96

0.95

95.71%

0.91

0.96

0.98

0.97

96.96%

0.94

0.97

Discretizations 1 and 2 are rather crude and have no concrete empirical basis. Discretization 3 is a refinement based on the
actual empirical distributions of days of supply vis-à-vis dispensed quantities, where “Corresponding Days of Supply” was the
most frequent (usually >90% of the time) days of supply observed for each quantity dispensed
25

Figure 2-3. Graphical assessment of the common trend assumption of adherence
disparities among Medicare seniors and near-elderly controls
Disparity is on the Y-axis and is empirically equal to the difference by race in the
adjusted average probability of overall cardiovascular medication adherence
(Pr(PDC≥80%)). PDC: Proportion of days covered; Tx: Treated; Ctrl: Control
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models with full covariate specification, for the H variables, namely: demographics,
health status, clinical need, and beliefs/preferences (including geography). By replacing
the distributions of H variables of minorities with those of their white counterparts, we
created counterfactual minority groups that possessed whites’ H distributions while
keeping their observed distributions of SES and other S variables. In essence, this is
similar to a hypothetical experiment where two clinically similar groups are randomly
assigned a treatment: here, the groups are the factual whites and the counterfactual
minorities, and the “treatment” is minority race with all the relevant facets of
disadvantage it typically involves. As Figure 2-4 shows, after ranking-and-replacement,
H distributions of minorities became virtually identical to those of whites.

Effect of Part D on Adherence Disparities in the Main Analysis
Table 2-3 shows the results of the main analysis. Following Part D introduction,
rates of adherence to cardiovascular medications improved a significant 59% among
Hispanic Medicare seniors (29% to 46%), 47% among whites (32% to 47%), and only
9% among blacks (35% to 38%). Among the near-elderly, adherence levels also
improved in 2007-2010, but with smaller magnitudes and significantly favored whites
over minorities. Prior to Part D, disparities in adherence were non-significant among
seniors. Over the same period (2002-2005), adherence was significantly better among
Hispanics than whites in the near-elderly population.
Following Part D implementation, there was a significant increase in white-black
disparities among seniors (+11 percentage points, P<0.01), and no significant change
among the near-elderly (+5% points, P>0.05). On the other hand, while there was no
statistically significant change in white-Hispanic disparities among seniors (-2% points,
P>0.05), there was a significant upsurge in these disparities among the near-elderly
(+14% points, P<0.05). Taking the trends in the treated and control groups together, we
estimated that Part D was associated with a significant 16%-point reduction in whiteHispanic disparities. There was however no statistically significant DID change due to
Part D in black-white disparities in overall cardiovascular medication adherence. These
findings are summarized in Figure 2-5.
Subgroup Analyses
In addition to estimating the overall average effect of Part D, we also assessed its
impact on the racial disparities among men, women, the dually eligible for Medicaid, and
the non-dually eligible. Additionally, we evaluated how results would change if we
included 2006 data or restricted the treated group to seniors 65-70 years of age. As shown
in Figure 2-6, the average DID estimate of Part D on adherence disparities in each of
these groups. Including 2006 data in the post-Part D period pushed the increase in blackwhite disparities further towards the null (+0.03 vs. +0.06% points in the main analysis,
P>0.05 for both), while yielding virtually the same reduction in white-Hispanic
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Figure 2-4. Observed and replaced distributions of the H linear predictor and
conditions count for whites and blacks
P values for Kolmogorov-Smirnov tests for the equality of black and white distributions:
Xβ distributions: observed white & black: P<0.001, observed white vs. replaced black:
P=1.000;
Condition Count: observed white & black: P<0.001, observed white vs. replaced black:
P=0.903.
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Table 2-3.
Overall cardiovascular medication adherence levels and disparities in
the treated/control groups before and after Medicare Part D
Medicare Elderly
Near Elderly Controls
Outcome
Pre-Part D
Post-Part D
Pre-Part D
Post-Part D
(2007-10)
(2002-05)
(2002-05)
(2007-10)
Estimate [95% CI]
Average Adherence
0.32
0.47
0.30
0.47
White
[0.30,0.34]
[0.45,0.48]
[0.26,0.34]
[0.43,0.51]
0.35
0.38
0.34
0.46
Black
[0.30,0.39]
[0.35,0.42]
[0.28,0.40]
[0.39,0.53]
0.29
0.46
0.39
0.42
Hispanic
[0.24,0.33]
[0.42,0.50]
[0.31,0.46]
[0.35,0.49]
Adherence Disparities
-0.03
-0.04
0.01
0.08
White-Black
[-0.07,0.02]
[-0.12,0.03]
[-0.09,0.07]
[0.04,0.12]
0.03
0.01
0.05
-0.09
White-Hispanic
[-0.01,0.08]
[-0.04,0.05]
[-0.03,0.13]
[-0.17,-0.01]
Change in Disparities over Time
White-Black
0.05 [-0.05,0.15]
0.11 [0.05,0.17]
White-Hispanic
-0.02 [-0.08,0.04]
0.14 [0.03,0.25]
Difference-in-Differences
White-Black
0.06 [-0.06,0.18]
White-Hispanic
-0.16 [-0.29,-0.03]
Boldface denotes P<0.05.
Estimates are probability-scale predictions, adjusted for health status/clinical need using
the rank-and-replace procedure. Disparities are the differences in the average probability
of adherence by race. Standard errors underlying confidence intervals were estimated via
Taylor series linearization and combined across 5 multiply imputed datasets.
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Figure 2-5. The impact of Part D impact on adherence disparities in overall
cardiovascular medication adherence
Pr(PDC≥80%) is the average probability of adherence. Capped spikes represent 95%
confidence intervals. Point estimates and 95% CIs are provided in the last four rows of
Table 2-3. PDC: Proportion of days covered; Tx: Treated; Ctrl: Control; DID:
Difference-in-differences
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Figure 2-6. The impact of Part D on adherence disparities in subgroups
Pr(PDC≥80%): average probability of adherence. Capped spikes represent 95%
confidence intervals. PDC: Proportion of days covered; DID: Difference-in-differences
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disparities as the main analysis. Among seniors 65-70 years old, Part D had the same
effect on white-black disparities, whereas the reduction in white-Hispanic disparities was
lower in magnitude and statistically non-significant (-9% points).
Further, as in Figure 2-6, while Part D was associated with a non-significant
change (-4%, P>0.05) in the disparity between white and black women, we found a
significant increase in white-black disparities among men (+21% points, P<0.05). DID
effects of Part D on white-Hispanic disparities by gender were statistically nonsignificant .Similarly, Part D effects on disparities by dual eligibility status were all nonsignificant.
We also investigated the DID effects of Part D on the disparities in adherence to
each cardiovascular medication class. As in the main analysis, Part D was associated with
no statistically significant changes in white-black disparities in adherence to each
medication class. White-Hispanic disparities followed the same direction as in the main
analysis, with beta-blocker adherence disparities showing a large, statistically significant
decrease (-30% points, P<0.05). Other changes in white-Hispanic disparities by
medication class were not significant. For reference, Appendix Table A-5 (Column 1)
lists all DID point estimates and confidence intervals for all subgroups.
Current Racial Disparities in Adherence in Medicare
While Part D was implemented to expand access to prescription drugs and
improve the quality of medication use, our data suggest that the policy may have had
some unintended consequences. In fact, as Figure 2-7 shows, large and statistically
significant disparities in adherence between white and black seniors remain in the postPart D era. Over 2007-2010, the white-black disparity in overall adherence was 8%
points in the entire sample, 11% points among men, 7% points among women, 8% points
among the non-dually eligible, and a high 19% points among the dually eligible (P<0.01
for all). White-Hispanic disparities, on the other hand, were much smaller (and
statistically non-significant), except among the dually eligible: 15% points (P<0.01).
We also examined levels of disparities in adherence to each drug class, over 20072010. While we did not detect statistically significant white-Hispanic disparities in
adherence to each medication class (all below 5% points, P>0.05), we found larger whiteblack disparities in adherence to ACE inhibitors/ARBs (6% points, P<0.05), betablockers (8% points, P<0.01), and diuretic agents (8% points, P<0.01). All point
estimates and 95% CIs for adherence disparities in Medicare over 2007-2010 are listed
for reference in Appendix Table A-5 (Column 2).
Sensitivity of Results to Disparity Definitions
Finally, we assessed the robustness of our estimates to various definitions of
disparities, starting from racial differences in crude, unadjusted adherence proportions to
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Figure 2-7. Racial disparities in overall cardiovascular medication adherence
among Medicare seniors in 2007-2010 by subgroup
Pr(PDC≥80%) is the average probability of adherence, predicted for each group using the
main logistic model and adjusted for H variables using the rank-and-replace procedure.
Capped spikes represent 95% confidence intervals.
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fully adjusted RDE disparities. Appendix Table A-6 lists the results of these analyses,
both DID estimates as well as estimates of disparities in the post-Part D period (2007-10).
When we estimated the DID effect of Part D on the racial differences in
unadjusted adherence proportions, we found no statistically significant change in whiteblack differences (+5% points, P>0.05) while white-Hispanic differences decreased by
18% points (P<0.01). Further, regardless of the level of adjustment of disparities to
various factors (e.g. demographics, health, beliefs, SES, etc), the DID effect of Part D
remained virtually the same: no statistically significant effect on white-black disparities,
and a 16%-point decrease in white-Hispanic disparities. As with our earlier analyses, the
magnitude of adherence disparities among seniors in the 2007-2010 period was not
sensitive to the how we empirically defined disparity (Appendix Table A-6, Column 2).
Discussion
Part D introduction was associated with a 59% improvement in cardiovascular
medication adherence among Hispanics, 47% among whites, and only 9% among blacks.
This finding largely agrees with a recent study, by Mahmoudi and Jensen, of the effects
of Part D on disparities in drug use and expenditure (also used MEPS data in a
difference-in-differences evaluation),62 which found that Part D significantly reduced
white-Hispanic disparities. These authors also reported Part D had no significant effect
on white-black disparities in measures of drug use and expenditure, except on the
disparity in total drug expenditure, which may have increased following Part D.62
The net reduction in white-Hispanic disparities is numerically the result of a
modest decrease in this disparity in the Medicare population and a large increase among
the near-elderly controls in the 2007-2010 period. There are a number of potential
explanations for the reduction in white-Hispanic disparities. First, our data and recent
literature59 show that after 2006, Hispanics were primarily covered by Part D Medicare
Advantage prescription drug (MA-PD) plans, significantly more so than whites and
blacks (41%, vs 33 and 29% among blacks and whites, respectively, in our sample). Most
MA-PD plan enrollees were enrolled in an MA plan prior to 2006;103 these beneficiaries
generally experienced a smoother transition to drug coverage with the advent of Part D
thanks to the subtle integration of the new benefit into the already existing managed care
structure.59 Further, these plans have been offering more generous drug coverage than
Part D stand-alone prescription drug plans (PDP),103 and their design is associated with
much less disparities in access to drugs and benefit information,59 as well as better
coordination of care.104
Hispanic seniors were more likely to be automatically eligible for the low-income
subsidy than blacks and whites (46%, vs. 30 and 8% among blacks and whites,
respectively, in our sample). They may also have been better primed for Part D given
their presumably higher participation rates in the pre-Part D drug discount card program
from 2004-2005 (this program was started by the Centers for Medicare and Medicaid
Services (CMS) to subsidize drug costs for non-dually eligible low-income beneficiaries,
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with income up to 135% of the federal poverty line, in anticipation of Part D
implementation).105 This could as well explain the decline in white-Hispanic adherence
disparities in Medicare starting in 2005, even before Part D launch in 2006.
Among the near-elderly, where 80% receive employer-sponsored insurance,
adherence disparities increased. As in Table 2-3, over 2007-2010, adherence rates rose
most for near-elderly whites, rose modestly for blacks, and least for Hispanics;
particularly worsening the disparity between whites and Hispanics. Our data show that
rates of prescription drug coverage declined 11% among near-elderly Hispanics, 7%
among blacks, and only 2% among whites, perhaps as a result of differential loss of
employment and employer-sponsored coverage. The economic recession and rising
unemployment rates that loomed in the 2007-2008 fiscal year might thus offer a potential
explanation for the increase in adherence disparities among the near-elderly controls.
Except among men, where Part D was associated with a significant 21%-point
increase in the white-black disparity, Part D was not associated with significant changes
in white-black disparities. For those over 65, however, average adherence to all
cardiovascular medications actually worsened 11% points more among blacks relative to
their white counterparts. A number of factors might explain this widening of the whiteblack adherence disparity. First, black seniors,60 especially non-duals and even those
enrolled in MA-PD plans59 found it much harder to get necessary information about their
covered prescription drugs compared to whites and Hispanics. Second, blacks were more
likely to enroll in Part D stand-alone PDPs, where they were more prone to significant
disparities compared to whites in accessing medications and benefit information,59 and to
lower overall adherence levels,106 relative to MA-PD plans. It is worth noting here that
the greater enrollment in MA-PD plans among Hispanics compared to blacks may be a
direct consequence of the disparate geographic concentration of these two groups: e.g.
Hispanics in the West enjoy greater access to these plans since Western states have much
higher market penetration by managed care plans.107
Third, our data show as above that black seniors were generally less likely than
Hispanics to be automatically signed up for the LIS. Black females, however, were more
likely than males to be eligible for the LIS, and, in fact, were more likely to enroll in Part
D coverage from the outset.60 This could explain why Part D was associated with a
significant increase in white-black disparities among men but not women. Fourth, blacks
are more likely than whites and Hispanics to have complex cardiovascular regimens, e.g.
concurrently taking multiple drugs (Table 2-1), which could be predisposing them to
persistently lower adherence rates compared to whites.
Our results, as in the literature,28-31 expectedly show that racial disparities in
adherence continue to exist in Medicare. White-black disparities were significant, while
white-Hispanic disparities were significant only among the dually eligible. The disparate
experiences we discussed above between minority seniors and their white counterparts
undoubtedly account for a sizable portion of these disparities. Three more Part D-related
issues set racial groups further apart. First, among non-Medicaid seniors who were still
eligible for the LIS (below 150% of the poverty line), minorities are less likely to be
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aware of this benefit,103 and predictably less likely to receive it. Second, these
beneficiaries (non-Medicaid, LIS-eligible minorities), especially high users, might be
more likely to fall in the coverage gap (so-called “donut hole”) further exacerbating their
medication-taking behavior.48 Third, recent evidence has shown that minorities are less
likely to meet Part D utilization-based eligibility criteria for medication therapy
management (MTM) services.63,64 This deprives scores of minority patients from a
benefit that is well-equipped to help them with their complex medication-related issues,
including adherence behavior.53
While it is important to identify access/quality issues that may disparately
compromise adherence behavior among minorities, it is at least equally as important to
envision adherence as a reflection of the structural, physical, and psychosocial
disadvantage racial minorities typically live in. Poverty, low educational attainment,
disordered physical and social environments, and policies that institutionalize racism are
systematically causal antecedents to almost every poor health outcome among
minorities.108 While achieving equity in these fundamental determinants of health must
remain a long-term goal for society, collaborative, creative, and holistic interventions by
healthcare professionals can provide some quick remedies in the short-run. In Medicare,
MTM programs can offer a platform to empower minorities to adhere to their appropriate
medication regimens and lifestyle recommendations, improve their health literacy, and
enhance their self-efficacy, central to a variety of self-management behaviors.109 Delivery
of MTM in collaborative/referral networks that bring together providers, pharmacists,
social workers, and community/home health workers can proactively identify and tackle
issues compromising medication adherence (and potentially other aspects of healthcare).
Further research110 is needed on how to optimize MTM delivery for minority and lowSES patients.
For effective interventional research on how to reduce adherence disparities,
greater appreciation of the complexity of adherence is warranted. Adherence should be
understood as a series of behaviors that start with keeping doctor’s appointments to actual
administration of medications, involving steps such as regularly filling prescriptions,
using reminders, exercising, and maintaining healthy diet.111 These contiguous behaviors
arise from complex interactions among multiple factors, pertinent to the patient and the
environment. Given this complexity, we need to build a deeper mechanistic
understanding of how this intricate system works and how/where it engenders disparities.
Parsing out this intricacy, through complex systems science and simulation approaches,
enables us to identify novel “leverage points” for effective intervention that were
potentially otherwise unidentifiable.112 Studying adherence this way can also help us
answer interesting clinical questions, some of which does arise in this study, such as why
the magnitude of adherence disparity differ by medication class (for example, why
disparities are larger in adherence to beta-blockers more than other classes, and only
among blacks).
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Limitations
The results of this study should be understood in the light of its limitations. First,
our derivation of refill days of supply from dispensed quantities was based on 2010 data
of MEPS, without validation against an external standard, claims data for example. Given
that previous research has demonstrated that MEPS prescription drug data are of
comparable quality to Medicare claims data,87 we believe benchmarking our analysis
solely to MEPS 2010 is credible. An alternative to “manually” deriving refill days of
supply from dispensed quantities would have been to formally impute days of supply in
earlier years of MEPS using a multiple imputation regression model informed by refilland respondent-level covariate data in the 2010 sample. We found however that
dispensed quantities overwhelmingly accounted for the variation in days of supply, with
all possible covariates explaining as little as 1% of the variation in days of supply (based
on R2 calculations). To do multiple imputation properly on missing data of this magnitude
(nine tenths of the data are missing, essentially), we would have needed to impute over
more than 90 datasets, which is computationally intensive and would require technically
challenging handling in subsequent analyses. Notwithstanding these caveats, the
substantial level of agreement we detected between adherence measures based on actual
vs constructed days of supply, consistently at all stages of adherence measurements and
across drug classes, reinforces the validity of our approach.
While data on dispensed quantities were 100% complete for all refills from 20022010, a large proportion of 2010 refills had missing days of supply data (about 33%). We
found the pattern of missing data to be very consistent across drug class and respondent
characteristics, indicating that a missing-completely-at-random (MCAR) assumption is
likely plausible. As such, we examined the pattern of refill days of supply vis-à-vis
dispensed quantities only among individuals with complete days of supply data for all
their listed refills. We also assumed that the patterns of supply days vis-à-vis dispensed
quantities in 2010 would hold in earlier years of MEPS. Although we believe this
assumption is likely true on average, changes in treatment guidelines and generic
availability might have affected the prescribed total daily doses of some cardiovascular
medications, especially in earlier years of our study period (for example, in 2002 and
2003 before the 7th Joint National Committee (JNC-7) guidelines on hypertension
management were issued/adopted).
Since we used the annual files of MEPS, sampled individuals were mostly
prevalent, rather than incident, users of the study medications, as it was not possible to
ascertain medication use in the year prior to the index refill. Although MEPS had dates
for when a drug was first taken, these dates were missing for about 80% of refills and no
inference could be made on whether respondents were new or prevalent users of
medications on the basis of these dates. Another complication of using the annual files is
that many covariates were not available at baseline (i.e. the first interview round), but,
rather at other time points (e.g. physical activity available in last round of the year). This
temporal ambiguity might have affected the identification of covariate associations with
adherence. We were primarily interested, however, in the identification of DID effects,
which we properly assessed over the pooled cross-sections before and after Part D. We
37

used covariates to make the DID assumptions more plausible and to fine-tune our
definitions of disparities.
We encountered the rather surprising finding that predicted disparity estimates
were not sensitive to various levels of adjustment using the rank-and-replace procedure.
It is unclear whether this is a statistical consequence of covariate assessment, outcome
variable construction, or it is indeed the case that our covariates could explain little about
adherence disparities. In the 2010 sample, we compared coefficient estimates from
models of adherence using: 1) actual vs constructed days of supply data and 2) using only
covariates temporally antecedent to adherence (e.g. first-round covariates on the righthand side with adherence in the remaining two rounds as the outcome) vs simultaneous
outcome-covariate models. We found no statistically significant differences in coefficient
estimates across these models.
An alternative to using the annual files would have been to use the longitudinal
two-year panel version of MEPS. This, however, would have cut our sample in half
(since annual files pool the two overlapping panels of the year), further inflating the
standard errors and rendering point estimates unstable and untrustworthy. We encounter
this problem to some extent in subgroup analyses (e.g. in the dually eligible sub-sample),
where quite large estimates are statistically no different from zero!
Based on previous research,47 we used the near-elderly as the control group that
provides the counterfactual scenario that would have prevailed in Medicare had Part D
not been implemented. Two issues challenge the validity of this control group. First, the
Medicare Modernization Act of 2003, which created Part D, also established the pre-Part
D drug discount card program for transitional assistance of low-income beneficiaries105
and further subsidized MA plans to expand their benefits, in 2004-2005.62 With minority
seniors taking advantage of these two changes together, the trend of adherence disparities
among seniors started to partially deviate from being parallel to its near-elderly
counterpart before Part D implementation in 2006. Further, growing enrollment of
minority beneficiaries in MA plans after Part D62 could also mean that some of the
observed changes in disparities might actually be attributed to changes in Medicare
Advantage and not directly to Part D. Second, the near-elderly experienced the shock of
the economic recession and job loss that loomed in 2007-2008. This has likely set the
trend of disparities among the near-elderly on an ascending path that would not have been
necessarily experienced by seniors in the absence of Part D (about 60% of the nearelderly were employed vs only 14% of seniors). Nonetheless, since the perfect control
group is lacking in this policy space (that is, 65-year plus old seniors without Medicare),
the near-elderly make a reasonable control group to study changes in healthcare delivery
and financing in Medicare. Despite the aforementioned limitations, findings in this study
are consistent with the published literature and can be readily accounted for by the
observed changes in healthcare access and delivery among Medicare seniors and the
near-elderly.
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Conclusion
In a nationally representative sample from MEPS, we used a quasi-experimental
difference-in-differences design to evaluate Medicare-wide effects of Part D introduction
on the racial disparities in adherence to cardiovascular medications. We took a nuanced
approach to conceptualizing and estimating adherence disparities according to the IOM
framework, and performed multiple subgroup and sensitivity analyses to assess the
robustness of our conclusions. Our results suggest that following Part D, the overall
cardiovascular medication adherence disparity between white and Hispanic seniors has
narrowed by 16% points, whereas there was no statistically significant change in the
white-black disparity, except among men where it increased by 21% points.. Significant
adherence disparities continue to remain among the elderly in Medicare, especially
among dually eligible beneficiaries. Differential awareness of and access to benefits, such
as the LIS among the non-dually eligible, as well as the institutionalized disparity in
access to MTM services may be immediate targets for policy interventions to improve
adherence behavior and the overall quality of medication therapy in Medicare. Research
on the determinants of adherence disparities and on optimizing the delivery of
interventions, such as MTM, to answer the needs of minority beneficiaries is much
needed.
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CHAPTER 3. RACIAL DISPARITIES IN ADHERENCE TO
CARDIOVASCULAR MEDICATIONS AMONG THE ELDERLY IN
MEDICARE: LOOKING BEYOND THE MEAN
Background
In cardiovascular diseases, adherence to evidence-based medication regimens is
key to achieving the goals of pharmacotherapy and slowing disease progression.15,74
Lower medication adherence rates exist among racial/ethnic minorities, relative to whites,
even in settings with equitable access to prescription drugs.11,33 In the Medicare program,
where Part D introduction enhanced adherence by improving the affordability and quality
of use of medications,41,45,46,53 adherence disparities continue to persist. After Part D
implementation, Holmes et al reported that among Medicare seniors with uncomplicated
hypertension, blacks and Hispanics were about 45% less likely to be adherent to their
antihypertensive medications, including alpha- and beta-blockers, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), Calcium channel
blockers (CCBs), diuretics and vasodilators.28 Zhang et al examined adherence to ACE
inhibitors/ARBs and diuretics among seniors with heart failure, and found blacks,
Hispanics, and Native Americans to be about 40% less likely to achieve adherence than
whites.29 Zhang et al also reported that black and Hispanic seniors surviving acute
myocardial infarction (AMI) were 20-30% less likely to adhere to beta-blocker, ACE
inhibitor, or statin therapy for 6 months or a year post-infarction.30 In an analysis across
race and gender of AMI survivors, Lauffenburger et al reported that black and Hispanic
women were least likely (having about 30-36% lower odds), compared with white men,
to be adherent to these post-AMI preventive therapies.31 In a meta-analysis of published
studies, Lewey et al estimated that generally patients of non-white race were at about
50% higher odds of non-adherence to statins than whites.32
Substantial disparities exist between whites and racial minorities in the control of
blood pressure and cholesterol levels,10,113-115 and predictably in cardiovascular disease
progression and mortality.3,4,6,7 Among the multiple social and behavioral factors that
might explain the disparities in these risk factors,8,12-14 the disparities in cardiovascular
medication adherence are repeatedly identified as a key culprit.7,8,12,15 Although extant
evidence documents adherence disparities, a full understanding of these disparities is still
lacking. One missing piece in this puzzle is a greater appreciation of how these disparities
vary across the distribution of adherence where different adherence levels may represent
populations with distinct patterns of behavior. Current literature have predominantly
documented disparities in the probability of 80% adherence, which has been the
traditional cutoff for adherence classification. Apart from the arbitrary nature of this
cutoff and its apparent lack of a clear clinical rationale,16,116,117 it represents only one
level of adherence behavior and indiscriminately lumps potentially distinct patterns of
behavior below and above 80% medication possession.
Studying disparities in the probability of 80% adherence (or some other cutoff),
albeit informative, thus risks ignoring disparities among populations at other levels of
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adherence, which may be driven by potentially different factors and amenable to distinct
interventions. Further, studying adherence (as a continuous outcome) in typical
regression frameworks falls prey to a similar phenomenon, where the modeled outcome
is mean adherence conditional on the included set of control variables. Because of the
nature of the mean as a summary statistic of central tendency, disparities at other
locations in the adherence distribution will only “show up” in the mean if they are
relatively large. Thus, using a single cutoff or a continuous measure of adherence may
obscure disparities that occur at other locations in the adherence distribution, even ones
that may be significant and policy-relevant.
Quantile regression70,118-120 is a powerful technique that allows assessment of how
predictors (e.g. race in this study’s context) influence the central and non-central
locations, scale, and shape of the outcome distribution.121 Widely applied in labor
economic evaluations, such as in the study of wage inequality,120 applications of quantile
regression to study health disparities have increased in recent years,122-127 including a few
applications in the context of adherence disparities.128,129 Besides enabling the
investigation of the heterogeneity of adherence disparities across the distribution, quantile
regression is well suited to accommodate the quasi-continuous left-skewed distributions
of medication possession measures.128 In one interesting example, Gebregziabher and
colleagues128 showed that black-white disparities in medication adherence among type 2
diabetes patients persisted across the distribution of the medication possession ratio
(MPR) and particularly around 60% MPR, whereas white-other race disparities were
significant only at the lowest quantile (corresponding to ~ 40% MPR) and were not
detectable at the mean. Juarez et al129 also examined disparities in adherence to antidiabetic and lipid-lowering medications between Pacific Islander and white Americans in
Hawaii. She found that disparities relative to whites were largest and most significant at
the 25th percentile of the PDC (proportion of days covered; a variant of the MPR)
distribution and decreased monotonically towards the higher percentiles of the
distribution. These findings point to sub-populations where adherence disparities may be
most amplified and potentially deserving priority intervention.
In this study, we sought to explore the heterogeneity of racial disparities across
the distribution of adherence to cardiovascular medications, among Medicare seniors
after 2006. We used a versatile unconditional quantile regression estimator, recently
developed by Firpo, Fortin, and Lemieux.70 As we further explain in the “Statistical
Analysis” section, in multivariable regression settings where predictors may have
interactive effects on the outcome, making the assumption of additive covariate effects
unrealistic, unconditional quantile regression directly provides the appropriate estimates
of marginal effects of covariates on outcome quantiles.130
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Methods
Data Source
We used longitudinal data from the household component of the Medical
Expenditure Panel Survey (MEPS), panels 11 to 14 spanning years 2006 to 2010. MEPS
is an annual overlapping panel survey of the US civilian non-institutionalized population,
administered by the US Agency for Healthcare Research and Quality (AHRQ).131 The
primary focus of MEPS is on healthcare access, use, and expenditure in the United States,
enabling calculation of national impact estimates for a wide variety of health policy
changes. Each year MEPS panel participants are sampled from the previous year’s
respondents to the National Health Interview Survey (NHIS), with oversampling of
minorities and other policy-relevant groups (such as adults with functional limitations
and low-income households).131 Each panel is then prospectively followed for two
calendar years and their data are collected over five rounds of computer-assisted personal
interviewing. Rounds 1 and 2 fall in the first year, rounds 4 and 5 fall in the second year,
while round 3 spans the end of the first and the beginning of the second year. AHRQ
provides two types of main data files that can be linked to Medical Conditions and event
files: longitudinal and annual/cross-sectional (known as Full Year Consolidated Data)
files. For this study, we linked the longitudinal panel files to the Medical Conditions and
Prescribed Medicines event files. Although all MEPS data are reported by respondents
during round interviews, further detailed health service use data, including on
prescription drugs, are collected from a sample of providers (e.g. medical and pharmacy)
with respondents’ permission. Then these data are used to supplement respondents’ selfreports of health service use and expenditure. Of particular relevance to this study, the
quality of MEPS prescription drug data, as well as Medicare Part D enrollment has been
shown to be comparable to that of claims data.87,88 MEPS also provides very rich data on
respondents’ sociodemographics, health and chronic conditions, as well as experience
with providers and the healthcare system, allowing a thorough study of adherence as
shaped by these determinants.
Cohort Identification
We included MEPS respondents who were:
1) Continuously included in all MEPS survey rounds for the two panel years,
excluding those who went “out of scope” because of death, institutionalization, or
other reasons.
2) Medicare beneficiaries 65 years or older as of Round 1, who reported receiving
Medicare until the end of the second year (Round 5).
3) Non-Hispanic white (henceforth “white”), non-Hispanic black (henceforth
“black”), or Hispanic. We excluded other racial/ethnic groups and did not further
distinguish Hispanic subgroups as their small sample sizes limited such
inferences. MEPS ascertains race/ethnicity as follows:132 first, respondent’s selfreport of their race/ethnicity is the primary way to procure this data. Then, if not
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available, race/ethnicity is obtained from the originally collected NHIS data in the
year prior to joining the MEPS panel. Finally if not available either way, MEPS
assigns race/ethnicity based on respondent’s relationship to other members of
his/her household starting with blood relatives in the immediate family. MEPS
survey questions assessing race/ethnicity have been consistent since 2002.132
4) Had at least one of the following six prevalent conditions in both year 1 and year
2: hypertension, hyperlipidemia, angina, congestive heart failure, myocardial
infarction, or stroke, listed in the linked Medical Conditions file. Clinical
Classification Codes and 3-digit ICD-9 codes in MEPS were used to identify
respondents with these conditions.133 Appendix Table A-1 (Chapter 2) lists all
the conditions and their associated codes. Identified respondents had at least one
event (inpatient, outpatient, or prescription drug) associated with one or more of
these conditions.
5) Were prevalent users of at least one chronic cardiovascular medication of the
following classes: ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs),
HMG-CoA Reductase Inhibitors (Statins), Beta-blockers, Calcium Channel
Blockers, Diuretics, or combination products of these medications. Use was
defined as having at least one refill for the same medication class in both years.
Second-year refills were used to estimate adherence.
Since our study sample only included a small portion of MEPS respondents, we
pooled MEPS panels 11-14 by year to create one analytical file with adequate sample size
for our analyses. Pooling MEPS data is commonly practiced and survey design variables
in MEPS files for our study period specify a common variance structure that takes into
account pooling when calculating standard errors.89 Our final analytical file contained
pooled data for year 1 (2006-2009), the baseline year, and year 2 (2007-2010) where
adherence was estimated.
Adherence Measurement
Using refill records for included respondents in the second year, we measured
adherence to each medication class as the proportion of days covered (PDC) by refills for
any medication from that class, expressed as a percentage and capped at 100%. Thus, in
the case of overlapping refills for two beta-blockers, for example, only one refill was
counted towards calculation of the beta-blocker-specific PDC. ACE inhibitors and ARBs
were also considered a single class for this purpose. Component medications of
combination products were also counted towards their respective classes. Since MEPS
does not collect refill dates, an index date specific to each medication class was identified
for each respondent as the first day of the round in which the first refill (for the specific
class) occurred. These rounds were either the fourth, the fifth, or the portion of the third
round that had fallen in the second year. Respondents were then followed until the last
day of the fifth round, which corresponded to December 31st of the second year in the
panel for all participants. Inpatient days were excluded from the follow-up period. For all
classes, while a majority of respondents (55-60%) had January 1st of the second year (i.e.
the part of round 3 that fell in year 2) as the class-specific index date, more than 95% of
43

index refills had occurred by March of the second year. To summarize adherence over all
medication classes, we calculated a respondent-specific PDC that was the average of all
his/her class-specific PDCs. The main outcome variable was the overall continuous PDC.
We explored class-specific adherence in sub-group analyses.
Although MEPS provides extensive data on prescription refills, including
dispensed quantity, strength, dosage form, and therapeutic class/subclass, data on days of
supply were not routinely collected until 2010. We used 2010 data, which was the second
year of Panel 14 in our sample, to characterize the patterns of observed days’ supply as
they relate to dispensed quantities of drug refills. In so doing, we identified the most
frequent number of supply days furnished by each level of dispensed quantity. Next, we
derived a scheme to smoothly approximate the distribution of days of supply for use in
prior years of MEPS (where actual days of supply data are not available). Then, in 2010
data, we calculated PDCs as explained above using the actual and constructed days of
supply distributions. To assess the validity of our derivation, we used Lin’s concordance
coefficient90,91 to compare the constructed distribution of days of supply as well as the
PDC based on it, to the actual distribution and its associated PDC. (We also derived
binary adherence at PDC≥80% based on the two distributions, and compared them using
C-statistics). Then, we used our validated scheme to construct refill days of supply from
dispensed quantities in all panels. The validity of computing refill days of supply in
earlier years using the pattern of days of supply vis-à-vis dispensed quantities in 2010
hinges on the potentially plausible assumption (based on discussions with two
cardiologists with more than 20 years of practice experience) that the dosing frequency of
a given strength of a specific cardiovascular drug has been stable over 2007-2010 in a
specific patient population. (For example: for the same patient population, if a 30-pill
refill of 40-mg simvastatin covers 30 days in 2010, on average, this would have also been
true in 2007).
Covariates
We modeled the PDC distribution as a function of a series of baseline covariates
assessed over the first year of the MEPS panel. In addition to race/ethnicity identifiers,
which were the primary predictors of interest, we used data on respondents’ demographic
characteristics; geographic location; self-reported health and functional (physical/
cognitive) status; depressive symptoms;134 cardiovascular conditions and other comorbid
conditions; beliefs regarding health, risk, and insurance; income and poverty status, and
educational attainment; health behaviors; type of primary insurance coverage for
prescription drugs; financial and pill burden associated with medications; access to/use of
primary care and other health services; and experience with providers and satisfaction
with the healthcare system.
In addition to binary indicators of which cardiovascular condition(s) respondents
had in the baseline year, we also enumerated other comorbid conditions, such as diabetes,
asthma, and cancer, and calculated a modified version of the Charlson comorbidity score
(excluding respondent-specific cardiovascular conditions and depression) adapted for use
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with 3-digit ICD-9 codes in MEPS.96 For socioeconomic status (SES), we used MEPSprovided categories of income as a percent of the Federal Poverty Line (FPL) and
categorized years of education into three levels: less than high school, high school
diploma (12 years), and above high school. High-income and having education beyond
high school served as the reference categories.
For drug coverage status, we used a series of variables on insurance status as well
as amounts paid by each payer for prescription drugs over the first year to ascertain drug
coverage for each respondent. We identified three principal categories of coverage, as of
December 31st of the first year: those who had no evidence of drug coverage by any
payer, those who had Medicare Part D, and those who had a private source of drug
coverage including employer-sponsored. Among Part D enrollees, we identified those
who were concurrently enrolled in Medicare managed care and those who were not. Thus
we were able to further split Part D recipients into those who had Medicare Advantage
Part D plans (MA-PD) and those who were just enrolled in stand-alone Part D plans
(PDPs) with no evidence of enrollment in MA. Further, we created an indicator for
whether a Part D respondent was deemed eligible for auto-enrollment for the low-income
subsidy (LIS), which included dually eligible beneficiaries and beneficiaries receiving
Supplemental Security Income (SSI) (both variables were available in MEPS).55,57 Other
LIS-recipients who are not automatically enrolled but their income is below 150% FPL
and have limited assets must apply to receive the LIS.54 Although we validated the
characteristics of these sub-categories of Part D recipients against the
literature,54,56,58,59,103 ascertaining drug plan type or actual receipt of the LIS is not
possible in MEPS.
Disparity Definition
In the primary multivariable analysis, we defined disparities in adherence
following the Institute of Medicine’s (IOM) framework for assessing healthcare
disparities.66,92 The IOM contends that racial healthcare disparities are differences in
healthcare that are not justified by the clinical appropriateness, health status needs, or by
patients’ informed preferences and attitudes towards medical care.66 Healthcare
disparities arise through two broad mechanisms:66 first, the legal and regulatory
environment in which healthcare systems operate, including policies and practice
patterns, insurance coverage, SES, and other differential factors that constrain healthcare
use disproportionately for minorities,92 and second, discrimination at the patient-provider
level, which may take multiple forms.95 As such, the IOM framework attempts to identify
the contributions of the current structural impediments to achieving equity in the
healthcare system, which are extrinsic to patients and potentially amenable to appropriate
policy and clinical practice interventions.
Accordingly, we defined racial disparities in adherence as the differences in
adherence across clinically comparable racial groups that arise due to inequitable social
and health-system factors, including SES, insurance coverage, access to primary care,
and potential discrimination in the clinical encounter. Clinical comparability enables
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isolating the disparities potentially engendered by social and health system factors,
similarly to a hypothetical experiment where there are two groups with identical health
profiles but only one receives racial disadvantage (socioeconomic and otherwise) as the
treatment. Since the two groups possess identical health and disease burdens, their
different rates of healthcare use (medication, in our case) must then be attributable to the
“treatment,” that is racial disadvantage.
We took a straightforward approach67,122,125,126 to empirically study adherence
disparities as defined above, where we adjusted the association between race/ethnicity
and adherence only for the effects of demographics, geographic location, health status
and medical conditions, and beliefs. Only controlling for these variables balances out
health characteristics of minority and white groups and allows the effects of variables
potentially mediating disparities, such as SES variables, to be reflected in the
race/ethnicity coefficients. This is also consistent with the empirical principle that if one
wishes to estimate the total effect of a variable, race/ethnicity in our case, one should not
adjust for intermediate variables on the causal pathway between the variable of interest
and the outcome.135 Notwithstanding our a priori empirical definition of adherence
disparities, we explored in secondary analyses the sensitivity of our primary findings to
various definitions of disparities, through sequentially adjusting for groups of covariates
up to full adjustment for all available covariates.
Statistical Analysis
We used unconditional quantile regression to explore how racial disparities
change across the distribution of adherence. Quantile regression118,120 is analogous to
ordinary least squares (OLS) regression except that it models conditional outcome
quantiles instead of conditional means. Originally started as median regression, quantile
regression allows exploration of the dependence of the outcome on covariates at other
locations of the distribution, i.e. other quantiles. Mathematically, as Equation 3-1 shows,
the qth conditional quantile of an outcome variable Y on covariates X can be written as,
q
Qq ሺYȁXሻ=αෝq + σKk=1 Xk .βqk (Eq. 3-1)

where 0 < q < 1 is the modeled quantile, indicating that the proportion of the sample
modeled is below the quantile q. This is not to say that quantile regression runs on a
subset of the population. It means that the distance of data points from the quantile line,
βk, is measured as a weighted sum of the absolute vertical distances (deviations) from the
line, and the weight is (1-q) for the observations below the line and (q) for those above
the line.121 For example, the 70th quantile regression can be thought of as a plane that
passes through the sample, weighing observations above it by 0.70 and observations
below it by 0.30.126 βk is estimated by minimizing these weighted absolute deviations.
Typical quantile regression applications have used conditional quantile
regression, as described above. The quantile regression coefficient of a variable is an
estimate of the effect of that variable on the conditional outcome quantile. As in linear
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regression, when there are no covariates or when covariate effects are assumed to be
independent of the values of other covariates (that is, no interaction/effect modification),
these coefficients are also consistent estimators of the effect on the unconditional mean of
the outcome distribution.130 This latter property of regression coefficients is what makes
them interpretable as population-level effects, which are of primary interest in most
empirical research.130 When covariate effects are realistically not additive/parallel but
rather interactive (for example, the association between race and adherence may differ by
geographic region), conditional and unconditional effects start to diverge.130 In such
(fairly typical) cases, quantile regression coefficients do not provide consistent estimates
of covariate effects on the unconditional distribution. In mean regressions, such as
generalized linear models and logistic regression, unconditional (average) marginal
effects can be recovered as recycled predictions following model estimation.99,136 In the
case of quantile regression, however, conditional effects captured by coefficients are very
complicated to convert to unconditional effects.
Firpo, Fortin, and Lemieux70 recently developed a computationally simple
approach that directly estimates unconditional quantile regression coefficients. Their
approach relies on modeling a quantity known as the re-centered influence function (RIF)
of outcome quantiles directly instead of the outcome quantiles themselves. The influence
function (IF) is a mathematical tool that assesses the “influence” of a particular
observation on a distributional statistic without having to recalculate that statistic.70 The
RIF is obtained by adding the IF of the statistic to the statistic itself. An interesting
property of the RIF is that its expected value is equal to the statistic. For example, if we
regress RIF of mean PDC in a linear regression on X variables, the IF would basically be
the residual (difference between observed y and estimated μ PDC) at a particular PDC
value (the observation of interest). Estimated RIF gives the mean PDC itself. As shown in
Equation 3-2, in simple notation,
IFሺy; μሻ=ሺy-μሻ
RIFሺy; μሻ=μ+ሺy-μሻ=y

(Eq. 3-2)

We would also get precisely the same coefficients as in the standard case of
regressing the mean itself instead of its RIF. Using this approach, Firpo, Fortin, and
Lemieux70 demonstrated that modeling the RIF of each outcome quantile as a function of
explanatory covariates in OLS regression yields coefficient estimates that are essentially
the effects of covariates on the unconditional outcome distribution. Racial disparity
would thus directly equal to the coefficient of the race variable, without the need to do
any further computation.
Using the -rifreg- STATA routine,137 and following the recommendations on
estimating RIF and the probability density function at each quantile,70,130 we estimated
unconditional quantile regressions of PDC at the 10th, 20th, up to the 70th quantile (where
adherence was almost perfect, PDC ~ 100%) as a function of race/ethnicity indicators as
well as other covariates as explained above. All analyses accounted for MEPS survey
design by including longitudinal weights and design variables as appropriate. We
estimated standard errors using 5,000 block bootstrap replications, to account for
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clustering of survey data in primary sampling units. Since rates of missing data in some
covariates (e.g. belief and experience with providers) were as high as 13%, we used
multiple imputation using chained equations (MICE) to impute missing data for each of
these variables.100 Regression analyses were estimated separately in each imputation
dataset and then point estimates and standard errors were combined using Rubin’s
rules138 to produce a single set of estimates that took into account uncertainty due to
imputation. All analyses were carried out in STATA® 13 (StataCorp; College Station,
TX).
Results
Sample Characteristics
The study sample included 3,749 MEPS respondents, nationally representing
20.7 million Medicare seniors with cardiovascular diseases. Average length of follow-up
for adherence measurement was 342 days. Table 3-1 lists characteristics of sampled
respondents by race. Compared with their white counterparts, black seniors were more
likely to be female, less likely to be married, and substantially more likely to reside in the
South. Hispanic seniors were also less likely to be married and substantially more likely
to reside in urban areas and in the West. Both black and Hispanic seniors had worse selfrated health and higher rates of cognitive limitation than whites. They were also more
likely to have hypertension and diabetes but less likely to have hyperlipidemia.
Interestingly, blacks were only half as likely to be diagnosed with depression but twice as
likely to screen positive for depressive symptoms using the Patient Health Questionnaire
ver. 2 (PHQ-2).134 Hispanics were also about twice as likely as whites to report
depressive symptoms on the PHQ-2 scale, but no more likely than whites to be diagnosed
with depression. Both minority groups were also much less likely to believe they did not
need medical care to manage illness. Both were less likely to exercise and more likely to
be obese.
Black and Hispanic seniors were much more likely to be at the lowest levels of
income and education. For more than 50% of Hispanics, English was not the primary
language spoken at home or with others. For drug coverage, nearly 19% of the cohort had
no evidence of drug coverage in MEPS, including from federal sources. Nonetheless,
rates of plan enrollment were very similar to what the Kaiser Family Foundation (KFF)
reported for January 2010.54 Overall Part D enrollment was 61.8%. In our sample of
elderly beneficiaries with cardiovascular diseases, the overall rate of auto-enrollment in
the LIS was ~10% (15.5% among Part D enrollees in the sample). Whites were more
likely than either minority group to have no drug coverage, and less likely to be eligible
for automatic receipt of the LIS. While Hispanics were more likely to have MA-PD
coverage, blacks were more likely to be enrolled in PDPs. Both minority groups were,
however, less likely than whites to have employer-sponsored or other private coverage.
These findings were also consistent with the literature on drug coverage by race.59,103,139
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Table 3-1.

Characteristics of sampled Medicare seniors by race

Characteristics

White

Black
Hispanic
% (unless otherwise noted)

Demographics
Age (Mean±SD)
75.42±6.34 74.55±6.13
Female
56.69
63.41
Married
56.08
31.31
Urban/MSA
79.34
84.06
Census Region
Northeast
21.24
18.22
Midwest
25.70
15.41
South
34.48
59.88
West
18.57
6.49
Self-Reported Health
Excellent
13.40
7.65
Very Good
31.32
23.72
Good
33.61
35.31
Fair
16.58
25.64
Poor
5.09
7.68
Any Physical
62.29
63.48
Limitation*
Any Cognitive
9.78
18.24
Limitation*
Medical Conditions
Quartiles of Charlson Comorbidity Score

Overall

74.51±6.04
58.74
45.14
91.77

75.28±6.31
57.44
53.08
80.60

13.67
6.95
42.84
36.53

20.46
23.50
37.36
18.68

6.66
17.08
35.00
30.41
10.84

12.42
29.67
33.86
18.34
5.71

66.69

62.69

17.03

11.04

1st/2nd Quartiles

56.35

46.43

43.37

54.57

3rd Quartile

31.53

39.52

40.54

32.86

12.12

14.05

16.09

12.56

5 (3, 8)

4 (2, 6)

4 (2, 7)

5 (3, 7)

82.57
66.24
21.79
4.02
8.89
6.00
10.85
7.41
22.42

93.65
56.95
17.38
3.54
7.21
6.14
5.35
14.69
36.50

89.86
58.53
21.26
2.80
7.63
4.86
11.30
16.42
41.71

84.07
64.88
21.35
3.90
8.65
5.94
10.38
8.68
25.00

th

4 Quartile
Count of Comorbid
Conditions,†
Median(IQR)
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke
Depression Diagnosis
Depressive Symptoms
Diabetes
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Table 3-1.

(Continued)

Characteristics

White

Asthma
8.40
Emphysema
6.90
Arthritis
60.21
Beliefs
More Likely to Take
16.45
Risks
Can overcome illness
11.31
without medical care
Does not need health
4.45
insurance
Behaviors
Current Smoker
8.30
Had
Moderate/Vigorous
47.43
Exercise
Obese (BMI≥30)
28.53
Socioeconomic Status
Income: ‡
15.38
Poor/Near-Poor
Low-Income
15.95
Middle-Income
31.44
High-Income
37.23
Education:
19.73
Less than High School
High School Diploma
52.97
College and Beyond
27.30
Language:
Interview Not in
0.13
English
No English at Home
1.13
Primary Drug Coverage- End of Year 1
No Known Rx
19.85
Coverage
Part D: PDPs
35.96
Part D: MA-PD
23.00
Employer/Other Private
21.19
Auto Eligible for PD
5.72
Low-Income Subsidy

Black
Hispanic
% (unless otherwise noted)
9.98
11.35
5.12
3.12
57.22
66.25
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Overall
8.78
6.48
60.56

14.13

12.84

16.00

7.05

7.11

10.64

5.01

5.81

4.60

10.91

6.10

8.39

37.43

38.65

45.92

36.67

35.39

29.73

32.56

31.51

18.03

20.71
31.15
15.58

21.05
30.54
16.89

16.73
31.35
33.89

47.42

65.57

25.31

39.00
13.59

22.77
11.66

49.68
25.01

0.00

52.00

3.61

1.02

59.91

5.08

12.99

11.77

18.68

43.66
30.37
12.97

39.55
41.72
6.96

36.91
24.93
19.49

25.92

38.99

9.81

Table 3-1.

(Continued)

Characteristics

White

Black
Hispanic
% (unless otherwise noted)

Use of CV Drug Classes in Year 2
ACE Inhibitors/ARBs
58.17
Statins
60.11
β-blockers
41.67
Ca Channel Blockers
19.72
Diuretics
43.85
Healthcare Use at Baseline

59.68
49.56
37.08
36.54
54.65

No. of concurrent CV Medications §
0-1
34.95
32.53
2-3
56.26
55.27
≥4
8.78
12.21
No. of concurrent medications overall
0-1
9.96
14.13
2-4
44.51
44.51
≥5
45.53
41.37
No. of Pharmacies
1 (1, 2)
1 (1, 1)
Used, Median(IQR)
Average Copay for CV
15.62
9.17
Drugs ($2010),
(6.70,
(3.07, 21.31)
Median(IQR)
31.84)
Had a Usual Source of
97.43
95.58
Care
Any Inpatient Stay17.23
17.88
Previous Year
Any Emergency
Department Visit17.33
21.06
Previous Year
Quintiles of ambulatory physician visits (range)
Q 1 (0-2)
17.99
28.83
Q 2 (3-4)
18.12
21.21
Q 3 (5-7)
20.47
21.75
Q 4 (8-12)
22.18
13.14
Q 5 (≥13)
21.23
15.08
Experience with Providers
Very Satisfied with
Received Healthcare

58.67

53.87
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Overall

69.16
48.71
44.33
29.71
35.29

59.05
58.38
41.43
21.93
44.26

37.34
55.94
6.72

34.89
56.15
8.96

12.82
48.76
38.42

10.54
44.80
44.67

1 (1, 1)

1 (1, 2)

6.67
(2.38, 21.19)

14.44
(5.79, 30.69)

95.13

97.11

14.81

17.13

20.12

17.86

24.92
22.09
19.62
17.85
15.51

19.45
18.67
20.53
21.07
20.29

52.69

57.83

Table 3-1.

(Continued)

Characteristics
Provider Always
Explained
Provider Always
Listened
Provider Always
Respected
Sample Size
Weighted Population

White

Black
Hispanic
% (unless otherwise noted)

Overall

56.79

58.28

50.71

56.52

61.24

62.36

54.69

60.90

63.11

64.49

56.91

62.82

2,585
17,447,543

703
1,891,319

461
1,396,116

3,749
20,734,978

Boldface estimates have P<0.05 for pairwise comparisons relative to whites.
* Physical limitations included functional or sensory limitations, or limitation in the
Instrumental Activities of Daily Living or in the Activities of Daily Living. Cognitive
limitations included confusion, dementia, problems making decisions, or needing
supervision for own safety.
† Excluded respondent-specific cardiovascular conditions.
‡ Poor/Near-Poor: <125% FPL; Low-Income: ≥125 to <200 %FPL; Middle-Income ≥200
to <400% FPL; High Income (reference): ≥400% FPL.
§ Same-pill combination products were counted as one drug
CV: Cardiovascular; SD: Standard Deviation; IQR: Interquartile Range; CHD: Coronary
Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial Infarction; BMI:
Body Mass Index; FPL: Federal Poverty Line; PDP: stand-alone prescription drug plan;
MA-PD: Medicare Advantage Prescription Drug plan; PD: Part D; ACE: AngiotensinConverting Enzyme; ARB: Angiotensin II Receptor Blocker
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Exposure to ACE inhibitors was highest among Hispanics and was similar among
whites and blacks. Statin use was much less among minorities compared to whites,
perhaps reflecting the lower prevalence of (diagnosed) hyperlipidemia. The use of
Calcium channel blockers was higher among minorities than among whites. Blacks were
the most exposed to diuretics whereas Hispanics were exposed the least. Black seniors
were more likely to concurrently take multiple cardiovascular medications, but
nonetheless more likely to take less medications concurrently overall. Both blacks and
Hispanics were less likely to report having a usual source of care and were more likely to
have fewest ambulatory physician care. No statistically significant differences were
present in rating the experience with providers or satisfaction with healthcare by race.
Adherence Validation
In the 2010 sub-cohort, we studied refill days of supply vis-à-vis dispensed
quantities to build a scheme that would allow us to derive days of supply from dispensed
quantities in earlier panels of MEPS, where days of supply data were not available. Based
on identifying the most frequent number of supply days furnished by each level of
dispensed quantity, we found the following scheme to work best for constructing days of
supply from dispensed quantities, (quantity vs days of supply): [8: 16; 15-16: 30; 45: 90;
46-75: 30; 76-119: 90; 120: 30; >120: 90; all other quantities: identical days of supply].
This scheme also worked equally well across medication classes. Comparing the PDC
distribution that is based on constructed days of supply versus the one based on actual
days of supply in the 2010 sub-sample gave a Lin’s concordance coefficient of 0.97,
indicating substantial agreement. Figure 3-1 shows how the two PDC distributions were
almost identical. (We also observed agreement of similar proportions when we compared
binary adherence classifications (at PDC≥80%) based on the two distributions: C-statistic
0.97).
Adherence Distribution by Race
Figure 3-2 and Table 3-2 compare the observed distributions of the average
overall PDC by race. Relative to whites, the PDC distribution for black seniors was
shifted to the left at central and non-central quantiles, with higher density than whites at
the lower quantiles (where adherence is poor). For Hispanics, the disparity relative to
whites was not apparent at the center of the distribution, and fluctuated across the
quantiles below the median. Adherence among white seniors was predominantly more
likely to fall in upper PDC quantiles than either minority group.
Adjusted Adherence Disparity Estimates
In the primary quantile regression analyses, we adjusted the association between
race/ethnicity and PDC for health/clinical need, including demographics, health
status/medical conditions, and the number of concurrently used medications, as well as
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Figure 3-1. Comparing distributions of average overall adherence calculated
using actual vs. constructed days of supply in the 2010 sample (n= 556)

Figure 3-2.

Observed distributions of average overall adherence by race
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Table 3-2.

Quantiles of the distributions of average overall adherence by race

PDC
Mean ±SD
Q10
Q20
Q30
Q40
Q50
Q60
Q70
Q80

White
72.78±25.15
32.97
49.45
59.91
70.05
77.59
86.29
93.2
99.27

Black
68.08±26.84
26.47
43.27
53.57
61.43
72.73
81.5
89.2
97.47

Hispanic
71.57±27.05
28.93
46.7
58.54
68.68
77.14
85.66
94.12
98.9

Overall
72.27±25.47
32.88
49.45
58.95
69.41
77.29
85.43
92.83
99.17

PDC: proportion of days covered; SD: standard deviation; Q: quantile.
beliefs and geographic location. Appendix Table B-1 lists regression coefficients for all
primary unconditional quantile regressions. Figure 3-3 plots black and Hispanic
coefficients from each unconditional quantile regression, graphically illustrating the
heterogeneity of disparities across the adherence (PDC) distribution. Black-white
disparities were large and statistically significant, starting with a spike of -9.05 PDC
percentage points at the 30th percentile (PDC≈60%), and then monotonically decreased to
-3.28% points as overall adherence approached its highest levels at the top quantile
(PDC=100%). Hispanic-white disparities of -4.07% points and -1.40% points were
statistically significant at the 20th and 40th percentiles (PDC≈48% and 74%), respectively.
Similarly to disparities in overall adherence, disparities in adherence to ACE
inhibitors/ARBs were large below the 30th percentile, as listed in Appendix Table B-2.
In contrast, black-white disparities in adherence to statins and diuretics were only notable
at the 40th and 50th percentiles (PDC ≈ 73-89% and 58-70%, respectively). Blacks were
less adherent to beta-blocker therapy than whites across all percentiles, with largest
disparity (-10.39% points) at the 20th percentile. Hispanics were significantly much less
adherent to diuretics than whites at every modeled quantile. Both black and Hispanic
seniors were in fact much less adherent to diuretics than whites, with disparities as large
as -19 and -15% points, respectively, at the 40th percentile (PDC ≈ 73%).
Regardless of how we empirically defined disparity, through various levels of
adjustment for covariates, the recurring pattern was consistent with the primary findings
above, despite a few changes in the statistical significance of estimates. Sensitivity of
findings to various levels of covariate adjustment is illustrated in Appendix Table B-3
and Appendix Figure B-1. Interestingly, full adjustment for all covariates resulted in
larger disparity estimates than all other paradigms of adjustment, particularly in the case
of black-white disparities.
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Figure 3-3. Heterogeneity in adjusted racial disparities across the distribution of
average overall adherence (entire sample, n=3,749)
Quantiles 10, 20, 30, 40, 50, 60, and 70 correspond to PDC values of 30, 48, 63, 74, 82,
95, and 100%, respectively.
Racial Disparities by Gender and LIS Status
As Figure 3-4 illustrates, elderly black men had lower adherence levels relative to
their white counterparts at all PDC percentiles (i.e. their adherence distribution was
significantly left-shifted), with largest disparities manifesting at the lowest percentiles
(PDC below 60%). Among women, elderly blacks had significantly lower adherence
rates starting at the 30th percentile (PDC≈61%). The disparity then declined as overall
adherence approached 100% at the 70th percentile, notwithstanding a large disparity that
re-emerged at the 60th percentile (PDC≈94%). Hispanic-white disparities, on the other
hand, were not statistically significant across all modeled quantiles among both genders.
Figure 3-5 shows the pattern of disparities across the adherence distribution by
LIS status. The lower panel shows the pattern among those who were auto-eligible for the
LIS, including dually eligible beneficiaries as well as beneficiaries receiving SSI. The
upper panel is for essentially the rest of the sample, who were not eligible for autoenrollment in the LIS, including those below 150% FPL who might be receiving the LIS
but not identifiable in MEPS. Not surprisingly, black-white disparities in the upper panel
showed the same pattern observed in the overall sample, although Hispanic-white
disparities were not significant across all percentiles. Among the auto-enrolled LIS
population, disparities took interesting courses. Black-white disparities started with a
peak of -15.7% points at the 10th percentile (PDC<30%) and then declined steadily until
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Figure 3-4. Pattern of adjusted racial disparities across the adherence
distributions among men (n=1,569) and women (n=2,180)
Quantiles 10, 20, 30, 40, 50, 60, and 70 correspond to PDC values: 28, 49, 60, 72, 81, 95,
and 99% among men, and 29, 51, 61, 74, 84, 94, and 100% among women, respectively.

Figure 3-5. Adjusted racial disparities across the adherence distribution among
auto-recipients of Part D LIS (n=617) and the rest of the sample (n=3,132)
Quantiles 10, 20, 30, 40, 50, 60, & 70 equal PDC values: 28, 47, 63, 73, 81, 94, & 100%.
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the 50th percentile, where they disappeared and then re-emerged at the 60th percentile
(PDC>90%). Hispanic-white disparities, though exhibited a similarly interesting trend,
they were only significant at the 20th and 30th percentiles.
Discussion
In a nationally representative sample of Medicare seniors with cardiovascular
conditions, we used unconditional quantile regression to unravel the heterogeneity of
racial disparities across the distribution of average adherence to 5 cardiovascular
medication classes. The most salient finding of our analysis was that disparities were
generally largest at the lower quantiles of the adherence distribution, around the 20th to
the 40th, corresponding to adherence levels of ~ 50 to 73% PDC. Notwithstanding a few
exceptions where disparities existed even among those with adherence ~ 90%, generally
speaking, as one moved towards the upper percentiles, race appeared to matter less as a
determinant of adherence behavior, that is: disparities declined among the populations
with increasingly better adherence. Statistically, these findings suggest that the adjusted
distribution of adherence behavior among minorities is most left-shifted from whites’
distribution at the lower quantiles. These findings align with the two other studies we
could identify which studied adherence disparities using quantile regression.128,129
Although more research is needed to identify the specific drivers of disparities
across the adherence distribution, available literature offer a number of possible
explanations for our findings. One interesting observation we found was that although
minorities were less likely to have healthcare events associated with depression, they
were twice as likely as whites to suffer depressive symptoms (Table 3-1). Depression is
known to compromise medication adherence and impair individuals’ self-efficacy,140
which is a key psychobehavioral determinant of adherence and a range of other selfmanagement behaviors.109 Self-efficacy refers to an individual’s conviction that s/he can
successfully carry out the behavior required to produce a desired outcome.141 Screening
minority patients for depression and promoting their self-confidence provides an
invaluable opportunity for providers to proactively address these key culprits in poor
adherence.142,143 Also, the lack of sufficient social support is a relevant barrier. Family
members, caregivers, friends, and providers can offer various forms of support, such as
easing depression, anxiety, and stress, helping with reminders to take medications, and
positively encouraging and reassuring patients of their ability to self-manage their
health.144 Unfortunately, no data on social support was available in MEPS.
A quality patient-provider relationship is crucial for helping patients with poor
adherence.142 Beyond behavioral support, provider communication can address patients’
beliefs and concerns about how medications work and their side effects (such as frequent
urination and impotence); issues identified to be barriers to adherence among
hypertensive blacks.144 Better communication with providers may particularly help with
minorities’ especially problematic adherence to diuretics and beta-blockers, as we report
in this study. Another potential barrier to adherence peculiar to blacks is their higher
likelihood to concurrently use multiple cardiovascular medications (Table 3-1). While
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understandably this may be due to clinical need, black seniors are less likely to have a
written list (record) of their medications and more likely to have medication-related
problems, such as suboptimal monitoring.145 They are also less likely to have adequate
health literacy.145,146 Further, elderly minorities who were not aware of Part D benefits
were found to be less adherent to their antihypertensive medications.147 Medicare Part D
Medication Therapy Management (MTM) programs148 provide an excellent mechanism
to address these drivers of poor adherence among minority seniors. Through
comprehensive medication reviews, collaboration with patient’s providers, and
establishing an empowering collaborative relationship with the patients themselves,
pharmacists providing MTM can properly educate patients about their medications,
address their medication-related problems and concerns, and promote their selfmanagement behavior.52,53,149 Towards this end, current evidence suggest that minorities’
adherence to cardiovascular medications significantly improves when there is race and
language concordance between them and their providers, which should be sought
whenever possible.150,151
The large magnitude of disparities towards the lower end of the adherence
distributions suggests that these barriers may be particularly pronounced among poorly
adherent minority patients. Two issues need to be addressed, however, before we can
effectively eliminate these barriers. First, although one could delineate the characteristics
of these populations, identifying them in routine clinical practice is challenging. This is a
result of the lack of alignment between the empirical refill-based measures of adherence
typically employed in research, and the measures that can be used to assess patient
adherence in routine clinical practice.117,152 Second, although using quantile regression
enabled us to get a more comprehensive picture of the adherence distribution, we still
lump adherence into a single number without further parsing out the underlying
behavioral details. Instead of using the PDC or MPR to summarize patient adherence
over (say) a year, a more informative alternative would be to examine the developmental
trajectories of adherence over time using group-based trajectory models.153 This would
enable us to capture more details about regimen execution, i.e. patterns of how the
prescribed compares to the actual regimen taken, and persistence over time.18,21
Identifiable patterns such as brief lapse in therapy due to occasional dose omissions,
longer drug holiday but then continuation, periodic gaps in therapy, and early
discontinuation provide a basis for more meaningful classification of adherence behavior
with implications for intervention and for studying disparities. It is worth noting here that
some recently developed questionnaire instruments, which can be administered in
practice settings, can help identify these distinct patterns as well, and can thus offer a
closer insight into real-world settings.152,154
Limitations
This study is not without limitations. First, our derivation of refill days of supply
from dispensed quantities was based on the 2010 data in our MEPS sample, without
validation against an external standard, e.g. Medicare claims data. Given that previous
research documented the validity of MEPS prescription drug data against Medicare
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claims,87 we believe benchmarking our analysis solely to MEPS 2010 is sufficient. While
data on dispensed quantities were complete for all refills in the study period, a large
proportion of 2010 refills had missing days of supply data (about 30%). We found the
pattern of missing data to be very consistent across drug class and respondent
characteristics, indicating that a missing-completely-at-random (MCAR) assumption is
likely plausible. As such, we examined the pattern of refill days of supply vis-à-vis
dispensed quantities only among individuals with complete days of supply data for all of
their listed refills.
We also assumed that the patterns of days of supply vis-à-vis dispensed quantities
in 2010 would hold in earlier years of MEPS. Although we believe this assumption is
likely true on average, changes in treatment guidelines, generic availability, and coverage
tier classifications of drugs might have affected the prescribed total daily doses of some
cardiovascular medications. Since MEPS did not have refill dates, a reasonable choice for
the index date was the first day of the MEPS round in which the refill occurred. We
might have thus underestimated adherence for respondents who started late in the round,
although it is not possible to identify them. If a respondent had too few refills over a
round (3-4 months), it might also be the case that they skipped refills and not necessarily
they started taking the medication later in the round.
Our approach to estimating disparities might have suffered from omitted variable
bias. As we adjusted the association between race and adherence for health-related
covariates in concordance with the IOM definition, we assumed that omitted variables,
such as income and education, would reflect predominantly in the race coefficients. It is
well-known, however, that these and other omitted variables are correlated with health
and demographics as well, and as such, race coefficients might not have necessarily
captured the entirety of race-related disadvantage as we had hoped. Given the technical
complexity of the analyses we undertook, it was more tractable to take this rather simple
approach to estimate disparities. Our sensitivity analyses involving various levels of
adjustment further confirmed the robustness of our primary findings. Last, although we
ensured that sample sizes for all analyses were well above the minimum recommended
by AHRQ, (n=100), we believe that small sample sizes may have contributed to the lack
of statistical significance in some of our sub-group analyses, especially those involving
Hispanics.
Conclusion
Using a nationally representative sample of Medicare seniors with cardiovascular
conditions in MEPS, we have found racial disparities to be more pronounced at the lower
end of the distribution of cardiovascular medication adherence. Among patient
populations with overall better adherence, disparities declined (although retaining their
statistical significance in the case of black-white disparities). The higher magnitude of
disparities among poorly adherent populations suggests that currently known barriers to
adherence, such as depression, low self-efficacy, lack of social support, and knowledge
and beliefs about medications, may be worse among minorities in these populations than
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among minorities in populations with better adherence. It may also suggest that other
peculiar barriers might be at play among these minority patients. Either way, our results
indicate that minority patients in poorly adherent populations may be deserving of
priority intervention. There is a considerable need to understand the specific barriers that
make these patients significantly lagging behind their white counterparts in adhering to
their cardiovascular medications.
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CHAPTER 4. EXPLAINING THE BLACK-WHITE GAP IN ADHERENCE TO
CARDIOVASCULAR MEDICATIONS AMONG MEDICARE SENIORS: A
DISTRIBUTION-WIDE APPLICATION OF OAXACA-BLINDER
DECOMPOSITION
Background
Poor adherence to cardiovascular medications is a strong risk factor for falling
short of drug therapy goals, such as blood pressure and cholesterol levels, with negative
consequences for cardiovascular morbidity and mortality, and healthcare costs.15,73,74,155
Several studies have found adherence levels among racial minorities, particularly black
Americans, to be significantly lower than whites, even where equal access to prescription
drugs is guaranteed.11,33 Among elderly recipients of Medicare, the advent of Part D was
an important step towards reducing the financial out-of-pocket burden of prescription
drugs and improving the quality of medication use, thus eventually reducing the negative
consequences of poor adherence.36,37 Despite the relative success of Part D,41,45,46,53 black
seniors have continued to experience disproportionately lower levels of adherence.
Among seniors with uncomplicated hypertension, Holmes and colleagues found blacks to
be 47% less likely to be adherent to their antihypertensive medications, including alphaand beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II
receptor blockers (ARBs), Calcium channel blockers (CCBs), diuretics and
vasodilators.28 Zhang et al estimated that blacks with heart failure were 39% less adherent
to ACE inhibitors/ARBs and diuretics than whites.29 In the year following acute
myocardial infarction, black seniors were also about 25%-35% less likely to adhere to
beta-blocker, ACE inhibitor, or statin therapy.30,31 In Chapter 2 of this dissertation,
analyses of the Medical Expenditure Panel Survey data on elderly Medicare beneficiaries
(2007-2010) have estimated an average black-white disparity of 8 percentage points
(~17%) in the probability of adherence (≥80% medication possession) to ACE
inhibitors/ARBs, statins, beta-blockers, CCBs, and diuretics. Further, in Chapter 3, as
other studies have reported,129 black-white disparities were most prominent towards the
lower end of the adherence distribution (around the 30th percentile), namely, among those
who were poorly adherent.
Not only does the black-white disparity appear to be the largest among racial
disparities in cardiovascular medication adherence, it also appears to be especially
consequential. Blacks bear the largest burden of cardiovascular morbidity, leading to 2-3
times higher likelihood of death due to cardiovascular disease at any given age.3,4 This
disparity in cardiovascular death accounts for the largest share (34%) of the black-white
all-cause mortality differential in the United States, with the disparity in uncontrolled
hypertension making up most of that share (44%).5 In the CARDIA study, BibbinsDomingo et al found adult blacks to be 20 times more likely than their white counterparts
to develop heart failure before the age of 50, pursuant to a striking disparity in
uncontrolled blood pressure that persisted over more than 10 years of follow-up.6 Based
on an analysis of the National Health and Nutrition Examination Survey, Fiscella et al
estimated that bringing the blood pressure level among blacks to that among whites could
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save more than 7,000 lives annually from death due to heart disease or stroke.7 Among
the social and behavioral factors that might explain the disparities in uncontrolled blood
pressure and other risk factors,8,12-14 the lower level of cardiovascular medication
adherence among blacks stands out as a proximal culprit that is amenable for healthcare
intervention.7,8,12,15
Adherence is shaped by the interplay of multiple patient-, environment-, disease-,
regimen-, provider-, and health system-related factors.77,156 Understanding how each of
these factors influences adherence behavior disparately among whites and blacks brings
us closer to comprehending adherence disparities. With a more concrete understanding of
how these disparities develop, we would become better able to tailor interventions to
reduce them. Despite a large literature on adherence behavior among blacks, the specific
drivers of adherence disparities are still largely ambiguous. For example, in a review of
the recent literature, Ogedegbe and colleagues have noted that self-efficacy, which is an
individual’s confidence that s/he can accomplish a desired outcome, particularly predicts
medication adherence among blacks.142 Depressive symptoms and younger age, on the
other hand, appeared to reduce the likelihood of adherence.142 Also, better provider
communication, especially in race-concordant relationships, was reportedly associated
with better adherence.142,150,151 Other studies have also shown a link between poor
adherence and inadequate health literacy.145,146 The evidence on the degree to which
social support and sociodemographic characteristics affected adherence among blacks
remains inconclusive.142 Among the elderly in Medicare, a national survey in 2003 found
racial disparities only in cost-related non-adherence, whereas there were no differences in
non-adherence due to experience with or beliefs about medications.81 Another study
among the elderly reported disparities in following provider recommendation but not in
forgetting to take medications.85 A systematic, deliberate comparison of how different
predictors operate differently among black and white seniors to produce the observed
patterns of adherence remains a critical gap in the literature.
In this study, we combined two powerful empirical techniques, Oaxaca-Blinder
decomposition with unconditional quantile regression, to quantify the contributions of
each predictor to the racial differences in cardiovascular medication adherence in a
nationally representative sample of white and black Medicare seniors. As we explain
below, these techniques enabled us to provide quantitative, “bottom-line,” estimates of
how much the differences in the distribution of individual characteristics as well as the
differences in how these characteristics influenced adherence among blacks and whites,
contributed to the observed racial differences in adherence. To our knowledge, this study
is the first application of decomposition analysis in the adherence literature. This study
contributes to the literature by identifying which predictors of adherence matter most,
from a disparity-reduction point of view, and also among which population sub-groups.
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Methods
Data Source
We used longitudinal data from the household component of the Medical
Expenditure Panel Survey (MEPS), panels 11 to 14 spanning years 2006 to 2010. MEPS
is an annual overlapping panel survey of the US civilian non-institutionalized population,
administered by the US Agency for Healthcare Research and Quality (AHRQ).131 The
primary focus of MEPS is on healthcare access, use, and expenditure in the United States,
enabling calculation of national impact estimates for a wide variety of health policy
changes. Each year MEPS panel participants are sampled from the previous year’s
respondents to the National Health Interview Survey (NHIS), with oversampling of
minorities and other policy-relevant groups (such as adults with functional limitations
and low-income households).131 Each panel is then prospectively followed for two
calendar years and their data are collected over five rounds of computer-assisted personal
interviewing. Rounds 1 and 2 fall in the first year, rounds 4 and 5 fall in the second year,
while round 3 spans the end of the first and the beginning of the second year. AHRQ
provides two types of main data files that can be linked to Medical Conditions and event
files: longitudinal and annual/cross-sectional (known as Full Year Consolidated Data)
files. For this study, we linked the longitudinal panel files to the Medical Conditions and
Prescribed Medicines event files. Although all MEPS data are reported by respondents
during round interviews, further detailed health service use data, including on
prescription drugs, are collected from a sample of providers (e.g. medical and pharmacy)
with respondents’ permission. Then these data are used to supplement respondents’ selfreports of health service use and expenditure. Of particular relevance to this study, the
quality of MEPS prescription drug data, as well as Medicare Part D enrollment has been
shown to be comparable to that of Medicare claims data.87,88 MEPS also provides very
rich data on respondents’ sociodemographics, health and chronic conditions, as well as
experience with providers and the healthcare system, allowing a thorough study of
adherence as shaped by these determinants.
Cohort Identification
We included MEPS respondents who were:
1) Continuously included in all MEPS survey rounds for the two panel years,
excluding those who went “out of scope” because of death, institutionalization, or
other reasons.
2) Medicare beneficiaries 65 years or older as of Round 1, who reported receiving
Medicare until the end of the second year (Round 5).
3) Non-Hispanic white (henceforth “white”) and non-Hispanic black (henceforth
“black”). MEPS ascertains race/ethnicity as follows:132 first, respondent’s selfreport of their race/ethnicity is the primary way to procure this data. Then, if not
available, race/ethnicity is obtained from the originally collected NHIS data in the
year prior to joining the MEPS panel. Finally if not available either way, MEPS
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assigns race/ethnicity based on respondent’s relationship to other members of
his/her household starting with blood relatives in the immediate family. MEPS
survey questions assessing race/ethnicity have been consistent since 2002.132
4) Had at least one of the following six prevalent conditions in both year 1 and year
2: hypertension, hyperlipidemia, angina, congestive heart failure, myocardial
infarction, or stroke, listed in the linked Medical Conditions file. Clinical
Classification Codes and 3-digit ICD-9 codes in MEPS were used to identify
respondents with these conditions.133 Appendix Table A-1 (Chapter 2) lists all
the conditions and their associated codes. Identified respondents had at least one
event (inpatient, outpatient, or prescription drug) associated with one or more of
these conditions.
5) Were prevalent users of at least one chronic cardiovascular medication of the
following classes: ACE Inhibitors, ARBs, HMG-CoA Reductase Inhibitors
(Statins), Beta-blockers, CCBs, Diuretics, or combination products of these
medications. Use was defined as having at least one refill for the same medication
class in both years. Second-year refills were used to estimate adherence.
Since our study sample only included a small portion of MEPS respondents, we
pooled MEPS panels 11-14 by year to create one analytical file with adequate sample size
for our analyses. Pooling MEPS data is commonly practiced and survey design variables
in MEPS files for our study period specify a common variance structure that takes into
account pooling when calculating standard errors.89 Our final analytical file contained
pooled data for year 1 (2006-2009), the baseline year, and year 2 (2007-2010) where
adherence was estimated.
Adherence Measurement
Using refill data for sampled respondents in the second year, we measured
medication class-specific adherence as the proportion of days covered (PDC) by refills
for any medication from that class, expressed as a percentage and capped at 100%. In the
case of overlapping refills for two statins, for example, only one refill was counted
towards calculation of the statin-specific PDC. ACE inhibitors and ARBs were counted
as one class for this purpose. Component medications of combination products were also
counted towards their respective classes. As refill dates were not available in MEPS, we
determined the follow-up index date specific to each medication class for each
respondent as the first day of the round in which the first refill (for the specific class)
occurred. These rounds were either the fourth, the fifth, or the portion of the third round
that had fallen in the second year. Respondents were then followed until the last day of
the fifth round, which corresponded to December 31st of the second year in the panel for
all participants. Inpatient days were excluded from the follow-up period. For all classes,
while over 50% of respondents had January 1st of the second year (i.e. the part of round 3
that fell in year 2) as the class-specific index date, more than 96% of index refills had
occurred by March of the second year. The main outcome variable was an overall
continuous PDC summarizing adherence over all medication classes, calculated for each
respondent as the average of all his/her class-specific PDCs. Dichotomous adherence
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classification based on having a PDC of at least 80% was explored in a secondary
analysis.
Although MEPS provided extensive data on prescription refills, including
dispensed quantity, strength, dosage form, and therapeutic class/subclass, data on days of
supply were not routinely collected until 2010. We used 2010 data, which was the second
year of Panel 14 in our sample, to characterize the patterns of observed days’ supply as
they related to dispensed quantities of drug refills. In so doing, we identified the most
frequent number of supply days furnished by each level of dispensed quantity. Next, we
derived a scheme to smoothly approximate the distribution of days of supply for use in
prior years of MEPS (where actual days of supply data are not available). Then, in 2010
data, we calculated PDCs as explained above using the actual and constructed days of
supply distributions. To assess the validity of our derivation, we used Lin’s concordance
coefficient90,91 to compare the constructed distribution of days of supply as well as the
PDC based on it, to the actual distribution and its associated PDC. We also compared
dichotomous adherence based on actual vs. constructed days of supply distributions using
C-statistics. Then, we used our validated scheme to construct refill days of supply from
dispensed quantities in all panels. The validity of computing refill days of supply in
earlier years using the pattern of days of supply vis-à-vis dispensed quantities in 2010
hinges on the potentially plausible assumption (based on discussions with two
cardiologists with more than 20 years of practice experience) that the dosing frequency of
a given strength of a specific cardiovascular drug has been stable over 2007-2010 in a
specific patient population. (For example: for the same patient population, if a 30-pill
refill of 40-mg simvastatin covers 30 days in 2010, on average, this would have also been
true in 2007).
Covariates
We modeled the PDC distribution for each racial group as a function of a series of
baseline covariates assessed over the first year of the MEPS panel. We used data on
respondents’ demographic characteristics; geographic location; self-reported health and
functional (physical/ cognitive) status; depressive symptoms;134 cardiovascular conditions
and other comorbid conditions; beliefs regarding health, risk, and insurance; income and
poverty status, and educational attainment; health behaviors; type of primary insurance
coverage for prescription drugs; financial and pill burden associated with medications;
access to/use of primary care and other health services; and experience with providers
and satisfaction with the healthcare system.
In addition to binary indicators of which cardiovascular condition(s) respondents
had in the baseline year, we also incorporated other comorbid conditions, such as
diabetes, asthma, and cancer, in a modified version of the Charlson comorbidity score
(excluding respondent-specific cardiovascular conditions and depression) adapted for use
with 3-digit ICD-9 codes in MEPS.96 For socioeconomic status (SES), we used MEPSprovided categories of income as a percent of the Federal Poverty Line (FPL) and
categorized years of education into three levels: less than high school, high school
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diploma (12 years), and above high school. High-income and having education beyond
high school served as the reference categories.
For identifying respondents’ primary type of drug coverage, we used a series of
variables on insurance status as well as amounts paid by each payer for prescription drugs
over the first year to ascertain drug coverage for each respondent. We identified three
principal categories of coverage, as of December 31st of the first year: those who had no
evidence of drug coverage by any payer, those who had Medicare Part D, and those who
had a private source of drug coverage including employer-sponsored. Among Part D
enrollees, we identified those who were concurrently enrolled in Medicare managed care
and those who were not. Thus we were able to further split Part D recipients into those
who had Medicare Advantage Part D plans (MA-PD) and those who were just enrolled in
stand-alone Part D plans (PDPs) with no evidence of enrollment in MA. Further, we
created an indicator for whether a Part D respondent was deemed eligible for autoenrollment for the low-income subsidy (LIS), which included dually eligible beneficiaries
and beneficiaries receiving Supplemental Security Income (SSI) (both variables were
available in MEPS).55,57 Other LIS-recipients who are not automatically enrolled but their
income is below 150% FPL and have limited assets must apply to receive the LIS.54
Although we validated the characteristics of these sub-categories of Part D recipients
against the literature,54,56,58,59,103 ascertaining drug plan type or actual receipt of the LIS is
not possible in MEPS.
Statistical Analysis
We used Oaxaca-Blinder decomposition (OBD)157-159 to quantify the
contributions of each covariate to the (unadjusted) racial difference in adherence. In
contrast to earlier work in this dissertation, where we defined inequitable racial
disparities and did a priori classification of covariates as to whether they represented
sources of disparities or not, this decomposition analysis explores unadjusted racial
differences in fitted levels of adherence allowing an empirical evaluation of how each
covariate contributes to the adherence difference. OBD has been a popular analytical tool
in labor economics, providing insights into the potential drivers of race and gender gaps
in wages.71 In prescription drug research, examples of OBD application include
decomposition of the racial difference in prescription drug utilization and spending
among Medicare beneficiaries,160 the racial differences in anti-obesity medication use
among US adults,161 and the sources of regional variation in Medicare Part D drug
spending.162 Also, the study of racial differences in access to primary healthcare is
another notable application of OBD in the US health services literature.163
Most commonly, OBD starts with estimating a separate regression model for each
racial group, which is then used to estimate the outcome level for each individual in the
dataset. Next, the difference in average estimated outcomes between the two racial
groups is calculated. Finally, this unadjusted difference is broken down into 1) an
“explained” component due to the difference in the distribution of individual
characteristics, or “endowments” as termed in Blinder’s original work,158 and 2) an
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“unexplained” component due to how these characteristics are associated with the
outcome (as captured by their model coefficients) differently across racial groups.71,159,164
This is termed two-fold decomposition. The explained component is interpreted as the
expected change in the outcome difference had the two groups had the same overall
composition or distribution of characteristics. For example, in decomposing the
difference in adherence, the explained component is an estimate of the expected change
in the adherence difference had blacks possessed the same demographic, social, health,
etc characteristics as whites. The unexplained component is interpreted as the expected
change in the outcome difference had the two groups had the same return on the outcome
due to their characteristics. Again, the unexplained component of the adherence
difference quantifies how much that difference would change had characteristics (e.g.
education, insurance, depression) worked the same way to determine adherence among
blacks and whites. Assuming no relevant covariates were left out of the model, the
unexplained component is traditionally interpreted as indicating discrimination in the
environment where covariates determine outcome levels (for instance, the healthcare or
broader social environment where the same insurance plan works better for whites than
blacks resulting in improved adherence for whites but not for blacks). A three-fold
decomposition can also be formulated, in which a third component that captures the
simultaneous effects of endowments and returns is calculated.159
Breaking down outcome differences into just the aggregate explained and
unexplained components is known as aggregate decomposition. For estimation of these
aggregate components, we have to invoke a conditional independence assumption, where
no relevant covariates were omitted/unobserved, or at least an ignorability assumption,
where unobservable characteristics correlated with controlled covariates in the same way
across the two groups compared. By further assuming that the aggregate components are
composed of additively separable linear functions, they can be further decomposed into
the contributions of each individual covariate. This further breakdown is known as
detailed decomposition.71
As the counterfactual language for interpreting decomposition components above
entails, one must decide which group would serve as the viewpoint group for the
analysis.159,164 Three potential alternatives exist: the lower-outcome group, the higheroutcome group, or the pooled average of the two groups. For example, decomposing the
racial difference from the viewpoint of whites confers the following interpretation on the
explained component: how much would adherence level of whites change were they to
have the characteristics of blacks? Alternatively, a black-viewpoint analysis would make
the explained component interpretable as the expected change in black’s adherence level
were they to have the same characteristics as whites. Choosing the pooled average would
mean that group-specific outcome estimates would come from a pooled regression model
instead of a separate group-specific model as described earlier. Results of the
decomposition analysis accordingly depend on which group is chosen, in what is termed
as an “index number problem.”165
OBD analyses have originally been based in the linear ordinary least squares
(OLS) regression framework, for both continuous and binary outcomes (using a linear
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probability model in this latter case). More generalized nonlinear extensions have been
developed over the years, including for example decompositions based on logit, probit,
and count regressions, such as Poisson and negative binomial.166-168 Nonlinear
decompositions work better when the racial difference is located in the tails of the
distribution or when there are large differences between the covariates that the linear
model’s prediction would fall outside a meaningful range (e.g. predicting probabilities
>1). In all these cases, decomposition of mean differences is carried out. Although
studying differences in mean outcomes is informative, policy-relevant differences might
exist elsewhere in the distribution but might be undetectable in the mean. In the case of
the racial differences in adherence, our analyses as well as other studies in the
literature128,129 have demonstrated the existence of large, significant disparities in the
lower percentiles of the adherence distribution. Conducting OBD across the adherence
distribution, by estimating race-stratified quantile regressions, can reveal the potential
heterogeneity in covariate contributions to the racial adherence gap.
Recently, OBD has been extended to quantile regression. Quantile regression is
analogous to OLS, except that conditional outcome quantiles as opposed to the
conditional mean are modeled, thus revealing how the outcome depends variably on the
covariates at different locations of the distribution. Quantile regression does not run on a
subset of the sample, but rather differentially weights the observations in the sample
above and below the modeled quantile. For example, the 70th quantile regression can be
thought of as a plane that passes through the sample, weighing observations above it by
0.70 and observations below it by 0.30.126 Coefficient estimates are then estimated by
minimizing weighted absolute deviations (as opposed to least squares in OLS). 118,120
Typical quantile regression modeling involves estimating covariate effects on conditional
outcome quantiles. The conditional outcome distribution is expectedly different from the
unconditional distribution, with the latter being integrated over all covariates.130 As noted
above, OBD breaks down the difference in estimated, unconditional outcome levels
across groups. OBD is not possible in the context of conditional quantile regression,71
except with computationally intensive calculations to generate the unconditional outcome
quantiles.169 Firpo, Fortin, and Lemieux70 have developed a simple approach to
estimating unconditional quantile regression, by first estimating a quantity known as the
re-centered influence function (RIF) for the desired outcome quantile and then regressing
it on the covariates in an OLS regression. This serves to readily generate the
corresponding unconditional outcome quantile, which is then used to generate detailed
OBD estimates as described above.71 While we found no application of RIFunconditional quantile regression-based OBD in the health services literature, recent
applications involved studying rural-urban inequality in education in Senegal,170 and
racial inequality in wages and occupation in the United States and Brazil.171,172
In this study, we used RIF-unconditional quantile regression, as implemented in
STATA® by Fortin137, together with the OBD routine –oaxaca- developed by Jann,159
to perform OBD on racial differences in adherence across the distribution of continuous
PDC, namely 10th, 20th, to the 80th percentile, as a function of the full set of covariates
described above. As Equation 4-1 shows, RIF-based OBD starts with estimating the τth
unconditional PDC quantile from race-stratified Qτth RIF-OLS models:
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For sensitivity analysis, we conducted a two-fold decomposition using βτ from
pooled RIF-unconditional quantile regressions. For comparability with the literature, we
also estimated OBD of differences in mean PDC in OLS as well as differences in the
average probability of 80% adherence in logit and linear probability models. All analyses
accounted for MEPS complex design by using survey design variables. Standard errors
were estimated by balanced repeated replications173 using MEPS provided weights and
half-sample indicators.174 Since rates of missing data in some covariates (e.g. beliefs and
experience with providers) were as high as 13%, we used multiple imputation using
chained equations (MICE) to impute missing data for each of these variables.100
Regression analyses were estimated separately in each imputation dataset and then point
estimates and standard errors were combined using Rubin’s rules138 to produce a single
set of estimates that took into account uncertainty due to imputation. Estimates with alpha
less than 5% were considered statistically significant. All analyses were carried out in
STATA® 13 (StataCorp; College Station, TX).
Results
The study sample included 3,288 MEPS respondents, nationally representative of
about 19 million white and black Medicare seniors with cardiovascular disease. Each
respondent was followed for an average period of 342 days. Table 4-1 lists overall
sample characteristics and Appendix Tables C-1 and C-2 list respondent characteristics
across PDC quantile categories (10th to 80th percentiles). Overall, black seniors were
more likely to be female, less likely to be married, and less likely to live in the Midwest
or the West, while more likely to live in the South. Blacks were also less likely to rate
their health status as “excellent” or “very good”, while more likely to rate it as “fair” or
“poor.” The prevalence rates of cognitive limitations and depressive symptoms, as
measured by the Patient Health Questionnaire (PHQ)-2,134 were higher among blacks
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Table 4-1.

Overall characteristics of sampled Medicare seniors, by race

Characteristics

White
Black
Overall
%, unless otherwise noted

Demographics
Female
56.69
Married
56.08
Urban/MSA
79.34
Census Region
Northeast
21.24
Midwest
25.70
South
34.48
West
18.57
Self-Reported Health Status
Excellent
13.40
Very Good
31.32
Good
33.61
Fair
16.58
Poor
5.09
Any Physical Limitation*
62.29
Any Cognitive Limitation*
9.78
Depressive Symptoms
7.41
Cardiovascular Conditions & Comorbidity
Hypertension
82.57
Lipidemia
66.24
Angina/CHD
21.79
CHF
4.02
AMI
8.89
Stroke
6.00
Count of Comorbid
5.61 ±3.53
Conditions,† Mean ±SD
Charlson Comorbidity Score†
56.35
Q1-2
Charlson Comorbidity Score†
31.53
Q3
Charlson Comorbidity Score†
12.12
Q4
Beliefs
More Likely to Take Risk
16.45
Can Overcome Illness
11.31
without Medical Care
No Need for Health Insurance
4.45
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63.41
31.31
84.06

57.34
53.66
79.80

18.22
15.41
59.88
6.49

20.95
24.69
36.97
17.39

7.65
23.72
35.31
25.64
7.68
63.48
18.24
14.69

12.84
30.58
33.78
17.46
5.34
62.41
10.61
8.13

93.65
56.95
17.38
3.54
7.21
6.14

83.65
65.33
21.35
3.98
8.72
6.02

4.57 ±3.13

5.51±3.51

46.43

55.38

39.52

32.31

14.05

12.31

14.13

16.22

7.05

10.89

5.01

4.51

Table 4-1.

(Continued)

Characteristics

White
Black
Overall
%, unless otherwise noted

Behaviors
Current Smoker
8.30
Moderate / Vigorous Exercise
47.43
Obese (BMI≥30)
28.53
Socioeconomic Status
Income:‡
15.38
Poor/Near Poor
Low-Income
15.95
Mid-Income
31.44
High-Income (Ref)
37.23
Education:
19.73
Less than High School
High School Diploma
52.97
Above High School (Ref)
27.30
Primary Drug Coverage at Baseline
No Known Rx Coverage
19.85
(Ref)
Part D: PDPs
35.96
Part D: MA-PD
23.00
Employer/Other Private
21.19
Auto Eligible for PD Low5.72
Income Subsidy
Use of CV Drugs in Year 2
ACEI/ARBs
58.17
Statins
60.11
Beta-Blockers
41.67
CCBs
19.72
Diuretics
43.85
Healthcare Use at Baseline
No. of Concurrent CV Medications §
0-1
34.95
2-3
56.26
≥4
8.78
No. of concurrent medications overall
0-1
9.96
2-4
44.51
≥5
45.53
No. of Pharmacies Used
1.33 ±0.54
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10.91
37.43
36.67

8.56
46.45
29.32

32.56

17.06

20.71
31.15
15.58

16.42
31.41
35.11

47.42

22.43

39.00
13.59

51.60
25.96

12.99

19.18

43.66
30.37
12.97

36.71
23.72
20.39

25.92

7.70

59.68
49.56
37.08
36.54
54.65

58.31
59.08
41.22
21.36
44.90

32.53
55.27
12.21

34.72
56.17
9.12

14.13
44.51
41.37
1.17 ±0.44

10.37
44.51
45.12
1.31±0.53

Table 4-1.

(Continued)

Characteristics

White
Black
Overall
%, unless otherwise noted
25.21
17.30 ±24.8 24.44±30.85
±31.34
97.43
97.25
95.58
17.23
17.88
17.29
17.33
17.70
21.06

Average Copay for CV Drugs
($2010)
Had a Usual Source of Care
Had any Inpatient Stay?
Had any ER visit?
Quintiles of ambulatory physician visits (range)
Q 1 (0-2)
17.99
28.83
Q 2 (3-4)
18.12
21.21
Q 3 (5-7)
20.47
21.75
Q 4 (8-12)
22.18
13.14
Q 5 (≥13)
21.23
15.08
Experience with the Healthcare System
Very Satisfied with Health
58.67
53.87
Care
Provider Always Explained
56.79
58.28
Provider Always Listened
61.24
62.36
Provider Always Respected
63.11
64.49
Sample Size
2,585
703
Weighted Population
17,447,543
1,891,319

19.05
18.43
20.59
21.30
20.63
58.20
56.94
61.35
63.25
3,288
19,338,862

Boldface estimates have P<0.05 for pairwise comparisons relative to whites.
Refer to Appendix Tables C-1 and C-2 for characteristics by race across PDC quantiles
10th-80th.
* Physical limitations included functional or sensory limitations, or limitation in the
Instrumental Activities of Daily Living or in the Activities of Daily Living. Cognitive
limitations included confusion, dementia, problems making decisions, or needing
supervision for own safety.
† Excluded respondent-specific cardiovascular conditions.
‡ Poor/Near-Poor: <125% Federal Poverty Line (FPL); Low-Income: ≥125 to <200
%FPL; Middle-Income ≥200 to <400% FPL; High Income (reference): ≥400% FPL.
§ Same-pill combination products were counted as one drug
MSA: Metropolitan Statistical Area; CHD: Coronary Heart Disease; CHF: Congestive
Heart Failure; AMI: Acute Myocardial Infarction; SD: Standard Deviation; Q: Quantile;
BMI: Body Mass Index; PD: Part D; PDP: stand-alone prescription drug plan; MA-PD:
Medicare Advantage Prescription Drug plan; ACE: Angiotensin-Converting Enzyme;
ARB: Angiotensin II Receptor Blocker
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than whites. While hypertension was more prevalent among black seniors,
hyperlipidemia was more prevalent among whites. Although blacks had less comorbid
conditions in addition to cardiovascular disease, they were more likely to have higher
severity of illness, as measured by the Charlson comorbidity score.96 Blacks were also
less likely to believe they could overcome illness without medical care. They were also
less likely to exercise and more likely to be obese.
Black seniors were highly represented in lower SES categories, such as being
poor/low-income or having no high-school diploma. While blacks were less likely to go
without drug coverage, including greater enrollment in Part D MA-PD and PDP plans as
well as being auto-enrolled in the LIS, they were less likely than whites to have
employer-sponsored or private coverage. Blacks were less likely to use statins, while
more likely to use CCBs or diuretics. Blacks were also more likely to concurrently use 4
or more cardiovascular medications, albeit using a smaller number of medications
overall. Blacks had smaller copays for their cardiovascular medications. While whites
were more likely to have a usual source of care, blacks were more likely to use the
emergency department and much less likely to frequent ambulatory care. No significant
differences were observed in rating of providers or satisfaction with care. With a few
exceptions, such as blacks at the 30th PDC percentile being more likely to have a usual
source of care or being substantially more likely to smoke at the 40th percentile, the
patterns of association of characteristics with race seemed to hold across PDC quantile
categories.
Adherence Validation
In the 2010 sub-sample where refill days of supply data were available, we
studied days of supply vis-à-vis dispensed quantities so as to build a scheme to derive
days of supply from dispensed quantities in earlier panels of MEPS (where days of
supply data were not available). Based on identifying the most frequent number of supply
days furnished by each level of dispensed quantity, we found the following scheme to
perform best in constructing days of supply from dispensed quantities, (quantity vs days
of supply): [8: 16; 15-16: 30; 45: 90; 46-75: 30; 76-119: 90; 120: 30; >120: 90; all other
quantities: identical days of supply]. This scheme also worked equally well across
medication classes. Comparing the PDC distribution that is based on constructed days of
supply versus the one based on actual days of supply in the 2010 sub-sample gave a Lin’s
concordance coefficient of 0.98, indicating substantial agreement. Figure 4-1 shows how
the two PDC distributions were virtually identical. We also observed similarly substantial
agreement between dichotomous adherence classifications (at PDC≥80%) based on the
two distributions: C-statistic 0.98).
Racial Differences in Adherence
Estimated RIFs of PDC quantiles were used in OBD to calculate the racial
difference across the PDC distribution. Appendix Tables C-3 and C-4 list coefficients
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Figure 4-1. Comparing distributions of average overall adherence calculated
using actual vs. constructed days of supply in the 2010 sample (n= 485)
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estimated in each of the RIF unconditional quantile regressions used in OBD. Figure 4-2
shows both the observed and fitted (unadjusted) differences in PDC across the
distribution. Racial differences were largest below the median, spiking at the 40th
percentile to about 9 percentage points, and then declining as one moves up the PDC
distribution.
Decomposition of the Racial Differences in Adherence
Tables 4-2 and 4-3 list the results of OBD of the racial difference across the
unconditional 10th-40th and 50th-80th of the PDC distribution, respectively. Black-white
differences were significant at all percentiles, except at the 50th and 80th percentile, and as
shown in Figure 3-2, they spiked at the 40th percentile to 9 percentage points. Except at
the 40th percentile, the aggregate contributions of the racial differences in composition
and the returns of compositional characteristics on adherence were not significant.
Among seniors at the 40th percentile of the PC distribution (PDC ~ 69%), if the way
covariates predicted adherence among blacks were identical to how they worked among
whites, the black-white PDC difference would have been reduced by about 12 percentage
points (~130%).
Demographics. The differences in neither the distribution of age, gender, urban
residence, or geographic location were associated with the racial difference in adherence.
Similarly for marital status, except at the 30th percentile. Had marriage been associated
with adherence the same way among blacks and whites, the racial difference in adherence
at the 30th percentile would have increased by 7.5 percentage points (~ 96%). In
Appendix Table C-2, being married was significantly associated with a large
improvement in adherence among blacks but not among whites.
Health. Two health-related factors appeared to matter for the racial difference in
adherence: hyperlipidemia and activity limitation. As in Table 4-2, holding everything
else constant, had the prevalence of hyperlipidemia been equal among whites and blacks
at the 10th percentile of the PDC distribution, the racial difference in adherence would
have increased by 0.93 percentage points (~15%). On the other hand, had the effect of
having hyperlipidemia among blacks been similar to that among whites, the racial
difference in adherence would have dropped by 9.7 percentage points (~150%). In
Appendix Table C-2, we have underlined the coefficients of hyperlipidemia in the black
and white RIF-Q10 models. Evidently, being black and hyperlipidemic reduced (i.e. leftshifted) the 10th PDC quantile significantly by about 13 percentage points, an effect that
was much larger and opposite in direction to its counterpart among whites.
Another notable health-related factor was having activity limitation (Table 4-3).
Among seniors at the 50th percentile of the PDC distribution (PDC ~77%), had physical
limitation among blacks been associated with the adherence the same way as among
whites, the racial difference in adherence would have increased by 7.32 percentage points
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Figure 4-2. Comparing observed and fitted black-white differences across
quantiles of the proportion of days covered (PDC)
Fitted values were estimated using race-stratified RIF-unconditional quantile regressions.
See Panel-A of Table 4-2 and 4-3 for point estimates and standard errors of the fitted
values.
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Table 4-2.
Oaxaca-Blinder decomposition of black-white differences in adherence across PDC quantiles, 10th-40th, from the
viewpoint of black seniors
Outcome

QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Panel A: Fitted Adherence Levels and Differences
QPDC, Blacks
QPDC, Whites
Difference

27.10 (2.72)
33.50 (1.26)
-6.40 (3.14)

42.99 (2.71)
49.77 (1.16)
-6.78 (3.05)

52.69 (2.29)
60.51 (1.30)
-7.82 (2.76)

61.59 (2.51)
70.60 (1.10)
-9.00 (2.84)

Panel B: Portion of Adherence Difference Due to:
Characteristics
Aggregate
Contribution
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban Residence
Census Region:
Midwest
South
West
Health Status:
Very Good
Good
Fair

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-1.40 (5.34)

-5.00 (6.04)

-1.74 (4.71)

-5.04 (5.33)

1.59 (3.83)

-9.41 (4.83)

2.94 (4.43)

-11.95 (5.42)

-0.71 (0.46)
0.21 (0.31)
0.51 (0.56)
-0.07 (0.54)
0.61 (2.07)
0.23 (0.42)

-1.91 (1.82)
-1.50 (1.93)
-0.42 (2.71)
0.38 (4.22)
-0.36 (4.68)
3.90 (6.30)

-0.06 (0.42)
0.05 (0.17)
0.17 (0.51)
0.53 (0.52)
-0.79 (1.83)
-0.14 (0.40)

1.07 (1.72)
0.52 (1.52)
0.93 (2.64)
4.90 (4.02)
4.25 (4.20)
-2.73 (6.42)

0.11 (0.42)
-0.01 (0.17)
-0.21 (0.44)
0.19 (0.41)
-1.87 (1.58)
-0.17 (0.40)

1.38 (1.64)
0.66 (1.43)
2.68 (2.25)
2.93 (3.29)
7.50 (3.80)
-2.40 (5.70)

0.02 (0.39)
-0.01 (0.17)
-0.20 (0.49)
-0.26 (0.45)
-0.96 (1.71)
-0.05 (0.45)

0.61 (1.60)
0.56 (1.45)
2.43 (2.47)
-0.50 (3.44)
3.95 (3.90)
0.67 (6.71)

-0.62 (0.85)

1.10 (2.23)

-1.50 (0.87)

2.96 (2.20)

-0.20 (0.83)

-1.08 (2.31)

-0.83 (0.93)

1.75 (2.47)

0.99 (1.86)
1.90 (2.31)

3.55 (3.08)
-1.96 (3.79)

1.87 (1.88)
0.86 (1.81)

3.34 (2.76)
-1.49 (2.89)

0.19 (1.52)
0.67 (1.36)

0.67 (2.56)
-1.44 (2.29)

0.86 (1.91)
0.68 (1.52)

2.47 (3.03)
-1.18 (2.50)

0.02 (1.05)

-2.32 (4.32)

-0.15 (0.97)

-1.23 (3.98)

-0.38 (0.78)

0.24 (3.48)

0.07 (0.93)

-2.12 (4.01)

0.01 (0.36)
-0.09 (1.50)

-1.61 (4.52)
-2.37 (2.66)

0.02 (0.32)
0.73 (1.31)

-1.85 (4.08)
-0.71 (2.27)

-0.01 (0.26)
0.92 (1.03)

-1.91 (3.38)
0.50 (2.01)

-0.03 (0.33)
0.35 (1.20)

-2.94 (4.17)
-0.63 (2.30)
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Table 4-2.

(Continued)

Characteristics

Poor
Any Physical
Limitation
Any Cognitive
Limitation
Depressive
Symptoms
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke
Count of
Comorbid
Conditions
Charlson
Comorbidity
Score Q3
Charlson
Comorbidity
Score Q4

QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.02 (0.51)

-0.24 (0.85)

0.34 (0.47)

0.38 (0.81)

0.29 (0.39)

0.54 (0.73)

0.23 (0.49)

0.56 (0.85)

0.07 (0.23)

2.00 (4.37)

0.03 (0.19)

3.20 (4.20)

-0.08 (0.20)

-0.34 (3.94)

0.08 (0.21)

3.94 (3.97)

-0.88 (0.68)

-0.45 (0.83)

0.05 (0.64)

0.49 (0.86)

0.55 (0.59)

1.05 (0.84)

0.59 (0.62)

0.88 (0.76)

-0.81 (0.78)

-0.27 (0.83)

-1.25 (0.73)

-0.89 (0.70)

-0.62 (0.62)

-0.38 (0.66)

-0.44 (0.60)

-0.13 (0.64)

-0.76 (1.29)
0.93 (0.47)
-0.24 (0.31)
0.00 (0.10)
-0.03 (0.31)
0.03 (0.18)

-9.90 (10.24)
-9.70 (3.82)
1.64 (1.58)
-0.16 (0.50)
-0.26 (1.09)
0.55 (0.69)

-0.59 (1.35)
0.30 (0.42)
-0.32 (0.36)
0.03 (0.13)
0.22 (0.33)
0.02 (0.16)

-7.54 (10.27)
-3.59 (4.15)
1.93 (1.75)
-0.51 (0.54)
-1.22 (1.13)
0.60 (0.71)

0.87 (1.09)
-0.06 (0.34)
-0.20 (0.27)
-0.00 (0.08)
0.20 (0.27)
0.01 (0.12)

1.78 (9.13)
-0.54 (3.79)
0.51 (1.52)
0.06 (0.45)
-1.00 (0.90)
0.42 (0.56)

0.69 (1.07)
-0.41 (0.40)
-0.19 (0.26)
-0.02 (0.10)
0.12 (0.28)
-0.00 (0.15)

1.30 (8.76)
3.00 (4.02)
0.67 (1.46)
0.28 (0.49)
-0.80 (0.97)
0.16 (0.75)

-1.61 (1.11)

8.72 (6.71)

-1.05 (1.00)

5.26 (6.29)

-0.30 (0.87)

3.43 (5.37)

-0.14 (0.96)

1.79 (5.75)

0.14 (0.55)

1.19 (2.34)

0.41 (0.55)

2.33 (2.06)

0.59 (0.45)

2.36 (1.89)

0.57 (0.50)

2.24 (1.79)

-0.00 (0.24)

0.37 (1.38)

0.10 (0.27)

0.95 (1.34)

0.19 (0.26)

1.13 (1.22)

0.24 (0.28)

1.59 (1.28)
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Table 4-2.

(Continued)

Characteristics

QPDC 10th

QPDC 20th

QPDC 30th

QPDC 40th

Estimate (Standard Error)
Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

More Likely to
Take Risks

-0.09 (0.19)

0.44 (1.27)

-0.17 (0.24)

1.59 (1.15)

0.03 (0.17)

-0.17 (1.23)

0.14 (0.21)

-0.77 (1.46)

Can overcome
illness without
medical care

0.09 (0.68)

-0.27 (1.45)

0.17 (0.65)

-0.67 (1.41)

0.63 (0.62)

-1.42 (1.28)

0.58 (0.68)

-1.25 (1.37)

-0.07 (0.19)

0.04 (0.61)

-0.08 (0.17)

0.01 (0.67)

0.01 (0.14)

0.44 (0.62)

0.06 (0.17)

0.90 (0.67)

0.17 (0.23)

0.67 (0.59)

0.02 (0.29)

0.37 (0.69)

-0.03 (0.21)

0.22 (0.60)

0.06 (0.24)

0.13 (0.64)

-0.05 (0.60)

0.73 (3.31)

0.42 (0.64)

-0.34 (3.10)

0.14 (0.55)

1.48 (2.77)

0.12 (0.58)

0.90 (3.08)

1.36 (0.66)

4.56 (1.98)

1.09 (0.56)

3.03 (1.77)

1.17 (0.53)

3.52 (1.66)

0.85 (0.58)

2.19 (1.81)

-0.95 (1.48)

-0.58 (1.49)

-2.33 (1.60)

-2.04 (1.44)

-0.39 (1.29)

-0.46 (1.26)

-1.17 (1.52)

-1.32 (1.44)

-0.28 (0.41)
0.01 (0.22)

-0.81 (1.33)
-2.62 (3.03)

-0.63 (0.47)
0.01 (0.28)

-2.56 (1.46)
-3.87 (3.19)

-0.26 (0.40)
0.01 (0.20)

-0.71 (1.26)
-1.74 (2.63)

-0.57 (0.54)
0.01 (0.31)

-1.95 (1.53)
-2.85 (3.26)

-2.06 (1.70)

-1.03 (1.31)

1.01 (2.10)

1.14 (1.63)

0.17 (2.00)

0.17 (1.61)

0.51 (2.06)

0.01 (1.55)

1.93 (0.92)

-7.28 (4.01)

0.12 (1.04)

1.74 (4.55)

0.37 (1.09)

-0.53 (4.86)

0.28 (1.17)

-1.48 (5.04)

Does not need
health insurance
Current Smoker
Had Moderate /
Vigorous
Exercise
Obese (BMI≥30)
Income:
Poor/Near-Poor
Low-Income
Middle-Income
Education:
Less than High
School
High School
Diploma
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Table 4-2.

(Continued)

Characteristics

QPDC 10th

QPDC 20th

QPDC 30th

QPDC 40th

Estimate (Standard Error)

Drug Coverage
Plan:
Part D: PDPs
Part D: MA-PD
Employer/Other
Private
Auto Eligible for
PD Low-Income
Subsidy
Average Copay
for CV Drugs
($2010)
Concurrently
taking:
2-3 CV Drugs
≥4 CV Drugs
Quantiles of
Ambulatory
Visits:
Q 3 (5-7)
Q 4 (8-12)
Q 5 (≥13)

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

2.38 (1.38)

8.78 (4.55)

1.38 (1.16)

4.51 (4.17)

0.75 (0.88)

2.22 (3.28)

1.00 (0.93)

4.11 (3.23)

1.42 (0.85)

4.86 (2.98)

0.87 (0.73)

2.41 (2.68)

0.83 (0.58)

2.25 (2.22)

0.89 (0.67)

2.66 (2.25)

-1.65 (1.11)

4.42 (2.95)

-1.59 (1.09)

3.71 (2.81)

-1.82 (0.89)

4.37 (2.14)

-2.39 (0.99)

6.30 (2.10)

-2.78 (1.86)

-1.05 (0.50)

-2.76 (1.62)

-0.76 (0.43)

-2.63 (1.43)

-0.83 (0.42)

-0.93 (1.51)

-0.22 (0.42)

-1.35 (0.68)

6.07 (2.47)

0.44 (0.80)

0.34 (2.77)

0.97 (0.74)

-2.15 (2.58)

1.42 (0.87)

-3.40 (2.77)

-0.05 (0.33)

0.04 (4.15)

-0.02 (0.21)

-0.91 (3.53)

0.00 (0.15)

-0.98 (3.40)

0.04 (0.28)

-4.52 (3.51)

0.49 (0.41)

-0.03 (1.02)

0.21 (0.39)

-0.10 (1.03)

0.06 (0.30)

-0.14 (0.89)

-0.44 (0.35)

-0.81 (0.82)

-0.05 (0.30)

-0.34 (1.86)

-0.11 (0.30)

-2.04 (1.62)

-0.12 (0.28)

-2.78 (1.36)

-0.17 (0.34)

-3.20 (1.37)

0.83 (0.90)
-0.26 (0.53)

-1.64 (2.33)
2.39 (1.79)

0.22 (0.83)
0.02 (0.59)

-0.25 (2.13)
0.20 (1.97)

0.79 (0.71)
-0.14 (0.50)

-2.35 (1.79)
0.78 (1.70)

1.01 (0.77)
0.05 (0.62)

-2.75 (2.05)
0.43 (2.01)

81

Table 4-2.

(Continued)

Characteristics

QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Had a Usual
Source of Care

0.24 (0.21)

-2.03 (10.38)

0.12 (0.25)

Any Emergency
Department VisitBaseline Year

-0.04 (0.24)

-0.83 (1.12)

No. of
Pharmacies Used

-0.19 (1.03)

Very Satisfied
with Received
Healthcare

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-10.35
(14.40)

-0.12 (0.24)

4.50 (13.60)

-0.03 (0.28)

7.42 (14.52)

0.21 (0.29)

0.51 (1.23)

0.40 (0.31)

1.09 (0.99)

0.35 (0.28)

1.39 (1.02)

5.44 (9.33)

0.75 (1.04)

-0.14 (8.78)

0.69 (0.94)

2.45 (8.32)

0.73 (1.08)

1.80 (9.18)

-0.14 (0.40)

0.63 (4.31)

-0.70 (0.59)

6.87 (4.38)

-0.42 (0.42)

2.88 (4.01)

-0.38 (0.39)

2.10 (4.08)

Provider Always
Explained

-0.03 (0.32)

-3.09 (5.42)

-0.06 (0.30)

-3.74 (5.10)

-0.07 (0.27)

-1.95 (4.51)

0.01 (0.24)

-0.33 (4.29)

Provider Always
Listened

-0.06 (0.22)

-1.27 (4.98)

-0.10 (0.23)

-3.52 (4.79)

-0.04 (0.16)

-0.53 (4.43)

0.05 (0.23)

3.99 (5.00)

Provider Always
Respected

-0.04 (0.20)

-1.14 (4.42)

-0.11 (0.30)

-4.21 (4.54)

-0.06 (0.22)

-3.63 (4.48)

-0.09 (0.31)

-5.31 (5.47)

Constant
(Base QPDC)
Sample Size

-10.03
(26.58)

Difference in
Returns to
Characteristics

QPDC 40th

-7.29 (27.29)

-34.15
(23.76)

-36.71
(28.67)

3,288

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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Table 4-3.
Oaxaca-Blinder decomposition of black-white differences in adherence across PDC quantiles, 50th-80th, from the
viewpoint of black seniors
Outcome

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Panel A: Fitted Adherence Levels and Differences
QPDC, Blacks
QPDC, Whites
Difference

72.89 (2.42)
77.78 (1.02)
-4.89 (2.62)

81.62 (1.76)
86.54 (0.94)
-4.93 (2.03)

88.90 (1.22)
93.41 (0.65)
-4.51 (1.44)

97.16 (1.06)
99.36 (0.43)
-2.20 (1.17)

Panel B: Portion of Adherence Difference Due to:
Characteristics
Aggregate
Contribution
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban Residence
Census Region:
Midwest
South
West
Health Status:
Very Good
Good

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

4.41 (4.50)

-9.31 (5.12)

2.19 (3.53)

-7.12 (4.25)

0.20 (2.95)

-4.70 (3.46)

1.33 (1.93)

-3.53 (2.24)

0.09 (0.42)
-0.01 (0.19)
-0.01 (0.48)
-0.45 (0.48)
-0.26 (1.54)
0.04 (0.42)

0.81 (1.63)
0.65 (1.65)
1.84 (2.61)
-3.82 (3.64)
1.35 (3.67)
1.87 (6.62)

-0.05 (0.34)
-0.02 (0.16)
-0.01 (0.41)
-0.03 (0.33)
0.84 (1.28)
-0.05 (0.31)

0.70 (1.38)
1.46 (1.39)
2.18 (2.28)
-0.72 (2.73)
-1.34 (3.17)
-0.40 (4.98)

-0.20 (0.33)
-0.05 (0.13)
0.03 (0.34)
-0.27 (0.26)
0.85 (0.96)
-0.07 (0.25)

-0.36 (1.19)
1.68 (1.14)
1.04 (1.86)
-2.22 (2.22)
-1.16 (2.39)
-2.38 (3.70)

-0.01 (0.23)
-0.07 (0.11)
-0.13 (0.23)
-0.22 (0.19)
0.66 (0.64)
-0.00 (0.19)

0.17 (0.82)
1.56 (0.78)
1.10 (1.32)
-1.61 (1.40)
-1.06 (1.56)
-1.10 (2.84)

-1.53 (0.90)

2.90 (2.20)

-0.91 (0.72)

1.91 (1.86)

-0.74 (0.52)

1.68 (1.32)

-0.30 (0.44)

0.75 (1.12)

1.87 (1.75)
0.18 (1.48)

3.39 (2.61)
-0.56 (2.37)

0.02 (1.24)
0.62 (1.34)

0.32 (1.95)
-1.33 (2.18)

0.06 (0.97)
-0.08 (1.18)

0.07 (1.56)
-0.07 (1.89)

0.13 (0.80)
0.29 (0.75)

0.17 (1.30)
-0.67 (1.21)

-0.31 (0.72)

-0.75 (3.03)

-0.39 (0.56)

0.37 (2.38)

-0.22 (0.51)

-0.04 (2.03)

-0.36 (0.39)

1.17 (1.47)

0.05 (0.30)

0.25 (3.09)

0.07 (0.29)

1.52 (2.57)

0.06 (0.27)

1.62 (2.27)

0.04 (0.18)

0.95 (1.71)
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Table 4-3.

(Continued)

Characteristics

Fair
Poor
Any Physical
Limitation
Any Cognitive
Limitation
Depressive
Symptoms
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke
Count of
Comorbid
Conditions
Charlson
Comorbidity
Score Q3
Charlson
Comorbidity
Score Q4

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.87 (0.92)
0.48 (0.43)

0.34 (1.75)
0.92 (0.70)

0.86 (0.81)
0.48 (0.38)

0.80 (1.46)
0.91 (0.59)

0.67 (0.66)
0.39 (0.29)

0.74 (1.21)
0.66 (0.47)

0.70 (0.52)
0.34 (0.23)

0.93 (0.95)
0.51 (0.36)

0.19 (0.34)

7.32 (3.44)

0.12 (0.23)

5.07 (2.90)

0.02 (0.13)

1.18 (2.37)

-0.02 (0.10)

0.09 (1.88)

0.44 (0.65)

0.87 (0.83)

0.03 (0.48)

0.33 (0.63)

-0.32 (0.37)

-0.14 (0.43)

-0.39 (0.27)

-0.15 (0.29)

-0.50 (0.58)

-0.60 (0.62)

-0.12 (0.46)

0.03 (0.52)

0.23 (0.36)

0.40 (0.38)

0.37 (0.29)

0.39 (0.28)

0.99 (1.10)
-0.08 (0.41)
-0.20 (0.26)
0.00 (0.11)
0.14 (0.21)
0.01 (0.17)

5.35 (8.62)
-0.57 (3.91)
0.72 (1.40)
-0.20 (0.54)
-0.87 (0.87)
0.44 (0.70)

1.54 (0.96)
-0.18 (0.36)
-0.13 (0.21)
0.00 (0.09)
0.04 (0.22)
0.01 (0.13)

8.87 (7.26)
0.64 (3.66)
0.38 (1.08)
-0.26 (0.46)
-0.26 (0.82)
0.08 (0.58)

0.82 (0.86)
-0.14 (0.25)
-0.02 (0.19)
-0.01 (0.08)
0.04 (0.21)
-0.01 (0.11)

5.39 (6.76)
0.52 (2.56)
-0.34 (0.88)
0.18 (0.32)
-0.30 (0.73)
-0.20 (0.47)

0.84 (0.61)
-0.10 (0.21)
0.00 (0.14)
0.01 (0.06)
0.06 (0.13)
0.00 (0.06)

6.41 (4.45)
0.85 (1.94)
-0.36 (0.63)
-0.17 (0.26)
-0.23 (0.45)
0.03 (0.31)

0.25 (0.89)

1.83 (5.19)

0.99 (0.89)

-2.60 (5.11)

0.67 (0.67)

-3.36 (3.67)

0.34 (0.55)

-2.49 (2.99)

0.72 (0.54)

2.95 (1.91)

0.24 (0.42)

1.53 (1.60)

-0.05 (0.30)

-0.25 (1.16)

-0.35 (0.27)

-1.43 (0.87)

0.21 (0.28)

1.31 (1.30)

0.08 (0.20)

0.77 (1.11)

0.11 (0.18)

1.08 (0.86)

-0.02 (0.12)

0.09 (0.56)
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Table 4-3.

(Continued)

Characteristics

QPDC 50th

QPDC 60th

QPDC 70th

QPDC 80th

Estimate (Standard Error)
Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

More Likely to
Take Risks

0.06 (0.18)

-0.03 (1.31)

0.06 (0.15)

-0.15 (1.11)

-0.00 (0.12)

0.41 (0.85)

0.03 (0.09)

-0.02 (0.59)

Can overcome
illness without
medical care

0.15 (0.67)

-0.45 (1.36)

-0.13 (0.60)

0.20 (1.25)

-0.17 (0.50)

0.18 (1.04)

-0.26 (0.40)

0.49 (0.81)

-0.03 (0.15)

0.01 (0.62)

-0.01 (0.12)

0.14 (0.51)

-0.02 (0.09)

-0.06 (0.38)

0.03 (0.08)

0.20 (0.28)

-0.19 (0.26)

-0.49 (0.64)

-0.12 (0.21)

0.14 (0.53)

-0.02 (0.15)

0.15 (0.39)

0.06 (0.12)

0.19 (0.32)

0.10 (0.59)

1.01 (3.09)

-0.29 (0.51)

2.63 (2.65)

-0.16 (0.40)

1.38 (2.05)

-0.16 (0.29)

0.83 (1.41)

0.38 (0.52)

0.76 (1.69)

0.06 (0.44)

-0.39 (1.44)

0.13 (0.37)

0.36 (1.13)

0.29 (0.27)

0.64 (0.91)

-1.33 (1.41)

-1.16 (1.36)

-1.09 (1.20)

-1.02 (1.20)

-0.58 (1.05)

-0.33 (0.99)

-0.93 (0.82)

-0.77 (0.74)

-0.49 (0.54)
0.01 (0.25)

-1.58 (1.54)
-1.42 (3.11)

-0.10 (0.42)
0.01 (0.20)

-0.48 (1.38)
-1.13 (2.54)

-0.10 (0.40)
-0.00 (0.18)

-0.45 (1.14)
0.18 (2.13)

-0.09 (0.27)
0.00 (0.12)

-0.13 (0.78)
-0.33 (1.38)

-0.65 (2.07)

-1.01 (1.58)

-1.31 (1.70)

-1.29 (1.28)

-1.23 (1.58)

-0.94 (1.13)

0.01 (1.10)

-0.16 (0.82)

0.51 (1.07)

-2.41 (4.76)

0.37 (0.87)

-1.47 (3.82)

0.42 (0.76)

-0.97 (3.27)

-0.07 (0.52)

0.67 (2.19)

Does not need
health insurance
Current Smoker
Had Moderate /
Vigorous
Exercise
Obese (BMI≥30)
Income:
Poor/Near-Poor
Low-Income
Middle-Income
Education:
Less than High
School
High School
Diploma
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Table 4-3.

(Continued)

Characteristics

QPDC 50th

QPDC 60th

QPDC 70th

QPDC 80th

Estimate (Standard Error)

Drug Coverage
Plan:
Part D: PDPs
Part D: MA-PD
Employer/Other
Private
Auto Eligible for
PD Low-Income
Subsidy
Average Copay
for CV Drugs
($2010)
Concurrently
taking:
2-3 CV Drugs
≥4 CV Drugs
Quantiles of
Ambulatory
Visits:
Q 3 (5-7)
Q 4 (8-12)
Q 5 (≥13)

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.19 (0.86)

0.74 (3.05)

0.11 (0.76)

0.16 (2.59)

0.15 (0.65)

-0.26 (2.20)

-0.25 (0.49)

-1.38 (1.69)

0.11 (0.61)

-0.46 (2.04)

-0.21 (0.56)

-2.11 (1.89)

-0.13 (0.43)

-1.44 (1.53)

-0.17 (0.34)

-1.32 (1.09)

-1.11 (0.76)

3.16 (1.84)

-0.77 (0.66)

1.86 (1.64)

-0.84 (0.56)

1.83 (1.37)

-0.71 (0.48)

1.79 (1.12)

0.28 (1.44)

0.19 (0.41)

-0.04 (1.15)

0.00 (0.35)

-0.03 (0.91)

0.03 (0.26)

0.66 (0.62)

0.26 (0.18)

1.78 (0.81)

-4.53 (2.39)

1.24 (0.67)

-2.79 (1.98)

0.49 (0.52)

-0.51 (1.57)

0.29 (0.41)

-0.70 (1.25)

0.06 (0.35)

-6.65 (3.24)

0.05 (0.32)

-3.45 (3.05)

0.05 (0.30)

-3.09 (2.57)

0.04 (0.26)

-3.71 (1.64)

-0.51 (0.36)

-1.01 (0.87)

-0.45 (0.31)

-0.47 (0.75)

-0.34 (0.26)

-0.10 (0.59)

-0.18 (0.18)

0.16 (0.38)

-0.09 (0.24)

-1.94 (1.27)

0.02 (0.15)

-0.10 (1.18)

-0.02 (0.11)

-0.32 (0.92)

-0.00 (0.08)

-0.15 (0.68)

1.36 (0.77)
-0.16 (0.58)

-3.86 (1.85)
0.77 (1.84)

0.06 (0.62)
-0.44 (0.50)

-0.44 (1.55)
1.64 (1.56)

-0.05 (0.49)
-0.27 (0.40)

0.09 (1.21)
1.46 (1.27)

-0.07 (0.41)
0.04 (0.29)

0.33 (0.99)
0.04 (0.97)
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Table 4-3.

(Continued)

Characteristics

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.04 (0.28)

3.25 (14.38)

0.08 (0.24)

-4.22 (13.36)

0.12 (0.21)

-9.85 (11.05)

0.14 (0.16)

-7.59 (8.08)

0.09 (0.20)

0.19 (0.98)

0.08 (0.19)

-0.08 (0.87)

0.08 (0.16)

0.12 (0.69)

0.14 (0.14)

0.47 (0.55)

1.10 (0.86)

-2.12 (7.53)

1.05 (0.75)

-6.34 (6.56)

1.11 (0.58)

-7.86 (5.11)

0.86 (0.43)

-6.52 (3.75)

Very Satisfied
with Received
Healthcare

-0.38 (0.39)

1.75 (3.57)

-0.13 (0.27)

0.79 (2.91)

-0.20 (0.24)

2.42 (2.46)

-0.19 (0.18)

1.79 (1.76)

Provider Always
Explained

0.04 (0.28)

0.23 (4.54)

-0.00 (0.20)

-1.28 (3.88)

-0.04 (0.15)

-2.57 (2.89)

-0.09 (0.17)

-3.46 (2.26)

Provider Always
Listened

0.00 (0.20)

1.96 (4.30)

0.05 (0.17)

2.85 (3.91)

0.03 (0.11)

1.78 (2.77)

0.03 (0.11)

2.22 (2.18)

Provider Always
Respected

-0.08 (0.29)

-4.23 (5.23)

0.01 (0.22)

0.29 (4.76)

0.06 (0.18)

2.72 (3.30)

0.04 (0.12)

1.38 (2.43)

Had a Usual
Source of Care
Any Emergency
Department
Visit- Baseline
Year
No. of
Pharmacies Used

Constant
(Base QPDC)
Sample Size

-17.71
(27.77)

-11.54
(22.20)

5.49 (18.78)

5.32 (14.23)

3,288

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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(~150%). As in Appendix Table C-4, having activity limitations was associated with
better adherence among blacks but not among whites at the 50th PDC percentile.
Differences in other health-related factors, including having depressive symptoms, were
not associated with the racial difference in adherence.
Beliefs and Behaviors. Except for obesity among seniors at the 10th and 30th
percentiles of the PDC distribution, none of the differences related to beliefs about
healthcare, insurance, risk-taking, exercise, or smoking contributed to the racial
difference in adherence. Among seniors at the 10th and the 30th percentiles of the PDC
distribution, had whites and blacks had the same prevalence rates of obesity, or had
obesity been associated with adherence to the same extent among both groups, the racial
differences in adherence would have surprisingly increased. This follows from a strong
positive association between adherence and obesity among black but not among white
seniors at the 10th and 30th percentiles (see Appendix Table C-2).
Socioeconomic Status and Insurance. Income-related differences were not
associated with the racial differences in adherence in this sample of Medicare seniors.
Similarly education, except for the difference in completing high-school diploma among
those at the 10th percentile. As in Appendix Table C-2, having high-school diploma,
relative to having education beyond high-school, had a strong negative association with
adherence among blacks but not among whites. Subsequently, if the rates of having a
high-school diploma were equal among whites and blacks, the racial difference in
adherence among seniors at the 10th percentile would have increased by about 30% (see
Table 4-2).
The differences related to enrollment in Part D PDPs or MA-PDs did not appear
to be associated with the racial difference in adherence. The lower likelihood among
black seniors to have employer-sponsored drug coverage was a significant contributor to
the racial difference in adherence. Among seniors at the 30th and 40th percentiles of the
PDC distribution, had the rates of enrollment in employer-sponsored (mostly retiree) drug
coverage been equal among blacks and whites, the racial difference in adherence would
have dropped by 1.82 and 2.39 percentage points (about 23% and 27%), respectively.
Having this type of coverage was associated with large improvements in adherence only
among black seniors at the 30th and 40th percentiles (see Appendix Table C-2).
Accordingly, making this coverage works the same way among blacks and whites, e.g.
changes to benefit design or employee contribution, might increase the racial difference
in adherence.
The difference in how being automatically eligible for the LIS is associated with
adherence appears to play a role in the racial difference in adherence at the 10th and the
30th percentiles. Appendix Table C-2 shows that auto-eligibility for LIS among black,
but not white, seniors had a strong negative association with adherence. Had autoeligibility for LIS (which also means receiving Medicaid) been associated with adherence
in the same way across blacks and whites, the racial difference in adherence would have
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been reduced by 1.05 and 0.83 percentage points (23% and 10%), respectively. Further,
among seniors at the 10th percentile of the PDC distribution, matching average copay
amounts for cardiovascular drugs among blacks to those among whites would reduce the
racial difference in adherence, whereas doing so among seniors at the 50th percentile
would increase the racial difference in adherence.
Use of the Healthcare System. Greater use of physician ambulatory care
appeared to work disparately among blacks and whites. In Appendix Table C-2, greater
use of ambulatory care was associated with a reduction in adherence among blacks but
improvement in adherence among whites at the 30th and 40th percentiles of the PDC
distribution. Making ambulatory care work equally well for black and white seniors
would reduce the racial difference in adherence by 2.78 and 3.2 percentage points (about
35%), respectively (Table 4-2).
Among seniors at the 50th and 80th percentiles, the concurrent use of multiple (23) cardiovascular medications was associated with worsening adherence more among
blacks than among whites (see Appendix Table C-4). Eliminating this differential in the
return to using multiple cardiovascular medications would reduce the racial difference in
adherence by 6.65 and 3.71 percentage points (more than 100%), respectively as listed in
Table 4-3. Differences related to satisfaction with healthcare or provider relationship
were not associated with the racial differences in adherence.
Results from Additional Analyses. In addition to the main analysis from the
perspective of black seniors, we also calculated detailed OBD estimates using
coefficients from race-pooled unconditional quantile regressions. These results, listed in
Appendix Tables C-5 and C-6, suggest the involvement of the same set of factors
discussed above as potential sources of the racial difference in adherence. In these
analyses, unexplained components of calculated differences were quite large, negative
quantities and statistically significant across all modeled quantiles. Some explained
components were significant only below the median and all had a plus sign. Mean OBD
analyses based on logit, linear probability, and OLS models only identified differences
related to employer-sponsored coverage rates and copay levels as potential sources of the
racial difference in mean adherence.
Discussion
Differences in the distribution of and/or in the behavioral returns to marital status,
having physical limitation, hyperlipidemia, obesity, enrollment in employer-sponsored
coverage, being auto-eligible for the LIS, drug copay, use of ambulatory care, and use of
multiple cardiovascular medications explained some of the racial differences in
adherence among seniors, especially below the median, where disparities were largest
and most significant. Such findings would not have been reachable if only differences in
mean adherence were studied as traditionally carried out. In fact, our OBD analyses of
the differences in mean adherence were of limited value.
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The large magnitude and significance of the unexplained component that
corresponds to the aggregate differential in returns to individual characteristics,
especially as demonstrated by OBD pooled-coefficient analyses, suggest a
discrimination-based explanation of adherence disparities. With discrimination, we
specifically mean how the (causal) process (es) linking individual characteristics to
adherence have been operating differently for blacks and whites. Although we found this
differential operation of characteristics on adherence to be a recurrent theme, the validity
of a discrimination argument further depends on whether relevant covariates were left out
from the analysis. Although we controlled for a rich set of covariates, data on individuals’
self-efficacy, health literacy, degree of social support, neighborhood/household
environment, and the degree of mistrust of the healthcare system,175,176 all relevant
covariates, were not available in MEPS.
We have found marriage to have a protective effect against poor adherence among
blacks, suggesting an element of social support, which seems to particularly help those
attempting to improve their adherence level (at the 30th percentile, ~ 59% PDC). This
finding is corroborated by what qualitative studies of adherence among blacks reported of
the positive association between family/friends’ support with adherence.144,176 Another
finding that also alludes to social support is the role of having physical limitation. Having
physical limitation was independently associated with better adherence among black but
not among white seniors. A potential explanation might be that with physical limitation,
seniors might be getting more time with their caregivers who maybe further assisting
them with their medication-taking behavior, which may be tapping as well into the social
support construct.
Although the lower prevalence of hyperlipidemia among blacks relative to whites
appeared protective, having hyperlipidemia, which is a largely asymptomatic condition,
differentially worsened adherence among blacks but not nearly as much among whites at
the lower end of the distribution (those who were most poorly adherent). This finding is
suggestive of a higher likelihood of early discontinuation of lipid-lowering therapy
among hyperlipidemic blacks than whites, leading to much less exposure to statins, a
finding also reported by several studies.177,178 Table 4-1 and Appendix Table C-1 show
that blacks were substantially less likely to use statins than whites.
We have found ambulatory care to work differently in determining adherence for
blacks and whites, where greater use of ambulatory care among blacks was associated
with lower adherence whereas the opposite was true for whites. The specific reasons for
why this was the case warrant investigation. A number of factors, however, can be
hypothesized as potential remedies for this disparate effect. The quality of
communication and compassion in the patient-provider relationship, especially when
race-concordance is possible,150,151 has been repeatedly cited as a versatile avenue for
intervention on medication adherence among blacks.142 Quality provider communication
can address patients’ beliefs and concerns about how medications work and their side
effects, and can address issues such as early discontinuation of statins, and the
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complexity of multi-drug regimens which we found to be associated with
disproportionately lower adherence among blacks.
Insurance benefit design and cost-sharing schemes may be another set of factors
amenable for intervention for disparity reduction. We found that employer-sponsored
coverage was associated with improved adherence among blacks, being auto-eligible for
the LIS worked worse among blacks, and matching white and black copay levels was
associated with opposing effects on disparities in two different locations in the
distribution. Optimizing the design and administration of prescription drug benefits and
setting copay amounts in Part D plans in a way so as to increase medication use among
those who would benefit the most out of using those drugs (e.g. by eliminating copays on
ACE inhibitors, statins, and beta-blockers after acute MI),179,180 in a value-based benefit
design framework,181 can improve adherence where it matters most and reduce
disparities, not only in adherence but also in associated clinical and economic
outcomes.180,182 Combining these reforms in benefit design with medication therapy
management services52,53 under Part D, can together address multiple dimensions of
patients’ pharmacotherapy experience, from affordability and access, to appropriateness
of prescribed medications, education about medications, resolution of medication-related
problems, and addressing issues that might be particular to individual patients.
In addition to the factors we have found to be significantly associated with the
racial difference in adherence, other factors that have been reported in the literature, such
as depression, did not turn out to be significant. Our analysis was limited to the Medicare
elderly population. Our results are certainly not generalizable to the general adult
population where depression and other factors that were not significant in our analysis
(such as SES) might be playing a greater role than in our sample. We’ve also encountered
the counterintuitive finding that higher rates of obesity among blacks were protective
against worse adherence especially among seniors at the 10th and 30th percentiles of the
PDC distribution. This findings is in contrast with research documenting that obesity is
associated with poor adherence183 and that blacks were more likely to experience weightbased discrimination which compromised their self-efficacy and consequently their
adherence behavior.184 Whether this effect is a statistical artifact or can be potentially
explained by other factors that were not accounted for in the analysis is a matter for
further investigation.
Limitations
Decomposition analyses are powerful in that they provide a breakdown of how
the differences in covariates contribute to the overall difference in the outcome. As we
have reported, these analyses only offer bottom-line estimates of the quantitative
contributions of covariates to the outcome difference, without providing any information
on the underlying mechanisms. These mechanisms are left for the analyst to hypothesize
and test in future research using appropriate methods. The analyses we reported here
were not meant to be comprehensive. It is very possible that the variables we did not have
data on may be playing a role in the racial differences in adherence. We also suspect that
the small sample size we had might have affected the statistical significance for some of

91

our estimates. Although all multivariable analyses had sample sizes above the limit
recommended by the AHRQ (n>100), our descriptive statistics across PDC quantile
categories had sample sizes less than 100, which may have rendered those estimates
unstable.
Our adherence estimation might have suffered a number of limitations. First, our
derivation of refill days of supply from dispensed quantities was based on the 2010 data
in our MEPS sample, without validation against an external standard, e.g. Medicare
claims data. Given that previous research documented the validity of MEPS prescription
drug data against Medicare claims,87 we believe benchmarking our analysis solely to
MEPS 2010 is sufficient. While data on dispensed quantities were complete for all refills
in the study period, a large proportion of 2010 refills had missing days of supply data
(about 30%). We found the pattern of missing data to be very consistent across drug class
and respondent characteristics, indicating that a missing-completely-at-random (MCAR)
assumption is likely plausible. As such, we examined the pattern of refill days of supply
vis-à-vis dispensed quantities only among individuals with complete days of supply data
for all of their listed refills.
We also assumed that the patterns of days of supply vis-à-vis dispensed quantities
in 2010 would hold in earlier years of MEPS. Although we believe this assumption is
likely true on average, changes in treatment guidelines, generic availability, and coverage
tier classifications of drugs might have affected the prescribed total daily doses of some
cardiovascular medications. Since MEPS did not have refill dates, a reasonable choice for
the index date was the first day of the MEPS round in which the refill occurred. We
might have thus underestimated adherence for respondents who started late in the round,
although it is not possible to identify them. If a respondent had too few refills over a
round (3-4 months), it might also be the case that they skipped refills and not necessarily
they started taking the medication later in the round.
Conclusion
In this study, we combined the two powerful empirical techniques of OaxacaBlinder decomposition and unconditional quantile regression, to explore the potential
sources of black-white differences in adherence to cardiovascular medications in a
nationally representative sample of Medicare seniors. Our findings suggest that
adherence differences were largely driven by differences in how the determinants of
adherence operated differently for blacks than whites, including marital status, having
hyperlipidemia, physical limitations, drug coverage, enrollment in Part D LIS, copay
amounts, cardiovascular drug regimen, and use of ambulatory care. As such, these
findings suggest a discrimination-based explanation of the racial differences in
adherence. Interventions focusing on promoting social support in patients’ environment,
more collaborative and compassionate patient-provider relationship, and value-based
drug benefit design along with medication therapy management may be immediate
avenues for intervention.
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CHAPTER 5.

CONCLUSION

Summary of Findings
Our difference-in-differences analyses showed that Medicare Part D was
associated with a 16-percentage-point decrease in the white-Hispanic disparity in overall
average adherence to cardiovascular medications among the elderly. This decrease was
most visible in adherence to beta-blockers, where the white-Hispanic disparity decreased
by 30 percentage points. While there was no significant change in overall and medication
class-specific black-white disparities, overall adherence among black men
disproportionately fell by 21 percentage points, relative to white men. Other subgroup
analyses across gender and Medicaid eligibility lines suggested no statistically significant
changes in disparities among these subgroups following Part D introduction. Estimates of
racial disparities in the post-Part D era, 2007-2010, indicate the existence of large and
significant black-white disparities, overall and in each sub-group. Overall adherence
levels among both black and Hispanic Medicaid-eligible seniors were 19- and 15percentage points lower than whites, which were the largest among all subgroups. Using
the near-elderly as a control group, with a few caveats, these findings took into account
the potential level of disparities had Part D not been implemented. These findings also
remained robust to the levels of empirical adjustment for covariates.
Among seniors, black-white disparities in adherence were largest (and statistically
significant) towards the lower end of the distribution, below the 40th percentile and
peaking around the 30th percentile, namely, among populations with poor adherence
levels (70 and 60% adherence, respectively). Disparities progressively waned towards the
upper end of the distribution. This pattern generally recurred among subgroups, with
some variation in magnitude and statistical significance. Additionally, among men and
the auto-enrolled LIS population (including Medicaid-eligibles), disparities were most
concentrated among populations at and below the 30th percentile (adherence levels <
60%). Although white-Hispanic disparities exhibited a similar pattern, they were smaller
in magnitude and sporadically significant.
Distribution-wide Oaxaca-Blinder decompositions analyzed how the racial
inequality in the determinants of adherence contributed to the adherence differential
between black and white seniors. These analyses suggested that differences in most
demographics, income, education, depression and most conditions, type of Part D drug
coverage plan, or covariates measuring experience with healthcare providers were not
associated with the adherence differential. Marriage and activity limitations appeared
protective against poor adherence more among black than among white seniors with
adherence levels below 60%, tapping into social support as the possibly underlying
mechanism. Having diagnosed hyperlipidemia, which is mostly an asymptomatic
condition, was mroe strongly associated with poorer adherence among blacks than among
whites with very poor adherence (30%), suggestive of higher likelihood of early
discontinuation of drug therapy (potentially statins) among blacks than among whites in
this population.
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The racial differential in enrollment rates in employer-sponsored insurance was
strongly associated with the adherence differential among seniors with adherence below
70%. This type of coverage was also independently associated with much higher
adherence among blacks than among whites. Eliminating the racial differential in
employer coverage rates was associated with an expected ~ 25% reduction in the
adherence differential. Being an auto-recipient of the LIS was independently associated
with worse adherence among blacks than among whites in this population. Matching the
average copay levels among poorly adherent blacks and whites was associated with an
increase in the adherence differential, whereas doing do among those with adherence
close to 80% would reduce the differential. Greater use of ambulatory physician visits
was associated with better adherence among whites but worse adherence among blacks
with adherence below 70%. This differential in how visits determined adherence was
responsible for about 35% of the adherence differential. Among seniors with adherence
above 77%, taking multiple cardiovascular medications was associated with much worse
adherence among blacks than among whites.
Implications for Research
One key limitation of current research on adherence, including this dissertation, is
studying adherence as an isolated behavioral phenomenon. Greater appreciation of the
complexity of adherence is much needed. Adherence should be understood as a series of
behaviors that start with keeping doctor’s appointments to actual administration of
medications, involving steps such as regularly filling prescriptions, using reminders,
exercising, and maintaining healthy diet.111 These contiguous behaviors arise from
complex interactions among multiple factors, pertinent to the patient and the
environment. Given this complexity, we need to build a deeper mechanistic
understanding of how this intricate system works and how/where it engenders disparities.
Parsing out this intricacy, through complex systems science and simulation approaches,
enables us to identify novel “leverage points” for effective intervention that were
potentially otherwise unidentifiable.112 Studying adherence this way can also help us
answer interesting behavioral and clinical questions, including ones identified in this
dissertation (for example: how the use of ambulatory care disparately affects adherence
between blacks and whites; why black LIS recipients fare worse than their white
counterparts in terms of their adherence behavior; and why disparities in adherence to
beta-blockers and diuretics are the largest among all cardiovascular drug classes).
Although one could delineate the characteristics of populations where adherence
disparities were found to be worst, identifying them in routine clinical practice is
challenging. This is a result of the lack of alignment between the empirical refill-based
measures of adherence typically employed in research (such as the proportion of days
covered, PDC, used here), and the measures that can be used to assess patient adherence
in routine clinical practice.117,152 Further, although using quantile regression enabled us to
get a more comprehensive picture of the adherence distribution, we still lumped
adherence into a single number without further parsing out the underlying behavioral
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details. Instead of summarizing patient adherence over (say) a year into a single number,
a more informative alternative would be to examine the developmental trajectories of
adherence over time using group-based trajectory models.153 This would enable us to
capture more details about regimen execution, i.e. patterns of how the prescribed
compares to the actual regimen taken, and persistence over time.18,21 Identifiable patterns
such as brief lapse in therapy due to occasional dose omissions, longer drug holiday but
then continuation, periodic gaps in therapy, and early discontinuation provide a basis for
more meaningful classification of adherence behavior with implications for intervention
and for studying disparities. It is worth noting here that some recently developed
questionnaire instruments, which can be administered in practice settings, can help
identify these distinct patterns as well, and can thus offer a closer insight into real-world
settings.152,154
Implications for Policy
While it is important to identify access/quality issues that may disparately
compromise adherence behavior among minorities, it is at least equally as important to
envision adherence as a reflection of the structural, physical, and psychosocial
disadvantage racial minorities typically live in. Poverty, low educational attainment, poor
social support, disordered physical and social environments, and policies that
institutionalize racism are systematic, causal antecedents to almost every poor health
outcome among minorities.108 One example of how social determinants affected
adherence in this dissertation manifested in the rates of employer-sponsored coverage.
The black-white differential in employer-sponsored insurance coverage (mostly retiree
coverage) was responsible for a sizable portion of the adherence differential. Our results
suggest that if blacks were equally likely to have been employed in a way that provides
them with generous insurance coverage upon retirement, the adherence differential would
have been reduced. The nature of employment and type of occupation are direct
correlates of educational attainment, which is much lower among blacks than whites (in
our sample, ~50% of black seniors had less than high school education, compared with
only 20% among whites). Achieving equity in these fundamental determinants of health
ought to remain a long-term goal for society.
Under Medicare Part D, MTM programs offer a versatile mechanism to address
the drivers of poor adherence among minorities and to reduce adherence disparities. First,
however, the utilization-based eligibility criteria for MTM services continue to be an
impediment to improving the quality of medication use in this population as it deprives
minorities who would greatly benefit from this service.63,185 Investigating more equitable
alternatives for these criteria remains an important step. Further, although having an optout, rather than an opt-in, policy for enrollment in MTM is a good step towards greater
enrollment of seniors for this service, there is still a low turnout rate in keeping up with
MTM appointments and medication reviews.148 Increasing awareness of the value of
MTM, particularly among minorities, may prove to be a good step towards improving
adherence among seniors and particularly minorities. Through comprehensive medication
reviews, collaboration with patient’s providers (including social workers, and
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community/home health workers), and establishing an empowering collaborative
relationship with the patients themselves, pharmacists providing MTM can proactively
identify and tackle issues compromising medication adherence (and potentially other
aspects of healthcare). 52,53,109,149 Examples of what MTM and, broadly, what other
providers can do, include: educating patients about their medications, addressing their
medication-related problems and concerns (e.g. issues related to discontinuation of statin
therapy, poor adherence to diuretics and beta-blockers, having to take multiple
medications), promoting their self-management behavior, improving their health literacy,
screening for depression, and enhancing their self-efficacy. Current evidence suggest that
minorities’ adherence to cardiovascular medications significantly improves when there is
race and language concordance between them and their providers, which should be
sought whenever possible.150,151 Further research110 is needed on how to optimize MTM
delivery for minority and low-SES patients.
Insurance benefit design and cost-sharing schemes may be another set of factors
amenable for intervention for disparity reduction. We found that employer-sponsored
coverage was associated with improved adherence among blacks, being auto-eligible for
the LIS worked worse among blacks, and matching white and black copay levels was
associated with opposing effects on disparities in two different locations in the
distribution. Optimizing the design and administration of prescription drug benefits and
setting copay amounts in Part D plans in a way so as to increase medication use among
those who would benefit the most from using those drugs (e.g. by eliminating copays on
ACE inhibitors, statins, and beta-blockers after acute MI),179,180 in a value-based benefit
design framework,181 can improve adherence where it matters most and reduce
disparities, not only in adherence but also in associated clinical and economic
outcomes.180,182 Combining these reforms in benefit design with medication therapy
management services52,53 under Part D, can together address multiple dimensions of
patients’ pharmacotherapy experience, from affordability and access, to appropriateness
of prescribed medications, education about medications, resolution of medication-related
problems, and addressing issues that might be particular to individual patients.
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APPENDIX A. SUPPLEMENTAL MATERIALS FOR CHAPTER 2
Table A-1.

Identifying information for included cardiovascular conditions
Condition
Essential
Hypertension
Hypertension with
complications /
Secondary
Hypertension

CCC
98
99

Hyperlipidemia
Angina and Coronary
Heart Disease
(atherosclerosis)
Congestive Heart
Failure

53
101

Acute Myocardial
Infarction

100

Acute
Cerebrovascular
Disease

109

108

ICD-9 Codes
4011

4019

4010
4030
40390
4041
40491
40591
2720
4110
4131
4149
39891
42830
42843
4100
41012
41031
41050
4107
41082
34660
4321
43391
4349

40200
40300
40391
40410
40492
40599
2721
4111
4139
V4581
4280
42831
4289
41000
4102
41032
41051
41070
4109
34661
4329
4340
43490

109

40201
40301
4040
40411
40493
4372
2722
4118
4140
V4582
4281
42832

40210
4031
40400
40412
40501

40211
40310
40401
40413
40509

40290
40311
40402
4049
40511

40291
4039
40403
40490
40519

2723
41181
41400

2724
41189
41401

412
41406

4130
4148

42820
42833

42821
42840

42822
42841

42823
42842

41001
41020
4104
41052
41071
41090
34662
43301
43400
43491

41002
41021
41040
4106
41072
41091
34663
43311
43401
436

4101
41022
41041
41060
4108
41092
430
43321
4341

41010
4103
41042
41061
41080

41011
41030
4105
41062
41081

431
43331
43410

4320
43381
43411

Table A-1.

(Continued)
Condition
Transient Cerebral
Ischemia

CCC
112

ICD-9 Codes
4350

4351

4352

4353

4358

4359

CCC: Clinical Classification Codes; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical
Modification.
Source: AHRQ. MEPS HC-137: 2010 Medical Conditions- Appendix 3: Clinical Classification Code to ICD-9-CM Code
Crosswalk. Rockville, MD 2012.
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Table A-2.

Included cardiovascular medications
MultumLexicon ®
Class
42

MultumLexicon ®
Subclass 1
None

56

None

173

None

47

274, 275

Calcium Channel
Blockers

48

None

Diuretics

49

154-158

Antihypertensive
Combinations

55

None

Drug Class
Angiotensin-Converting
Enzyme (ACE) Inhibitors
Angiotensin II Receptor
Blockers
HMG-CoA Reductase
Inhibitors (Statins)
Beta-Blockers

Specific Agents
Benazepril, Captopril, Enalapril, Fosinopril,
Lisinopril, Moexipril, Perindopril, Quinapril,
Ramipril, Trandolapril
Candesartan, Eprosartan, Irbesartan, Losartan,
Olmesartan, Telmisartan, Valsartan
Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin,
Pravastatin, Rosuvastatin, Simvastatin
Acebutolol, Atenolol, Betaxolol, Bisoprolol,
Carvedilol, Labetalol, Metoprolol, Nadolol,
Nebivolol, Penbutolol, Pindolol, Propranolol,
Sotalol, Timolol
Amlodipine Besylate, Diltiazem, Felodipine,
Isradipine, Nicardipine, Nifedipine, Nisoldipine,
Verapamil
Acetazolamide, Spironolactone, Amiloride,
Bumetanide, Chlorothiazide, Chlorthalidone,
Furosemide, Hydrochlorothiazide, Indapamide,
Methyclothiazide, Metolazone, Torsemide,
Triamterene
Multiple combinations of these drugs with
diuretics, especially

Source: AHRQ. MEPC HC-135A: 2010 Prescribed Medicines. Rockville, MD 2012.
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Figure A-1. Sequential adjustment for covariates and the magnitude of the difference-in-differences coefficients
DID: Difference-in-Differences. All analyses were conducted in the main sample (n=17,677), excluding 2006 data.
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Table A-3.
Covariate

Multivariable logistic regression results in the main sample and by subgroup
Main
Analysis

Difference-in-Difference Setup
Treated Group
1.11
(Medicare Seniors)
[0.90,1.38]
2.15
Post-Part D Period
[1.71,2.69]ǂ
Medicare Post Part
0.89
D
[0.70,1.14]
0.97
Black
[0.18,5.09]
0.94
Black in Medicare
[0.64,1.39]
0.79
Black Post-Part D
[0.50,1.24]
Black in Medicare
0.78
Post-Part D
[0.45,1.33]
1.35
Hispanic
[0.62,2.95]
Hispanic in
0.57
Medicare
[0.37,0.88]†
Hispanic Post-Part
0.55
D
[0.34,0.90]†
Hispanic in
2.04
Medicare Post-Part
[1.14,3.63]†
D

2006
Analysis

Medicare
65-70 Tx
Men
Women
Group
Odds Ratio [95%CI]

Non-Dual

Dual
Eligibles

1.13
0.95
1.12
[0.92,1.39] [0.70,1.28]
[0.83,1.51]
1.80
2.09
2.70
[1.44,2.24]ǂ [1.66,2.63]ǂ [1.93,3.77]ǂ
0.89
1.09
0.89
[0.70,1.14] [0.82,1.46]
[0.62,1.27]
1.34
1.28
0.60
[0.26,6.78] [0.10,15.87] [0.05,8.02]
0.93
0.87
1.12
[0.63,1.37] [0.54,1.41]
[0.64,1.97]
0.74
0.80
1.04
[0.48,1.14] [0.50,1.27]
[0.46,2.36]
0.91
0.78
0.42
[0.56,1.49] [0.41,1.47] [0.18,0.96]†
1.69
1.13
0.97
[0.77,3.69] [0.46,2.80]
[0.23,4.13]
0.56
0.76
0.47
[0.36,0.86]ǂ [0.46,1.25]
[0.19,1.17]
0.54
0.54
0.55
[0.33,0.87]† [0.33,0.89]† [0.20,1.50]

1.08
[0.84,1.41]
1.76
[1.35,2.29]ǂ
0.95
[0.71,1.28]
1.11
[0.60,2.03]
0.85
[0.50,1.46]
0.64
[0.36,1.13]
1.17
[0.60,2.29]
1.20
[0.42,3.41]
0.64
[0.39,1.05]*
0.57
[0.32,1.01]*

1.08
[0.87,1.36]
2.12
[1.68,2.68]ǂ
0.91
[0.70,1.18]
3.27
[0.29,36.74]
1.08
[0.66,1.76]
0.89
[0.51,1.53]
0.64
[0.33,1.25]
1.38
[0.43,4.49]
0.52
[0.32,0.87]†
0.68
[0.38,1.22]

1.86
[0.87,3.96]
2.53
[1.05,6.13]†
0.71
[0.27,1.86]
0.62
[0.06,6.25]
0.37
[0.14,0.99]†
0.35
[0.10,1.22]*
2.06
[0.53,8.03]
2.26
[0.28,18.40]
0.45
[0.15,1.34]
0.31
[0.09,1.10]*

2.04
[1.17,3.55]†

1.88
[0.94,3.75]*

1.83
[0.93,3.63]*

3.03
[0.75,12.25]

1.34
[0.66,2.76]
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2.44
[0.81,7.32]

Table A-3.

(Continued)
Main
Analysis

2006
Analysis

Medicare
65-70 Tx
Group

Men

Women

Non-Dual

Dual
Eligibles

0.99
0.99
1.00
[0.99,1.00]* [0.98,1.00]ǂ [0.96,1.05]
1.05
1.05
1.02
[0.96,1.14] [0.97,1.14] [0.89,1.16]
0.94
0.92
1.00
[0.86,1.03] [0.84,1.00]† [0.87,1.15]
1.07
1.04
1.18
[0.95,1.20] [0.93,1.16] [0.99,1.41]*

0.99
[0.98,1.01]

0.99
[0.98,1.00]

N/A

N/A

1.02
[0.88,1.18]
1.01
[0.85,1.19]

0.90
[0.81,1.01]*
1.11
[0.96,1.27]

0.99
[0.98,1.00]*
1.06
[0.97,1.16]
0.94
[0.85,1.04]
1.08
[0.95,1.22]

1.00
[0.98,1.02]
0.93
[0.70,1.23]
1.01
[0.71,1.42]
0.89
[0.66,1.21]

1.23
1.20
1.29
[1.07,1.41]ǂ [1.05,1.37]ǂ [1.05,1.57]†
1.04
1.03
1.07
South
[0.91,1.18] [0.91,1.17] [0.89,1.30]
1.02
1.01
1.09
West
[0.88,1.18] [0.87,1.16] [0.87,1.37]
Self-Reported Health
1.01
1.02
0.98
Very Good
[0.89,1.15] [0.90,1.15] [0.80,1.21]
0.95
0.95
0.87
Good
[0.83,1.09] [0.83,1.08] [0.70,1.07]
1.01
1.00
0.96
Fair
[0.86,1.19] [0.86,1.16] [0.74,1.25]
1.06
1.05
1.00
Poor
[0.87,1.29] [0.88,1.26] [0.73,1.36]

1.31
[1.06,1.61]†
1.13
[0.93,1.37]
1.09
[0.89,1.34]

1.20
[1.02,1.41]†
0.98
[0.84,1.15]
0.97
[0.80,1.18]

1.25
[1.08,1.44]ǂ
1.04
[0.91,1.20]
1.04
[0.89,1.21]

1.02
[0.70,1.46]
0.91
[0.64,1.30]
0.86
[0.59,1.27]

1.11
[0.89,1.37]
0.90
[0.74,1.11]
1.04
[0.82,1.33]
1.32
[0.97,1.80]*

0.97
[0.82,1.14]
0.99
[0.84,1.17]
1.01
[0.83,1.22]
0.94
[0.74,1.21]

0.99
[0.86,1.13]
0.94
[0.81,1.08]
1.01
[0.85,1.20]
1.10
[0.89,1.37]

2.07
[1.07,3.97]†
1.40
[0.75,2.61]
1.38
[0.74,2.57]
1.19
[0.59,2.37]

Covariate
Demographics
Age
Female gender
Married
Urban Residence
Census Region
Midwest
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Table A-3.
Covariate

(Continued)
Main
Analysis

Any Physical
1.07
Limitation
[0.98,1.17]
Any Cognitive
1.14
Limitation
[0.99,1.31]*
Conditions (over survey year)
0.85
Charlson Score Q3
[0.77,0.93]ǂ
0.82
Charlson Score Q4
[0.70,0.97]†
0.96
Comorbidity Count
[0.94,0.97]ǂ
1.47
Hypertension
[1.30,1.65]ǂ
1.03
Lipidemia
[0.94,1.13]
1.05
Angina/CHD
[0.94,1.17]
1.20
CHF
[0.98,1.48]*
0.92
AMI
[0.77,1.10]
0.87
Stroke
[0.72,1.06]
1.04
Depression
[0.91,1.19]

1.06
[0.98,1.15]
1.11
[0.97,1.26]

Medicare
65-70 Tx
Group
1.01
[0.88,1.16]
1.14
[0.85,1.55]

1.06
[0.92,1.22]
1.10
[0.88,1.38]

1.07
[0.95,1.20]
1.17
[0.98,1.39]*

1.07
[0.98,1.18]
1.14
[0.96,1.34]

1.06
[0.74,1.52]
1.15
[0.84,1.57]

0.89
[0.82,0.97]ǂ
0.89
[0.76,1.03]
0.96
[0.95,0.97]ǂ
1.48
[1.32,1.66]ǂ
1.03
[0.95,1.12]
1.16
[1.05,1.30]ǂ
1.15
[0.95,1.40]
0.99
[0.83,1.17]
0.90
[0.75,1.08]
1.06
[0.93,1.20]

0.82
0.83
[0.72,0.96]† [0.71,0.95]ǂ
0.83
0.77
[0.65,1.04] [0.60,0.98]†
0.96
0.94
[0.94,0.99]ǂ [0.91,0.96]ǂ
1.55
1.41
[1.26,1.90]ǂ [1.19,1.68]ǂ
1.13
1.02
[0.97,1.31]
[0.88,1.18]
1.06
1.14
[0.88,1.29]
[0.97,1.35]
1.57
1.22
[1.03,2.39]† [0.89,1.66]
1.15
0.86
[0.84,1.57]
[0.68,1.09]
0.72
0.94
[0.52,1.00]* [0.70,1.27]
0.94
1.18
[0.76,1.15]
[0.90,1.53]

0.87
[0.78,0.98]†
0.89
[0.73,1.08]
0.97
[0.95,0.99]ǂ
1.51
[1.27,1.79]ǂ
1.02
[0.91,1.14]
0.94
[0.80,1.11]
1.20
[0.91,1.58]
0.96
[0.72,1.28]
0.84
[0.66,1.07]
0.98
[0.84,1.14]

0.84
[0.76,0.93]ǂ
0.77
[0.64,0.91]ǂ
0.95
[0.94,0.97]ǂ
1.45
[1.28,1.65]ǂ
1.02
[0.93,1.13]
1.07
[0.95,1.20]
1.18
[0.95,1.47]
0.93
[0.76,1.12]
0.89
[0.72,1.10]
1.05
[0.91,1.22]

0.90
[0.68,1.19]
1.20
[0.80,1.79]
0.97
[0.93,1.02]
1.84
[1.18,2.88]ǂ
1.08
[0.80,1.45]
0.94
[0.66,1.33]
1.39
[0.85,2.26]
0.92
[0.55,1.53]
0.82
[0.51,1.31]
0.94
[0.67,1.31]

2006
Analysis
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Men

Women

Non-Dual

Dual
Eligibles

Table A-3.
Covariate

(Continued)
Main
Analysis

2006
Analysis

Beliefs & Behaviors
More Likely to
0.94
0.94
Take Risks
[0.85,1.05] [0.85,1.05]
Do Not Need
0.96
0.90
Insurance
[0.78,1.18] [0.74,1.09]
Can Overcome
1.03
1.05
Illness without
[0.91,1.17] [0.93,1.18]
Medical Care
0.99
1.00
Currently Smoking
[0.87,1.13] [0.89,1.13]
Moderate/Vigorous
1.03
1.01
Exercise
[0.95,1.12] [0.93,1.10]
Socioeconomic Status & Insurance
Income:
1.06
1.06
Poor
[0.92,1.22] [0.93,1.21]
1.06
1.04
Low-Income
[0.92,1.23] [0.91,1.19]
1.02
1.01
Middle-Income
[0.93,1.13] [0.92,1.11]
Education:
1.14
1.11
Less than High
[1.00,1.30]* [0.98,1.26]*
School
High School
1.05
1.04
Diploma
[0.95,1.16] [0.95,1.15]
Language:
0.78
0.94
Interview in
[0.46,1.32] [0.54,1.61]
English

Medicare
65-70 Tx
Group

Men

Women

Non-Dual

Dual
Eligibles

0.92
[0.79,1.07]
0.96
[0.66,1.39]

0.94
[0.80,1.10]
1.03
[0.74,1.42]

0.94
[0.81,1.10]
0.92
[0.69,1.23]

0.94
[0.83,1.06]
1.00
[0.80,1.25]

1.01
[0.72,1.41]
0.67
[0.39,1.15]

1.09
[0.91,1.30]

1.03
[0.84,1.27]

1.04
[0.88,1.23]

1.03
[0.90,1.18]

0.95
[0.65,1.40]

1.08
[0.92,1.28]
0.99
[0.87,1.11]

0.98
[0.80,1.19]
1.18
[1.02,1.35]†

0.99
[0.84,1.17]
0.94
[0.84,1.04]

0.99
[0.86,1.14]
1.03
[0.94,1.12]

0.95
[0.68,1.33]
0.97
[0.73,1.29]

1.21
[0.95,1.53]
1.04
[0.82,1.32]
1.06
[0.90,1.25]

1.14
[0.91,1.45]
1.05
[0.84,1.32]
0.98
[0.84,1.15]

1.04
[0.87,1.24]
1.04
[0.87,1.26]
1.05
[0.92,1.20]

0.98
[0.84,1.15]
1.07
[0.92,1.23]
1.01
[0.92,1.12]

1.60
[0.65,3.92]
1.06
[0.41,2.75]
1.57
[0.60,4.10]

1.10
[0.89,1.36]

1.25
[1.01,1.54]†

1.06
[0.88,1.27]

1.15
[1.00,1.33]*

0.84
[0.43,1.62]

1.04
[0.89,1.21]

1.04
[0.89,1.23]

1.04
[0.90,1.20]

1.05
[0.94,1.16]

1.01
[0.48,2.12]

0.63
[0.34,1.18]

0.35
[0.14,0.87]†

1.26
[0.60,2.64]

0.76
[0.30,1.94]

1.15
[0.65,2.02]
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Table A-3.
Covariate
Insurance:
Medicaid

(Continued)
Main
Analysis

2006
Analysis

1.00
0.97
[0.86,1.16] [0.84,1.11]
0.96
0.90
Private, Non-HMO
[0.87,1.05] [0.83,0.99]†
0.98
0.94
Private, HMO
[0.85,1.13] [0.82,1.08]
Healthcare Use (over survey year)
Concurrently Taken Drugs
0.58
0.58
2-3 CV Drugs
[0.52,0.64]ǂ [0.53,0.63]ǂ
0.41
0.40
≥4 CV Drugs
[0.34,0.50]ǂ [0.34,0.48]ǂ
1.66
1.63
2-4 Other Drugs
[1.46,1.89]ǂ [1.44,1.84]ǂ
2.83
2.65
≥5 Other Drugs
[2.41,3.33]ǂ [2.28,3.09]ǂ
0.78
0.77
No. of Pharmacies
[0.72,0.84]ǂ [0.71,0.83]ǂ
Used
Had a Usual Source
1.18
1.12
of Care
[0.93,1.51] [0.89,1.41]
Quintiles of Ambulatory Physician Visits
1.03
1.00
Q 2 (3-4 Visits)
[0.92,1.16] [0.89,1.12]
0.92
0.88
Q 3 (5-7 Visits)
[0.80,1.05] [0.77,1.00]†

Medicare
65-70 Tx
Group
0.95
[0.76,1.20]
1.00
[0.86,1.17]
1.00
[0.82,1.22]

Men

Women

1.06
[0.82,1.37]
0.94
[0.82,1.07]
0.98
[0.81,1.20]

0.98
[0.83,1.15]
0.97
[0.85,1.10]
1.00
[0.83,1.19]

0.58
[0.50,0.68]ǂ
0.41
[0.29,0.58]ǂ
1.58
[1.31,1.91]ǂ
2.84
[2.19,3.68]ǂ
0.81
[0.72,0.90]ǂ
1.10
[0.77,1.56]

0.58
[0.50,0.68]ǂ
0.36
[0.27,0.47]ǂ
1.67
[1.38,2.01]ǂ
2.97
[2.33,3.79]ǂ
0.76
[0.67,0.85]ǂ
1.25
[0.91,1.73]

1.03
[0.87,1.23]
0.92
[0.76,1.12]

1.02
[0.85,1.22]
0.95
[0.77,1.17]
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Non-Dual

Dual
Eligibles

N/A

N/A

0.97
[0.88,1.06]
0.99
[0.85,1.14]

0.81
[0.36,1.81]
0.32
[0.13,0.78]†

0.57
[0.50,0.64]ǂ
0.46
[0.36,0.60]ǂ
1.66
[1.39,1.99]ǂ
2.75
[2.22,3.40]ǂ
0.79
[0.72,0.88]ǂ
1.15
[0.82,1.60]

0.58
[0.52,0.64]ǂ
0.39
[0.32,0.48]ǂ
1.68
[1.47,1.92]ǂ
2.89
[2.42,3.45]ǂ
0.76
[0.70,0.83]ǂ
1.15
[0.89,1.50]

0.51
[0.37,0.70]ǂ
0.57
[0.32,1.03]*
1.61
[1.00,2.59]†
2.69
[1.62,4.47]ǂ
1.01
[0.77,1.33]
1.41
[0.79,2.53]

1.05
[0.91,1.23]
0.91
[0.78,1.07]

1.06
[0.94,1.20]
0.94
[0.81,1.09]

0.78
[0.54,1.14]
0.79
[0.54,1.14]

Table A-3.

(Continued)

Covariate

Main
Analysis

0.91
[0.79,1.04]
0.93
Q 5 (≥13 Visits)
[0.80,1.07]
Experience with Providers
1.08
Always Listens
[0.86,1.34]
1.00
Always Explains
[0.83,1.19]
1.01
Always Respects
[0.81,1.25]
Satisfied with
1.08
Healthcare
[0.92,1.26]
Very Satisfied with
1.02
Healthcare
[0.87,1.19]
0.7
H-L GOF P Value
17,677
Sample Size
Weighted
24,915,354
Population
Q 4 (8-12 Visits)

Men

Women

Non-Dual

Dual
Eligibles

0.86
[0.76,0.98]†
0.86
[0.75,0.99]†

Medicare
65-70 Tx
Group
0.97
[0.80,1.18]
1.06
[0.86,1.32]

1.00
[0.81,1.24]
0.94
[0.74,1.19]

0.86
[0.72,1.02]*
0.93
[0.78,1.11]

0.93
[0.80,1.08]
0.97
[0.83,1.14]

0.75
[0.49,1.16]
0.72
[0.46,1.13]

1.06
[0.87,1.29]
1.02
[0.86,1.21]
1.05
[0.86,1.27]
1.09
[0.94,1.26]
1.03
[0.88,1.20]
0.93
19,919

1.21
[0.85,1.72]
0.77
[0.57,1.05]
1.26
[0.92,1.73]
1.02
[0.81,1.28]
1.01
[0.79,1.29]
0.97
7,447

1.09
[0.77,1.54]
0.98
[0.73,1.33]
0.95
[0.67,1.35]
1.03
[0.79,1.34]
0.95
[0.72,1.25]
0.83
7,180

1.08
[0.81,1.43]
1.03
[0.80,1.34]
1.04
[0.78,1.39]
1.08
[0.90,1.30]
1.04
[0.87,1.25]
0.39
10,495

1.14
[0.89,1.45]
0.97
[0.79,1.18]
1.00
[0.79,1.28]
1.06
[0.90,1.26]
1.02
[0.86,1.22]
0.79
15,012

0.81
[0.45,1.46]
1.21
[0.73,2.00]
0.98
[0.56,1.73]
1.13
[0.76,1.69]
0.91
[0.62,1.34]
0.88
2,665

24,801,597

10,757,736

10,688,687

14,225,567

22,746,778

2,168,576

2006
Analysis

*P <0.1 † P<0.05 ǂ P<0.01
Estimates were also adjusted for interactions terms of black and Hispanic indicators with income and education levels. CV:
Cardiovascular; Q: Quartile; CHD: Coronary Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial
Infarction; HMO: Health Maintenance Organization; H-L GOF: Hosmer-Lemeshow Goodness-of-Fit test (modified for survey
data).
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Table A-4.

Multivariable logistic regressions of adherence to each cardiovascular medication class

Covariate

ACEIs/ARBs

Statins

Beta Blockers

Ca Channel
Blockers

Diuretics

Odds Ratio[95%CI]
Difference-in-Difference Setup
Treated Group
1.11
(Medicare Senior)
[0.87,1.43]
1.99
Post-Part D Period
[1.51,2.62]***
Medicare Post Part
0.84
D
[0.62,1.15]
1.64
Black
[0.17,15.64]
0.83
Black in Medicare
[0.51,1.35]
0.77
Black Post-Part D
[0.42,1.43]
Black in Medicare
0.98
Post-Part D
[0.51,1.86]
1.80
Hispanic
[0.63,5.16]
Hispanic in
0.66
Medicare
[0.37,1.18]
0.67
Hispanic Post-Part D
[0.34,1.35]
Hispanic in
1.59
Medicare Post-Part
[0.74,3.43]
D

0.94
[0.69,1.29]
2.29
[1.68,3.13]***
1.06
[0.75,1.50]
0.68
[0.04,10.48]
1.79
[1.00,3.20]**
1.21
[0.64,2.27]
0.50
[0.23,1.08]*
2.00
[0.19,20.82]
0.50
[0.21,1.19]
0.61
[0.26,1.44]

1.12
[0.77,1.62]
1.37
[0.95,1.98]*
1.02
[0.68,1.53]
0.56
[0.27,1.14]
1.14
[0.57,2.28]
1.49
[0.67,3.32]
0.49
[0.19,1.23]
1.18
[0.32,4.33]
0.59
[0.27,1.33]
0.40
[0.16,1.00]*

1.15
[0.75,1.78]
1.71
[1.06,2.76]**
0.83
[0.49,1.40]
1.33
[0.62,2.88]
0.71
[0.34,1.51]
1.06
[0.43,2.62]
0.99
[0.35,2.80]
2.85
[0.55,14.88]
0.43
[0.18,0.99]**
0.90
[0.33,2.46]

1.06
[0.78,1.46]
1.56
[1.08,2.24]**
0.85
[0.57,1.26]
1.53
[0.11,21.47]
1.36
[0.78,2.40]
1.22
[0.62,2.40]
0.56
[0.27,1.18]
0.95
[0.19,4.88]
0.45
[0.21,0.99]**
0.68
[0.28,1.67]

2.30
[0.83,6.32]

3.35
[1.21,9.28]**

1.06
[0.35,3.23]

1.76
[0.65,4.81]
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Table A-4.

(Continued)

Covariate

ACEIs/ARBs

Statins

Beta Blockers

Ca Channel
Blockers

Diuretics

1.00
[0.99,1.01]
1.02
[0.91,1.13]
0.93
[0.83,1.04]
0.98
[0.86,1.12]

1.00
[0.99,1.01]
1.02
[0.90,1.15]
0.97
[0.85,1.10]
1.07
[0.92,1.25]

0.99
[0.98,1.00]*
1.11
[0.98,1.26]
0.98
[0.85,1.14]
0.94
[0.81,1.09]

0.99
[0.98,1.01]
1.13
[0.95,1.35]
0.87
[0.74,1.03]
0.97
[0.79,1.20]

0.99
[0.98,1.00]
0.95
[0.83,1.09]
0.92
[0.80,1.05]
1.11
[0.95,1.29]

1.18
[1.01,1.39]**
0.93
[0.80,1.09]
1.01
[0.84,1.22]

1.16
[0.95,1.42]
0.96
[0.81,1.15]
0.94
[0.79,1.12]

1.13
[0.94,1.36]
1.10
[0.92,1.32]
1.02
[0.84,1.25]

1.26
[0.98,1.62]*
1.17
[0.93,1.47]
1.03
[0.80,1.33]

1.30
[1.08,1.57]***
1.04
[0.89,1.23]
1.03
[0.85,1.25]

1.09
[0.90,1.32]
1.10
[0.92,1.31]
1.18
[0.96,1.44]
1.19
[0.93,1.52]

1.11
[0.92,1.35]
0.97
[0.80,1.16]
1.08
[0.88,1.33]
1.03
[0.75,1.41]

1.10
[0.89,1.35]
1.02
[0.81,1.28]
1.03
[0.81,1.32]
1.00
[0.75,1.33]

1.03
[0.76,1.39]
0.98
[0.73,1.32]
0.96
[0.69,1.33]
1.14
[0.75,1.74]

0.96
[0.78,1.17]
1.01
[0.83,1.24]
0.98
[0.78,1.23]
0.93
[0.68,1.27]

Demographics
Age
Female gender
Married
MSA residence
Census Region
Midwest
South
West
Self-Reported Health
Very Good
Good
Fair
Poor
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Table A-4.

(Continued)

Covariate

ACEIs/ARBs

Any Physical
0.97
Limitation
[0.87,1.09]
Any Cognitive
1.08
Limitation
[0.90,1.29]
Conditions (over survey year)
0.96
Condition Count
[0.94,0.98]***
Charlson
0.90
Comorbidity Score
[0.79,1.02]*
Q3
Charlson
0.94
Comorbidity Score
[0.77,1.14]
Q4
1.49
Hypertension
[1.12,1.97]***
1.02
Lipidemia
[0.92,1.13]
1.05
Angina/CHD
[0.90,1.22]
1.17
CHF
[0.92,1.48]
0.78
AMI
[0.63,0.96]**
0.87
Stroke
[0.68,1.12]

1.12
[0.97,1.28]
1.14
[0.92,1.42]

Ca Channel
Blockers
1.21
[1.02,1.44]**
1.07
[0.83,1.39]

1.01
[0.88,1.16]
1.15
[0.93,1.42]

0.98
[0.96,1.01]

0.98
[0.95,1.01]

0.96
[0.94,0.99]***

0.81
[0.69,0.96]**

0.79
[0.69,0.91]***

0.66
[0.49,0.89]***

0.99
[0.79,1.24]

1.22
[0.79,1.90]
0.96
[0.81,1.14]
1.35
[1.05,1.73]**
0.86
[0.56,1.32]
1.09
[0.76,1.55]
0.96
[0.68,1.36]

1.29
[0.94,1.77]
1.01
[0.88,1.15]
1.09
[0.91,1.31]
1.12
[0.89,1.42]
0.98
[0.75,1.27]
0.82
[0.61,1.11]

Statins

Beta Blockers

1.11
[0.98,1.26]*
1.09
[0.88,1.34]
0.97
[0.94,0.99]***

0.84
0.83
[0.73,0.96]*** [0.72,0.95]***
0.82
[0.66,1.01]*

0.82
[0.64,1.04]*

1.19
1.54
[0.99,1.44]* [1.20,1.96]***
1.79
1.05
[1.31,2.44]***
[0.91,1.20]
1.08
1.18
[0.94,1.25]
[1.00,1.40]*
1.04
1.38
[0.75,1.44]
[1.04,1.83]**
0.97
0.91
[0.77,1.21]
[0.74,1.10]
0.98
1.00
[0.76,1.27]
[0.75,1.35]
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Diuretics

Table A-4.

(Continued)

0.94
[0.77,1.15]

Ca Channel
Blockers
0.97
[0.72,1.29]

1.01
[0.81,1.27]

1.03
[0.88,1.21]
0.85
[0.62,1.17]

1.04
[0.86,1.24]
0.83
[0.60,1.15]

0.92
[0.74,1.16]
0.82
[0.52,1.30]

0.91
[0.77,1.07]
1.15
[0.84,1.57]

1.05
[0.89,1.24]

0.97
[0.80,1.17]

1.14
[0.93,1.40]

1.27
[0.94,1.70]

0.93
[0.76,1.13]

1.13
[0.95,1.34]
0.96
[0.86,1.07]

1.03
[0.86,1.23]
1.10
[0.98,1.23]*

1.03
[0.84,1.26]
0.99
[0.85,1.15]

1.12
[0.85,1.47]
1.01
[0.86,1.19]

0.97
[0.79,1.18]
1.08
[0.96,1.21]

1.09
[0.90,1.32]
0.95
[0.80,1.14]
1.00
[0.87,1.16]

1.09
[0.91,1.32]
1.03
[0.85,1.24]
1.02
[0.88,1.19]

1.05
[0.83,1.33]
1.08
[0.87,1.34]
1.12
[0.94,1.33]

1.01
[0.74,1.38]
1.04
[0.79,1.36]
1.02
[0.82,1.27]

0.98
[0.78,1.22]
1.15
[0.91,1.46]
1.07
[0.91,1.26]

1.12
[0.93,1.34]

1.23
[1.02,1.48]**

1.06
[0.84,1.33]

1.26
[0.95,1.67]

1.07
[0.87,1.31]

Covariate

ACEIs/ARBs

Statins

Beta Blockers

Depression

0.93
[0.78,1.10]

1.24
[1.04,1.48]**

0.91
[0.79,1.06]
1.04
[0.80,1.36]

Beliefs & Behaviors
More Likely to Take
Risks
Do Not Need
Insurance
Can Overcome
Illness without
Medical Care
Currently Smoking
Moderate/Vigorous
Physical Activity

Diuretics

Socioeconomic Status & Insurance
Income:
Poor
Low-Income
Middle-Income
Education:
Less than High
School
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Table A-4.

(Continued)

Covariate

ACEIs/ARBs

High School
1.11
Diploma
[0.97,1.28]
Language: Interview
0.84
in English
[0.40,1.79]
Insurance: Received
1.01
Medicaid
[0.84,1.21]
Had Private Non1.03
HMO Coverage
[0.91,1.16]
Had Private HMO
1.00
Coverage
[0.84,1.20]
Use of Healthcare (over survey year)
Concurrently Taken Drugs
0.90
2-3 CV Drugs
[0.78,1.04]
0.79
≥4 CV Drugs
[0.64,0.98]**
1.65
2-4 Other Drugs
[1.35,2.01]***
2.87
≥5 Other Drugs
[2.25,3.66]***
Number of
0.75
Pharmacies Used
[0.68,0.83]***
Had a Usual Source
1.09
of Care
[0.79,1.50]

Statins

Beta Blockers

1.05
[0.91,1.21]
0.86
[0.11,6.60]
1.08
[0.87,1.36]
1.04
[0.92,1.18]
1.12
[0.94,1.35]

1.04
[0.86,1.25]
0.72
[0.31,1.68]
0.97
[0.78,1.22]
0.92
[0.79,1.07]
1.06
[0.85,1.33]

0.90
1.01
[0.74,1.09]
[0.86,1.20]
0.81
0.96
[0.63,1.04]
[0.74,1.23]
1.82
1.02
[1.46,2.27]***
[0.80,1.31]
2.96
1.47
[2.29,3.81]*** [1.10,1.98]**
0.84
0.73
[0.76,0.93]*** [0.64,0.82]***
0.99
1.30
[0.72,1.36]
[0.90,1.87]
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Ca Channel
Blockers
1.06
[0.85,1.32]
0.85
[0.28,2.57]
1.07
[0.81,1.42]
1.02
[0.84,1.24]
1.12
[0.86,1.47]

0.98
[0.82,1.16]
1.30
[0.42,4.00]
1.03
[0.83,1.28]
0.95
[0.82,1.11]
0.90
[0.74,1.10]

0.70
[0.57,0.86]***
0.50
[0.37,0.68]***
1.92
[1.44,2.57]***
2.94
[2.10,4.13]***
0.69
[0.59,0.81]***
1.07
[0.64,1.81]

0.77
[0.65,0.92]***
0.69
[0.55,0.87]***
1.60
[1.29,1.99]***
2.56
[2.01,3.27]***
0.76
[0.68,0.86]***
1.04
[0.73,1.48]

Diuretics

Table A-4.

(Continued)

Covariate

ACEIs/ARBs

Quintiles of Ambulatory Physician Visits
0.87
Q 2 (3-4 Visits)
[0.74,1.02]*
0.93
Q 3 (5-7 Visits)
[0.78,1.11]
0.92
Q 4 (8-12 Visits)
[0.77,1.10]
0.86
Q 5 (≥13 Visits)
[0.71,1.04]
Experience with Providers
0.98
Always Listens
[0.73,1.31]
Always Explains
1.29
Care
[1.00,1.67]**
0.90
Always Respects:
[0.68,1.18]
Satisfied with
1.00
Healthcare Received
[0.80,1.24]
Very Satisfied with
0.97
Healthcare
[0.79,1.21]
0.95
H-L GOF P Value
9,917
Sample Size
Weighted Population
13,802,972

Statins

Beta Blockers

Ca Channel
Blockers

Diuretics

1.09
[0.92,1.30]
1.03
[0.87,1.23]
1.07
[0.89,1.29]
0.99
[0.80,1.24]

0.91
[0.74,1.12]
0.85
[0.69,1.05]
0.94
[0.75,1.17]
0.85
[0.67,1.08]

1.03
[0.80,1.32]
0.91
[0.71,1.18]
1.03
[0.78,1.37]
0.84
[0.63,1.11]

1.04
[0.86,1.26]
0.96
[0.80,1.16]
0.86
[0.71,1.05]
0.96
[0.77,1.20]

1.06
[0.78,1.45]
1.08
[0.82,1.42]
1.12
[0.82,1.54]
0.98
[0.78,1.23]
0.91
[0.72,1.15]
1.00
8,851
13,139,144

1.15
[0.80,1.65]
1.00
[0.75,1.34]
0.97
[0.69,1.37]
0.96
[0.76,1.23]
0.98
[0.77,1.25]
0.88
6,535
9,253,278

1.13
[0.73,1.75]
0.82
[0.57,1.17]
1.24
[0.82,1.88]
1.14
[0.84,1.56]
1.18
[0.88,1.60]
0.89
4,649
6,123,863

0.80
[0.56,1.15]
0.93
[0.67,1.28]
1.07
[0.76,1.52]
1.27
[1.02,1.58]**
1.22
[0.96,1.55]
0.44
7,228
10,084,654

*P <0.1 † P<0.05 ǂ P<0.01
Estimates were also adjusted for interactions terms of black and Hispanic indicators with income and education levels. CV:
Cardiovascular; Q: Quartile; CHD: Coronary Heart Disease; CHF: Congestive Heart Failure; AMI: Acute Myocardial
Infarction; HMO: Health Maintenance Organization.
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Table A-5.
subgroup

Effect of Part D on adherence disparities, and estimates of disparities among seniors in 2007-2010 by

Analysis

Sample
Size

(1)
Difference-in-Differences Effect
White-Black
Disparities

White-Hispanic
Disparities

(2)
Current Racial Disparities in Medicare
(2007-10)
White-Black
White-Hispanic
Disparities
Disparities

Main Analysis
Main
Analysis,
including 2006
Medicare 6570 Tx Group
Men
Women
Non-Dual
Dual Eligibles
ACEIs/ARBS
Statins
Beta-Blockers
Ca Channel
Blockers

17,677

0.06

[-0.06,0.18]

-0.16

[-0.29,-0.03]†

0.08

[0.04,0.12]‡

0.01

[-0.04,0.05]

19,919

0.03

[-0.08,0.14]

-0.16

[-0.28,-0.03]†

0.06

[0.03,0.10]‡

0.02

[-0.03,0.06]

7,447

0.06

[-0.08,0.20]

-0.09

[-0.25,0.08]

0.10

[0.05,0.16]‡

0.05

[-0.03,0.14]

7,180
10,495
15,012
2,665
9,917
8,851
6,535

0.21
-0.04
0.10
-0.16
0.01
0.15
0.17

[0.03,0.38]†
[-0.19,0.12]
[-0.05,0.25]
[-0.45,0.13]
[-0.14,0.16]
[-0.02,0.33]*
[-0.04,0.39]

-0.20
-0.14
-0.13
-0.25
-0.09
-0.21
-0.30

[-0.44,0.04]
[-0.29,0.01]*
[-0.29,0.03]
[-0.54,0.03]*
[-0.27,0.09]
[-0.45,0.02]*
[-0.55,-0.06]†

0.11
0.07
0.08
0.19
0.06
0.04
0.08

[0.06,0.16]‡
[0.02,0.12]‡
[0.03,0.12]‡
[0.09,0.28]‡
[0.01,0.11]†
[-0.02,0.10]
[0.03,0.14]‡

-0.02 [-0.08,0.04]
0.03 [-0.03,0.09]
-0.02 [-0.08,0.04]
0.15 [0.04,0.26]‡
-0.01 [-0.06,0.04]
-0.01 [-0.07,0.05]
-0.03 [-0.11,0.04]

4,649

0.01

[-0.22,0.24]

0.00

[-0.25,0.26]

0.01

[-0.07,0.08]

0.05

[-0.05,0.15]

Diuretics

7,228

0.12

[-0.06,0.30]

-0.15

[-0.38,0.09]

0.08

[0.02,0.13]‡

0.02

[-0.05,0.10]

* P <0.1; † P<0.05; ǂ P<0.01
CI: confidence interval. ACEIs/ARBs: Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers.
Estimates in Column (1) are the double differences between race-specific adherence margins, across time and treatment/control
groups. Column (2) estimates are the differences between race-specific adherence margins among Medicare seniors in the
post-Part D period only. All estimates are probability-scale predictions, and all were adjusted for health status and clinical need
using the rank-and–replace procedure. Standard errors underlying confidence intervals were estimated via Taylor series
linearization and combined across 5 multiply imputed datasets.
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Table A-6.

Sensitivity of results to various definitions of adherence disparities

Disparity Definition

0.05
0.06
0.06
0.06
0.06

[-0.07,0.17]
[-0.06,0.18]
[-0.06,0.18]
[-0.06,0.18]
[-0.06,0.18]

(2)
Current Racial Disparities in
Medicare (2007-10)
White-Hispanic
White-Black
White-Hispanic
Disparities
Disparities
Disparities
Estimate [95% CI]
-0.18 [-0.31,-0.05]‡
0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05]
-0.16 [-0.29,-0.02]†
0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05]
-0.16 [-0.29,-0.03]†
0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05]
-0.16 [-0.29,-0.02]†
0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05]
-0.15 [-0.28,-0.02]†
0.08 [0.04,0.12]‡ 0.01 [-0.04,0.05]

0.06

[-0.06,0.18]

-0.16

[-0.29,-0.03]†

0.08

[0.04,0.12]‡ 0.01

[-0.04,0.05]

0.06

[-0.06,0.18]

-0.15

[-0.28,-0.02]†

0.10

[0.06,0.15]‡ 0.02

[-0.05,0.08]

(1)
Difference-in-Differences Effect
White-Black
Disparities

Adjusted

Unadjusted
Demographics
Demo+Health
Demo+Health+Rx
Demo+Geography+Health+Rx
Main Analysis:
Demo+Geo+Health+Rx+Beliefs
Full Adjustment, RDE

* P <0.1; † P<0.05; ǂ P<0.01.
CI: confidence interval; RDE: residual direct effect (of race).
All analyses were conducted on the main sample (n=17,677, representing 24,915,354 treated and control individuals).
As in Table 2, demographics included age, gender, marital status, and urban residence. Health included self-reported health as
well as diagnosed conditions. “Rx” included the number of other prescription drugs concurrently taken. Geography was
represented by the Census Region. Unadjusted disparities (and difference-in-differences) were calculated as differences across
race-specific adherence proportions. RDE disparities, were estimated directly from the main analysis using predictive margins.
All other stages of adjustment were conducted using the rank-and-replace procedure prior to estimating race-specific,
probability-scale predictions. Disparities were then the differences between these predictions (margins) Standard errors
underlying confidence intervals were estimated via Taylor series linearization and combined across 5 multiply imputed
datasets.
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APPENDIX B. SUPPLEMENTAL MATERIALS FOR CHAPTER 3
Table B-1.

Main unconditional quantile regression analyses of overall adherence

Characteristics
(at baseline)
Black
Hispanic
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban Residence
Census Region:
Midwest
South
West
Health Status:
Very Good

10th QPDC
-7.26
[-17.80,3.28]
-2.09
[-5.44,1.26]
-2.62
[-6.52,1.29]
-10.47
[-17.37,-3.57]
-5.61
[-19.70,8.49]
1.82
[-2.88,6.51]
-0.55
[-8.18,7.08]
-2.54
[-16.51,11.44]
2.25
[-6.62,11.12]
-4.69
[-12.32,2.94]
-4.09
[-7.76,-0.42]
6.18
[1.60,10.75]

20th QPDC
-7.73
[-15.67,0.21]
-4.07
[-8.04,-0.10]
-3.80
[-6.39,-1.22]
-8.44
[-11.55,-5.34]
-4.99
[-14.44,4.46]
1.05
[-7.90,9.99]
-5.30
[-13.63,3.02]
-0.50
[-8.20,7.20]
2.21
[-5.54,9.96]
-2.22
[-8.00,3.57]
-1.23
[-4.11,1.64]
6.16
[2.88,9.44]

30th QPDC

40th QPDC

50th QPDC

Coefficient [95% Confidence Interval]
-9.05
-7.28
-5.55
[-14.32,-3.77]
[-8.97,-5.59]
[-7.60,-3.50]
-1.71
-1.98
-1.40
[-6.18,2.76]
[-5.42,1.47]
[-2.48,-0.32]
-3.56
-4.91
-3.23
[-7.65,0.53]
[-7.99,-1.83]
[-6.18,-0.29]
-3.43
-2.82
-4.77
[-7.22,0.35]
[-7.15,1.51]
[-7.00,-2.53]
-4.75
-5.40
-6.44
[-12.21,2.71]
[-14.92,2.05]
[-14.12,3.32]
-0.07
-0.39
1.72
[-4.50,4.36]
[-2.14,1.35]
[-1.42,4.85]
-6.66
-4.47
-3.77
[-13.32,0.00]
[-11.86,2.91]
[-9.35,1.80]
-0.80
-1.55
-0.79
[-10.41,8.81] [-16.55,13.44] [-18.09,16.50]
3.82
2.26
4.02
[-1.47,9.11]
[0.26,4.27]
[1.53,6.52]
-2.80
-2.41
-2.15
[-7.75,2.15]
[-4.30,-0.52]
[-3.30,-1.00]
0.79
0.75
1.47
[-1.65,3.22]
[-2.33,3.84]
[-0.11,3.05]
4.87
5.76
6.18
[1.79,7.94]
[1.37,10.15]
[2.49,9.86]
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60th QPDC

70th QPDC

-5.08
[-7.49,-2.67]
-1.12
[-3.48,1.24]
-4.24
[-5.74,-2.74]
-5.75
[-9.78,-1.72]
-6.62
[-12.67,-0.57]
1.27
[-0.17,2.70]
-2.46
[-4.33,-0.59]
-0.74
[-21.57,20.09]
1.62
[-0.36,3.60]
-2.00
[-5.23,1.23]
1.57
[-2.73,5.87]
4.69
[-0.92,10.30]

-3.28
[-4.29,-2.27]
0.48
[-0.70,1.67]
-1.37
[-4.41,1.67]
-3.42
[-5.24,-1.59]
-3.63
[-7.92,0.67]
0.41
[-0.67,1.49]
-1.99
[-2.59,-1.38]
0.73
[-15.17,16.63]
0.94
[-2.22,4.09]
-0.18
[-2.43,2.06]
1.06
[-3.26,5.37]
2.65
[-0.07,5.36]

Table B-1.

(Continued)

Characteristics
(at baseline)
Good
Fair
Poor
Any Physical
Limitation
Any Cognitive
Limitation
Charlson
Comorbidity
Score Q3
Charlson
Comorbidity
Score Q4
Count of
Comorbid
Conditions
Hypertension
Hyperlipidemia
Angina/CHD
CHF

10th QPDC

20th QPDC

30th QPDC

40th QPDC

50th QPDC

60th QPDC

70th QPDC

2.47
[-7.01,11.96]
6.47
[0.27,12.66]
3.45
[-1.35,8.25]
1.32
[-5.75,8.39]
-6.10
[-17.12,4.93]

6.38
[1.06,11.71]
9.40
[6.61,12.18]
2.26
[-2.58,7.09]
-1.46
[-6.24,3.32]
-1.48
[-13.39,10.42]

4.51
[-1.93,10.94]
7.47
[3.07,11.87]
0.85
[-5.89,7.59]
-0.25
[-1.68,1.18]
-1.86
[-10.93,7.21]

5.55
[-1.54,12.65]
7.25
[1.35,13.16]
-0.62
[-9.46,8.21]
0.11
[-3.63,3.85]
-0.68
[-9.27,7.92]

4.09
[-3.42,11.61]
5.89
[-0.63,12.40]
-1.96
[-12.98,9.06]
0.50
[-3.61,4.62]
0.90
[-5.63,7.43]

2.34
[-6.61,11.30]
5.17
[-3.68,14.02]
-1.03
[-10.51,8.44]
-0.00
[-4.17,4.16]
-0.13
[-6.68,6.42]

0.85
[-3.33,5.03]
2.34
[-3.09,7.77]
-2.40
[-9.55,4.75]
-0.14
[-2.49,2.20]
-1.13
[-4.91,2.64]

-2.32
[-5.29,0.66]

-2.33
[-4.17,-0.50]

-0.44
[-4.96,4.09]

-0.40
[-4.67,3.87]

-1.24
[-6.67,4.20]

-1.92
[-7.05,3.21]

-0.51
[-3.12,2.11]

-1.23
[-7.94,5.48]

-2.07
[-13.74,9.61]

0.81
[-3.99,5.61]

1.35
[-0.20,2.90]

0.91
[-0.25,2.07]

-0.08
[-1.78,1.62]

-2.02
[-4.40,0.35]

-0.93
[-2.10,0.25]

-0.85
[-2.13,0.43]

-0.99
[-2.07,0.09]

-0.99
[-1.65,-0.33]

-1.12
[-1.92,-0.31]

-0.73
[-1.26,-0.21]

-0.30
[-0.65,0.05]

6.06
[-1.52,13.64]
2.01
[-3.18,7.21]
1.54
[-4.93,8.01]
3.15
[-5.30,11.59]

3.61
[-2.04,9.26]
0.86
[-1.43,3.15]
2.54
[-0.69,5.77]
5.23
[-3.18,13.63]

4.55
[-2.28,11.38]
0.61
[-0.76,1.98]
5.21
[-2.86,13.27]
1.04
[-12.90,14.98]

3.00
[-5.52,11.52]
-0.27
[-3.95,3.40]
3.21
[-3.30,9.73]
-0.84
[-9.83,8.14]

2.47
[-5.86,10.80]
0.94
[-0.44,2.31]
3.49
[-2.23,9.20]
1.59
[-1.28,4.46]

0.39
[-8.51,9.29]
-0.77
[-1.78,0.24]
2.17
[-1.39,5.72]
2.62
[-1.16,6.41]

-1.67
[-8.22,4.88]
-1.27
[-2.44,-0.10]
1.32
[-0.47,3.10]
0.56
[-0.75,1.88]
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Table B-1.

(Continued)

Characteristics
(at baseline)
AMI
Stroke
Depressive
Symptoms
More Likely to
Take Risks
Can overcome
illness without
medical care
Does not need
health insurance
Took 2-4 Drugs
Concurrently
Took ≥5 Drug
Concurrently
Constant
(Base QPDC)
Sample Size

10th QPDC

20th QPDC

30th QPDC

40th QPDC

50th QPDC

60th QPDC

70th QPDC

2.29
[-7.30,11.88]
0.23
[-8.91,9.37]
-6.25
[-17.08,4.58]
0.83
[-10.83,12.48]

0.61
[-8.62,9.83]
0.02
[-14.07,14.10]
-4.77
[-10.55,1.00]
1.51
[-4.88,7.89]

-2.67
[-26.58,21.25]
-2.51
[-5.00,-0.01]
-3.11
[-9.44,3.23]
-1.08
[-9.03,6.87]

0.14
[-13.40,13.67]
-1.53
[-4.01,0.95]
-3.44
[-8.53,1.64]
-2.44
[-4.87,-0.01]

-1.72
[-10.71,7.27]
-2.64
[-6.71,1.43]
0.95
[-4.47,6.37]
-2.98
[-6.53,0.57]

-2.37
[-9.10,4.37]
0.95
[-6.51,8.40]
-0.02
[-7.84,7.81]
-2.60
[-4.02,-1.18]

-0.07
[-3.56,3.43]
-0.64
[-5.64,4.36]
-2.17
[-5.18,0.85]
-2.57
[-3.83,-1.30]

0.09
[-5.69,5.88]

-0.36
[-4.54,3.81]

-1.08
[-9.98,7.81]

-1.98
[-8.60,4.63]

-0.80
[-6.33,4.74]

-0.19
[-6.01,5.62]

1.20
[-2.06,4.45]

-3.93
[-12.50,4.64]
4.25
[-1.22,9.72]
11.51
[4.49,18.53]
30.35
[10.83,49.88]

-8.31
[-18.45,1.83]
4.56
[-2.16,11.27]
10.90
[1.13,20.67]
48.45
[26.33,70.58]

-7.05
[-15.39,1.29]
-0.32
[-3.17,2.54]
4.54
[-2.95,12.03]
63.22
[50.57,75.86]

-9.59
[-15.02,-4.16]
0.22
[-1.46,1.90]
5.53
[1.88,9.17]
73.95
[61.13,86.78]
3,743

-3.50
[-7.86,0.85]
-2.73
[-6.22,0.76]
2.03
[-0.03,4.09]
82.15
[70.01,94.28]

-4.71
-2.30
[-8.52,-0.89]
[-4.36,-0.25]
-2.38
-2.67
[-6.33,1.56]
[-4.62,-0.72]
0.09
-0.79
[-2.45,2.64]
[-2.43,0.85]
94.53
100.17
[76.16,112.91] [84.08,116.27]

Boldface estimates have P values <0.05. Q: Quantile, PDC: proportion of days covered, CHD: Coronary Heart Disease, CHF:
Congestive Heart Failure, AMI: Acute Myocardial Infarction. Main models adjust race coefficient estimates for demographics and
health status only, following the Institute of Medicine’s framework on disparities. Standard errors underlying confidence intervals
were estimated using 5,000 replications of a block bootstrap procedure.
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Table B-2.
Subgroup

Racial disparities in adherence across the PDC distribution by subgroup
10th QPDC

20th QPDC

30th QPDC

40th QPDC

50th QPDC

60th QPDC

70th QPDC

Race Coefficient [95% Confidence Interval]
Black-White Disparity in PDC among:
-7.26
-7.73
Entire Sample
[-17.80,3.28]
[-15.67,0.21]
(n=3,749)
-10.07
-11.31
Men (n=1,569)
[-11.78,-8.36]
[-14.55,-8.06]
-6.24
-5.47
Women
[-22.72,10.24]
[-19.09,8.15]
(n=2,180)
Auto Recipients
-15.70
-14.81
of LIS (n=617)
[-22.18,-9.22] [-19.47,-10.16]
Non-Auto. LIS
-6.37
-5.04
Recipients
[-13.65,3.57]
[-18.27,5.53]
(n=3,132)
ACE Inhibitor
-7.13
-11.40
/ARB Users
[-20.54,-2.27]
[-13.43,-0.84]
(n=2,250)
-4.31
-2.68
Statin Users
[-11.89,3.27]
[-10.99,5.62]
(n=2,138)
β-Blocker Users
-6.13
-10.39
(n=1,536)
[-8.18,-4.08]
[-15.86,-4.92]
Ca Channel
-6.17
-5.25
Blocker Users
[-13.45,2.95]
[-12.54,0.20]
(n=872)
-12.71
Diuretic Users
-4.48
[-29.40,3.99]
(n=1,650)
[-8.83,-0.12]

-9.05
[-14.32,-3.77]
-10.16
[-14.99,-5.33]
-9.24
[-16.76,-1.71]
-8.35
[-12.33,-4.37]

-7.28
[-8.97,-5.59]
-4.83
[-9.47,-0.19]
-7.79
[-11.05,-4.53]
-3.86
[-6.84,-0.88]

-5.55
[-7.60,-3.50]
-5.06
[-7.56,-2.56]
-3.75
[-6.62,-0.87]
0.94
[-4.55,6.42]

-5.08
[-7.49,-2.67]
-3.78
[-6.90,-0.66]
-7.27
[-12.31,-2.24]
-5.45
[-7.69,-3.21]

-3.28
[-4.29,-2.27]
-2.53
[-3.99,-1.07]
-3.89
[-6.35,-1.44]
-2.22
[-6.62,2.18]

-9.23
[-15.38,-3.07]

-8.67
[-11.40,-5.93]

-7.25
[-10.41,-4.09]

-5.22
[-8.54,-1.89]

-4.10
[-5.31,-2.89]

-10.75
[-31.77,10.28]

-13.21
[-29.44,3.01]

-8.41
[-18.07,1.25]

-4.34
[-8.94,0.26]

-3.30
[-6.08,-0.53]

-3.80
[-9.39,1.79]
-10.18
[-14.21,-6.16]

-4.55
[-7.92,-1.18]
-8.58
[-10.58,-6.58]

-5.97
[-8.22,-3.72]
-8.84
[-10.11,-7.57]

-2.70
[-3.97,-1.44]
-3.25
[-3.70,-2.80]

-2.80
[-4.87,-0.74]
-2.23
[-2.82,-1.65]

-2.99
[-13.73,7.75]

-3.96
[-8.76,0.85]

-3.46
[-9.87,2.95]

4.46
[-1.25,10.18]

0.90
[-2.33,4.13]

-7.33
[-17.95,3.28]

-18.60
[-23.50,-13.69]

-15.55
[-21.52,-9.58]

-5.93
[-8.69,-3.16]

-4.91
[-5.98,-3.83]
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Table B-2.

(Continued)

Subgroup
10th QPDC
20th QPDC
Hispanic-White Disparity in PDC among:
-2.09
Entire Sample
-4.07
[-5.44,1.26]
(n=3,749)
[-8.04,-0.10]
-9.25
-10.56
Men (n=1,569)
[-24.73,6.24]
[-23.80,2.68]
4.01
0.70
Women
[-4.09,12.11]
[-10.20,11.61]
(n=2,180)
-7.65
Auto Recipients
-8.03
[-16.38,1.07]
of LIS (n=617)
[-12.42,-3.64]
Non-Auto LIS
0.85
-0.22
Recipients
[-1.96,1.53]
[-9.88,11.58]
(n=3,132)
ACE Inhibitor
-5.84
-3.37
/ARB Users
[-14.18,2.51]
[-5.37,-1.38]
(n=2,250)
-0.90
-0.13
Statin Users
[-9.64,7.84]
[-16.45,16.20]
(n=2,138)
3.58
7.23
β-Blocker Users
[-4.31,11.48]
[-3.01,17.47]
(n=1,536)
Ca Channel
-8.18
-4.00
Blocker Users
[-17.07,9.07]
[-17.35,0.98]
(n=872)
Diuretic Users
-12.63
-13.58
(n=1,650)
[-18.35,-6.91]
[-23.32,-3.84]

30th QPDC

40th QPDC

50th QPDC

60th QPDC

70th QPDC

-1.71
[-6.18,2.76]
-5.70
[-14.50,3.10]
0.64
[-8.99,10.28]
-4.36
[-7.68,-1.05]

-1.40
[-2.48,-0.32]
-3.04
[-12.11,6.02]
0.63
[-4.98,6.24]
0.44
[-4.39,5.27]

-1.98
[-5.42,1.47]
-2.79
[-7.93,2.36]
0.33
[-5.16,5.82]
5.97
[-1.57,13.51]

-1.12
[-3.48,1.24]
-3.30
[-7.85,1.26]
0.66
[-5.48,6.80]
1.49
[-2.88,5.85]

0.48
[-0.70,1.67]
-0.32
[-4.67,4.02]
0.71
[-1.61,3.04]
1.77
[-1.07,4.61]

0.72
[-2.15,3.60]

0.38
[-6.85,7.61]

-3.37
[-8.77,2.02]

-1.29
[-8.36,5.78]

-0.26
[-3.61,3.09]

-3.38
[-5.38,-1.37]

-6.36
[-13.84,1.12]

-2.46
[-12.59,7.67]

-0.28
[-5.49,4.93]

-2.69
[-8.80,3.41]

0.87
[-9.02,10.75]
5.78
[3.36,8.21]

1.62
[-7.22,10.46]
6.06
[-4.56,16.68]

1.99
[-11.21,15.19]
0.02
[-14.55,14.59]

0.85
[-1.92,3.63]
-0.46
[-5.01,4.09]

1.80
[0.56,3.04]
-0.33
[-3.02,2.36]

-1.56
[-9.65,6.54]

-3.89
[-10.19,2.41]

-6.69
[-12.92,-0.46]

-2.15
[-7.09,2.78]

0.84
[-1.70,3.39]

-10.48
[-18.83,-2.14]

-15.42
[-24.39,-6.46]

-7.86
[-14.92,-0.80]

-4.55
[-6.76,-2.34]

-2.49
[-4.26,-0.71]

Boldface estimates have P values <0.05. Q: Quantile, PDC: proportion of days covered, LIS: Low-income subsidy, ACE:
Angiotensin-converting enzyme, ARB: Angiotensin II receptor blocker. Disparity estimates correspond to race coefficients estimated
in the primary models adjusted for demographics and health status only, following the IOM framework on disparities. Standard errors
underlying confidence intervals were estimated using 5,000 replications of a block bootstrap procedure.
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Table B-3.

QPDC

Sensitivity of disparity estimates to various adjustments/definitions of racial disparity

Demo

Black-White Disparity at QPDC:
-8.33
Q10
[-16.99,0.34]
-7.80
Q20
[-13.60,-2.00]
-8.98
Q30
[-12.67,-5.29]
-7.02
Q40
[-9.60,-4.44]
-5.15
Q50
[-8.48,-1.83]
-4.98
Q60
[-8.69,-1.27]
-3.58
Q70
[-5.03,-2.13]
Hispanic-White Disparity at QPDC:
-4.32
Q10
[-6.98,-1.66]
-4.89
Q20
[-7.44,-2.33]
-1.64
Q30
[-5.77,2.49]

Demo+Geo
+Health
Demo+Health
+Rx +Beliefs
“Main Analysis”
Race Coefficient [95% Confidence Interval]
Demo+Health
+Rx

Demo+Geo
+Health+Rx

-8.46
[-18.30,1.37]
-8.60
[-16.62,-0.58]
-10.18
[-14.55,-5.82]
-8.12
[-9.13,-7.10]
-6.53
[-8.01,-5.04]
-5.82
[-7.82,-3.82]
-3.49
[-4.38,-2.60]

-8.18
[-17.93,1.57]
-8.33
[-16.19,-0.46]
-10.07
[-14.38,-5.77]
-7.98
[-9.06,-6.90]
-6.49
[-7.93,-5.06]
-5.82
[-7.78,-3.87]
-3.52
[-4.38,-2.67]

-7.26
[-17.96,3.44]
-7.70
[-16.00,0.60]
-8.92
[-14.23,-3.62]
-7.06
[-8.13,-6.00]
-5.42
[-7.18,-3.65]
-4.97
[-7.32,-2.63]
-3.26
[-4.25,-2.28]

-7.26
[-17.80,3.28]
-7.73
[-15.67,0.21]
-9.05
[-14.32,-3.77]
-7.28
[-8.97,-5.59]
-5.55
[-7.60,-3.50]
-5.08
[-7.49,-2.67]
-3.28
[-4.29,-2.27]

-7.37
[-17.85,3.11]
-9.57
[-16.99,-2.14]
-11.36
[-16.00,-6.71]
-8.97
[-12.00,-5.93]
-7.04
[-9.86,-4.22]
-6.40
[-9.59,-3.20]
-4.07
[-5.46,-2.69]

-4.25
[-8.71,0.21]
-5.47
[-10.68,-0.27]
-2.78
[-7.72,2.17]

-3.68
[-7.77,0.40]
-4.96
[-9.63,-0.29]
-2.44
[-7.15,2.26]

-2.15
[-5.60,1.30]
-4.16
[-8.40,0.09]
-1.67
[-6.11,2.77]

-2.09
[-5.44,1.26]
-4.07
[-8.04,-0.10]
-1.71
[-6.18,2.76]

2.47
[-17.28,22.22]
-2.63
[-9.64,4.37]
-0.55
[-13.89,12.80]
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Fully
Adjusted

Table B-3.

QPDC
Q40
Q50
Q60
Q70

(Continued)

Demo

Demo+Health

Demo+Health
+Rx

Demo+Geo
+Health+Rx

-1.23
[-2.54,0.08]
-1.66
[-4.81,1.49]
-0.74
[-3.59,2.11]
0.15
[-1.25,1.56]

-2.16
[-2.91,-1.41]
-2.77
[-6.57,1.03]
-1.38
[-3.76,1.01]
0.42
[-0.32,1.16]

-1.78
[-2.56,-1.00]
-2.48
[-5.95,0.98]
-1.24
[-3.40,0.92]
0.51
[-0.36,1.38]

-1.28
[-2.23,-0.34]
-1.86
[-5.22,1.51]
-1.05
[-3.36,1.26]
0.51
[-0.73,1.74]

Demo+Geo
+Health
+Rx +Beliefs
“Main Analysis”
-1.40
[-2.48,-0.32]
-1.98
[-5.42,1.47]
-1.12
[-3.48,1.24]
0.48
[-0.70,1.67]

Fully
Adjusted
-3.37
[-13.31,6.58]
-3.46
[-15.31,8.39]
-1.88
[-9.08,5.31]
-2.72
[-4.04,-1.39]

Boldface estimates have P values <0.05. Q: Quantile, PDC: proportion of days covered. All analyses were conducted on the entire
sample (n=3,749). As in Table 2-1 in the text, demographics included age, gender, marital status, and urban residence. Health
included self-reported health as well as diagnosed conditions. “Rx” included the number of other prescription drugs concurrently
taken. Geography was represented by the Census Region. “Fully adjusted” estimates were adjusted for all covariates in Table 2-1 as
appropriate. Standard errors underlying confidence intervals were estimated using 5,000 replications of a block bootstrap procedure.
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Figure B-1. Sensitivity of disparity estimates to various adjustments/definition of disparity
PDC: proportion of days covered. All analyses were conducted on the entire sample (n=3,749). As in Table 2-1 in the text,
demographics included age, gender, marital status, and urban residence. Health included self-reported health as well as diagnosed
conditions. “Rx” included the number of other prescription drugs concurrently taken. Geography was represented by the Census
Region. “Fully adjusted” estimates were adjusted for all covariates in Table 2-1 as appropriate. Standard errors for confidence
intervals were estimated using 5,000 replications in a block bootstrap procedure.
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APPENDIX C. SUPPLEMENTAL MATERIALS FOR CHAPTER 4
Table C-1.

Characteristics of sampled Medicare seniors by race across PDC quantile categories, Q10th-Q40th

Characteristics

QPDC 10th
White
Black

Demographics
Female
56.70
Married
58.07
Urban/MSA
80.29
Census Region
Northeast
16.82
Midwest
20.05
South
40.24
West
22.89
Self-Reported Health Status
Excellent
18.91
Very Good
29.21
Good
33.81
Fair
12.36
Poor
5.71
Any Physical
59.60
Limitation
Any Cognitive
11.89
Limitation

QPDC 20th
QPDC 30th
White
Black
White
Black
%, unless otherwise noted

QPDC 40th
White
Black

57.13
28.60
87.14

54.12
63.84
77.71

63.48
26.86
85.93

57.44
59.84
79.48

67.61
37.36
82.45

57.64
50.40
82.03

74.69
31.69
85.22

23.86
9.60
53.54
13.00

22.04
25.48
35.82
16.65

15.90
19.12
59.45
5.52

23.19
22.26
37.97
16.58

14.00
11.34
69.64
5.01

20.45
27.70
35.12
16.74

28.90
10.31
53.91
6.88

10.21
24.03
32.02
26.63
7.12

15.51
33.71
28.27
15.71
6.80

9.83
24.76
43.85
17.57
3.99

11.38
29.24
34.52
18.64
6.22

3.89
22.13
40.13
26.86
7.00

15.58
29.17
31.35
17.24
6.66

10.67
24.97
37.08
20.69
6.59

63.68

64.03

60.45

64.84

51.00

63.15

51.97

24.20

9.83

8.31

10.80

13.71

9.82

15.86
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Table C-1.

(Continued)

Characteristics

QPDC 10th
White
Black

Depressive
8.43
21.23
Symptoms
Cardiovascular Conditions & Comorbidity
Hypertension
74.61
89.29
Lipidemia
63.12
53.77
Angina/CHD
19.17
14.18
CHF
3.28
2.57
AMI
5.69
8.33
Stroke
6.21
2.78
Count of
5.88
Comorbid
3.85
±3.89
Conditions,
±2.61
Mean±SD
Charlson
Comorbidity
54.56
58.50
Score Q1-2
Charlson
Comorbidity
33.01
30.99
Score Q3
Charlson
12.43
10.51
Comorbidity
Score Q4

QPDC 20th
QPDC 30th
White
Black
White
Black
%, unless otherwise noted

QPDC 40th
White
Black

7.96

11.18

8.14

8.37

8.35

14.20

81.42
66.63
20.80
2.69
9.63
7.71

94.58
55.93
12.78
3.24
5.92
4.24

83.99
67.45
18.59
6.62
10.50
6.03

96.40
62.69
17.21
1.19
9.32
6.96

83.47
67.39
24.51
4.51
7.39
6.26

96.95
52.28
19.26
5.03
5.99
3.42

5.63
±3.74

4.44
±2.96

6.08
±3.77

4.73
±3.31

5.69
±3.21

4.74
±3.50

54.34

50.38

57.41

50.77

55.97

44.43

31.40

39.62

29.94

41.76

31.18

41.95

14.26

10.00

12.64

7.47

12.84

13.62
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Table C-1.

(Continued)

Characteristics

QPDC 10th
White
Black

Beliefs
More Likely to
16.15
Take Risk
Can Overcome
Illness without
12.02
Medical Care
No Need for
6.41
Health Insurance
Behaviors
Current Smoker
8.06
Moderate /
50.71
Vigorous
Exercise
Obese
26.71
Socioeconomic Status
Income:
14.72
Poor/Near Poor
Low-Income
15.95
Mid-Income
26.49
High-Income
42.84
(Ref)
Education:
Less than High
18.81
School

QPDC 20th
QPDC 30th
White
Black
White
Black
%, unless otherwise noted

QPDC 40th
White
Black

10.35

17.90

18.38

17.74

22.79

21.10

10.90

9.11

11.67

6.84

11.91

14.22

13.93

5.40

5.80

5.67

3.31

4.86

7.85

7.89

3.67

10.69

10.18

12.29

9.81

6.52

5.56

16.06

39.70

53.42

44.42

48.66

43.95

46.70

36.11

22.52

24.37

37.46

28.40

33.72

24.62

49.83

38.59

14.32

27.78

13.90

26.51

14.87

33.08

18.30
35.13

14.24
29.39

25.49
27.76

17.08
31.77

23.99
35.21

14.69
35.17

21.20
23.17

7.98

42.05

18.97

37.26

14.29

35.28

22.56

52.11

15.97

44.57

20.94

37.12

18.49

51.09
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Table C-1.

(Continued)

Characteristics

QPDC 10th
White
Black

High School
52.65
41.24
Diploma
Above High
28.54
6.65
School (Ref)
Primary Drug Coverage at Baseline
No Known Rx
21.35
21.04
Coverage (Ref)
Part D: PDPs
31.71
39.89
Part D: MA-PD
22.78
33.00
Employer/Other
24.16
6.07
Private
Auto Eligible for
PD Low-Income
3.46
31.42
Subsidy
Use of CV Drugs in Year 2
ACEI/ARBs
49.45
53.82
Statins
52.69
34.07
Beta-Blockers
29.41
26.10
CCBs
13.92
33.93
Diuretics
33.57
49.62
Healthcare Use at Baseline
No. of Concurrent CV Medications
0-1
51.14
39.94

QPDC 20th
QPDC 30th
White
Black
White
Black
%, unless otherwise noted

QPDC 40th
White
Black

58.78

34.63

49.25

51.50

52.83

40.56

25.25

20.80

29.81

11.37

28.68

8.35

21.78

12.98

20.92

14.39

18.38

9.47

34.43
20.42

52.89
22.80

34.26
21.43

42.69
32.70

38.67
20.09

41.44
34.60

23.37

11.34

23.38

10.22

22.87

14.49

5.29

31.54

5.47

9.51

7.00

18.49

57.32
62.16
42.23
24.46
41.60

67.08
63.59
38.91
26.38
59.15

60.55
62.03
39.87
24.68
48.47

70.84
54.38
41.75
38.96
59.08

58.00
64.55
51.46
23.69
47.08

59.69
42.82
37.11
40.48
67.56

34.84

30.50

27.20

15.01

28.47

24.30
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Table C-1.

(Continued)

Characteristics

QPDC 10th
White
Black

QPDC 20th
QPDC 30th
White
Black
White
Black
%, unless otherwise noted
56.44
60.61
63.28
64.19
8.72
8.89
9.52
20.81

2-3
42.90
53.21
≥4
5.96
6.85
No. of concurrent medications overall
0-1
13.63
19.08
10.77
2-4
49.47
54.56
47.19
≥5
36.90
26.36
42.04
No. of
1.38
1.14
1.4 ±0.60
Pharmacies Used
±0.54
±0.45
Average Copay
29.92
27.23
16.01
for CV Drugs
±40.09
±35.2
±32.39
($2010)
Had a Usual
98.61
98.08
94.91
Source of Care
Had any Inpatient
16.91
22.15
19.52
Stay?
Had any ER
15.95
15.85
16.03
visit?
Quintiles of ambulatory physician visits (range)
Q 1 (0-2)
17.85
16.56
34.28
Q 2 (3-4)
14.18
18.98
21.30
Q 3 (5-7)
21.12
24.68
16.62
Q 4 (8-12)
20.43
11.92
25.56
Q 5 (≥13)
26.42
10.14
19.97

QPDC 40th
White
Black
59.08
12.45

59.54
16.16

15.36
43.13
41.51
1.22
±0.45

6.25
43.56
50.19
1.37
±0.57

11.14
40.24
48.62
1.16
±0.37

10.51
47.05
42.44
1.38
±0.54

17.82
40.81
41.37
1.15
±0.48

20.24
±24.27

23.69
±30.25

25.18
±31.67

24.98
±34.45

21.66
±24.57

89.61

97.12

99.65

99.17

97.30

12.73

20.82

14.87

16.27

14.16

13.10

16.48

22.43

21.42

26.02

26.28
17.80
28.41
14.86
12.64

18.74
19.19
17.20
17.52
27.36

30.66
20.21
21.00
11.05
17.08

18.67
16.37
18.98
23.18
22.79

25.31
25.01
17.39
19.77
12.52
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Table C-1.

(Continued)

Characteristics

QPDC 10th
White
Black

Experience with the Healthcare System
Very Satisfied
57.32
58.23
with Health Care
Provider Always
53.37
67.46
Explained
Provider Always
60.96
70.60
Listened
Provider Always
63.66
72.88
Respected
259
95
Sample Size
Weighted
1,746,012 276,837
Population

QPDC 20th
QPDC 30th
White
Black
White
Black
%, unless otherwise noted

QPDC 40th
White
Black

54.25

48.44

58.81

49.42

57.70

51.37

53.23

58.59

60.55

52.42

57.12

55.27

59.00

63.41

62.00

51.44

62.27

58.08

62.28

66.80

58.46

54.91

64.99

64.09

269

90

225

63

256

72

1,780,105 221,492

1,592,621 190,496

1,754,713 181,076

Boldface estimates have P<0.05 for pairwise comparisons relative to whites.
PDC: Proportion of Days Covered; MSA: Metropolitan Statistical Area; CHD: Coronary Heart Disease; CHF: Congestive Heart
Failure; AMI: Acute Myocardial Infarction; SD: Standard Deviation; Q: Quantile; BMI: Body Mass Index; PD: Part D; PDP: standalone prescription drug plan; MA-PD: Medicare Advantage Prescription Drug plan; ACE: Angiotensin-Converting Enzyme; ARB:
Angiotensin II Receptor Blocker
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Table C-2.

Characteristics of sampled Medicare seniors by race across PDC quantile categories, Q50th-Q80th

Characteristics

QPDC 50th
White
Black

Demographics
Female
52.77
Married
53.57
Urban/MSA
78.71
Census Region
Northeast
23.57
Midwest
22.10
South
35.88
West
18.45
Self-Reported Health Status
Excellent
12.98
Very Good
26.28
Good
39.05
Fair
16.61
Poor
5.07
Any Physical
63.56
Limitation
Any Cognitive
9.53
Limitation
Depressive
4.30
Symptoms

QPDC 60th
QPDC 70th
White
Black
White
Black
%, unless otherwise noted

QPDC 80th
White
Black

46.53
41.01
84.13

57.54
52.30
78.71

74.43
31.83
83.27

57.38
57.30
74.50

66.11
32.26
84.95

57.81
55.25
80.62

61.14
28.40
81.48

16.47
7.47
69.96
6.10

20.41
32.31
31.09
16.19

12.93
20.33
64.59
2.15

24.53
28.15
28.42
18.90

13.67
20.66
57.60
8.08

20.53
26.26
33.50
19.71

18.30
19.26
57.63
4.81

5.66
21.77
23.72
41.91
6.94

9.51
32.42
36.86
17.22
3.99

8.84
20.55
36.84
24.28
9.49

10.18
28.53
35.26
19.33
6.71

5.20
21.55
36.95
27.16
9.14

13.24
34.79
32.39
16.30
3.28

6.69
26.14
33.28
24.55
9.35

65.55

64.07

72.77

63.81

78.57

60.05

63.39

17.41

9.48

24.63

11.88

29.50

8.26

15.04

8.82

8.81

16.05

12.52

15.68

5.30

16.33
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Table C-2.

(Continued)

Characteristics

QPDC 50th
White
Black

Cardiovascular Conditions & Comorbidity
Hypertension
85.28
84.63
Lipidemia
64.31
67.10
Angina/CHD
22.44
20.05
CHF
2.98
4.94
AMI
10.81
9.10
Stroke
6.67
7.00
Count of
Comorbid
5.99
5.00
Conditions,
±3.56
±2.87
Mean±SD
CCI Q1-2
53.00
35.10
CCI Q3
34.56
44.64
CCI Q4
12.44
20.26
Beliefs
More Likely to
16.73
10.69
Take Risk
Can Overcome
8.95
1.98
Illness without
Medical Care
No Need for
Health
0.52
4.66
Insurance

QPDC 60th
QPDC 70th
White
Black
White
Black
%, unless otherwise noted

QPDC 80th
White
Black

85.88
70.88
25.14
3.34
11.04
2.94

95.86
61.76
16.44
2.43
7.24
16.94

88.22
67.25
21.90
5.50
7.64
8.95

97.50
59.41
22.37
5.45
7.09
1.82

81.01
65.22
21.69
3.87
8.77
5.08

93.99
52.18
18.17
3.80
6.15
6.73

5.47
±3.34

4.81
±2.95

5.48
±3.53

5.09
±3.01

5.31
±3.40

4.45
±3.44

54.22
34.03
11.75

31.84
48.81
19.35

56.54
25.97
17.49

33.40
51.27
15.33

59.17
31.66
9.17

52.00
32.00
16.00

15.76

12.58

16.58

15.21

14.23

13.49

11.11

5.13

8.24

3.74

11.76

7.62

4.62

8.36

2.98

0.00

3.90

5.51
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Table C-2.

(Continued)

Characteristics

QPDC 50th
White
Black

Behaviors
Current Smoker
7.18
9.64
Moderate /
Vigorous
46.35
37.00
Exercise
Obese
28.45
35.80
Socioeconomic Status
Income:
18.07
39.24
Poor/Near Poor
Low-Income
16.69
14.98
Mid-Income
29.04
33.87
High-Income
36.20
11.91
(Ref)
Education: Less
19.48
than High
55.80
School
High School
49.33
29.97
Diploma
Above High
31.18
14.23
School (Ref)
Primary Drug Coverage at Baseline
No Known Rx
18.58
8.19
Coverage (Ref)
Part D: PDPs
38.46
36.10

QPDC 60th
QPDC 70th
White
Black
White
Black
%, unless otherwise noted

QPDC 80th
White
Black

13.39

16.64

7.09

6.19

7.34

10.40

43.66

27.91

42.26

27.79

47.48

38.79

29.09

44.10

34.10

33.12

29.87

39.59

15.67

32.32

19.25

37.97

14.30

29.00

13.96
35.88

20.41
32.43

17.20
30.52

22.06
24.72

16.59
32.09

19.90
33.07

34.50

14.85

33.03

15.25

37.02

18.02

21.59

53.24

20.78

50.91

20.47

41.82

54.84

38.88

58.03

34.62

51.26

39.16

23.57

7.88

21.19

14.47

28.27

19.02

24.01

9.20

23.71

13.48

16.70

12.08

37.88

42.71

32.64

50.97

37.10

42.74
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Table C-2.

(Continued)

Characteristics

QPDC 50th
White
Black

Part D: MA-PD
20.01
34.51
Employer/Other
22.96
21.20
Private
Auto Eligible
for PD Low7.38
21.40
Income Subsidy
Use of CV Drugs in Year 2
ACEI/ARBs
66.78
58.45
Statins
60.42
55.63
Beta-Blockers
44.74
35.06
CCBs
21.63
37.58
Diuretics
44.77
54.73
Healthcare Use at Baseline
No. of Concurrent CV Medications
0-1
33.33
40.74
2-3
58.09
48.01
≥4
8.58
11.25
No. of concurrent medications overall
0-1
5.80
3.27
2-4
44.24
55.42
≥5
49.95
41.30
No. of
1.28
1.26
Pharmacies
±0.48
±0.5

QPDC 60th
QPDC 70th
White
Black
White
Black
%, unless otherwise noted
19.51
25.49
25.50
38.43

QPDC 80th
White
Black
26.67

27.03

18.60

9.66

18.16

10.05

19.53

18.14

5.09

36.62

6.85

21.24

5.55

28.63

63.08
68.42
51.34
20.65
54.69

59.07
61.36
39.19
40.28
53.48

64.96
64.28
44.46
20.77
50.65

77.96
47.11
47.80
48.08
58.09

53.96
55.66
37.75
15.96
39.48

48.06
46.69
36.12
33.61
47.69

23.59
65.34
11.07

27.67
60.44
11.89

25.46
63.06
11.48

22.15
67.24
10.60

41.62
51.65
6.74

43.71
43.36
12.93

8.43
39.53
52.04
1.26
±0.52

17.03
37.14
45.83
1.12
±0.32

7.10
46.81
46.09
1.29
±0.53

9.40
34.91
55.69
1.22
±0.49

12.24
42.39
45.37
1.30
±0.52

14.96
45.70
39.34
1.17
±0.44
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Table C-2.

(Continued)

Characteristics

QPDC 50th
White
Black

QPDC 60th
QPDC 70th
White
Black
White
Black
%, unless otherwise noted

Average Copay
25.84
24.62
17.45
for CV Drugs
±29.08
±29.3
±19.39
($2010)
Had a Usual
98.06
94.76
96.58
Source of Care
Had any
16.84
17.66
17.74
Inpatient Stay?
Had any ER
18.36
26.87
14.46
visit?
Quintiles of ambulatory physician visits (range)
Q 1 (0-2)
14.37
16.43
17.94
Q 2 (3-4)
19.48
16.31
33.01
Q 3 (5-7)
21.41
19.63
23.75
Q 4 (8-12)
22.39
21.76
23.55
Q 5 (≥13)
22.35
9.17
18.45
Experience with the Healthcare System
Very Satisfied
with Health
55.06
50.55
64.39
Care
Provider Always
52.53
53.43
55.81
Explained
Provider Always
58.50
60.41
60.64
Listened

QPDC 80th
White
Black

12.68
±15.64

25.99
±32.54

14.09
±15.74

23.28
±26.56

15.04
±24.05

97.21

96.11

99.20

97.90

92.80

20.90

18.69

18.07

15.31

19.18

20.58

19.89

19.21

16.88

24.40

40.42
11.99
21.44
5.91
20.24

15.78
19.16
20.80
20.79
23.47

27.35
22.94
23.94
7.89
17.88

20.03
18.41
21.52
22.63
17.41

27.50
22.09
18.77
13.56
18.08

47.15

59.09

59.10

60.08

58.46

57.76

55.71

53.96

59.96

59.98

55.46

60.16

61.63

62.96

67.01
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Table C-2.

(Continued)

Characteristics

QPDC 50th
White
Black

Provider Always
59.33
58.31
Respected
274
59
Sample Size
Weighted
1,784,639 163,306
Population

QPDC 60th
QPDC 70th
White
Black
White
Black
%, unless otherwise noted

QPDC 80th
White
Black

63.26

51.04

61.90

68.09

65.59

68.78

264

74

264

72

774

178

1,722,877 196,246

1,737,023 196,465

5,329,553 465,402

Boldface estimates have P<0.05 for pairwise comparisons relative to whites.
PDC: Proportion of Days Covered; MSA: Metropolitan Statistical Area; CHD: Coronary Heart Disease; CHF: Congestive Heart
Failure; AMI: Acute Myocardial Infarction; SD: Standard Deviation; Q: Quantile; BMI: Body Mass Index; PD: Part D; PDP: standalone prescription drug plan; MA-PD: Medicare Advantage Prescription Drug plan; ACE: Angiotensin-Converting Enzyme; ARB:
Angiotensin II Receptor Blocker
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Table C-3.

RIF unconditional quantile regressions for by race, Q10th-Q40th

Covariate

QPDC 10th
Whites Blacks

QPDC 20th
Whites Blacks

QPDC 30th
Whites Blacks

QPDC 40th
Whites Blacks

Coefficient Estimate (Standard Error)
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban Residence
Census Region:
Midwest
South
West
Health Status:
Very Good
Good

-2.78
(3.36)
-7.04
(2.08)
-6.95
(6.60)
-1.55
(1.87)
-1.74
(3.09)
-0.13
(7.20)
1.96
(3.96)
-6.14
(1.28)
-5.93
(1.81)
7.06
(3.67)
5.89
(6.19)

-10.67
(2.89)
-14.19
(3.30)
-8.29
(3.79)
-0.88
(3.84)
-2.39
(7.74)
4.79
(2.28)
6.19
(6.65)
4.10
(9.17)
-16.81
(10.94)
-0.32
(8.03)
1.07
(7.71)

-5.28
(1.71)
-6.15
(1.43)
-5.80
(5.43)
-1.39
(3.33)
-4.46
(3.70)
0.49
(8.92)
3.62
(5.47)
-1.83
(3.20)
0.69
(3.85)
6.03
(3.84)
7.59
(5.80)
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-0.86
(4.69)
-3.65
(2.79)
-2.81
(3.24)
7.18
(3.01)
3.12
(3.08)
-2.95
(2.73)
15.01
(4.18)
7.78
(7.28)
-7.59
(14.78)
2.12
(3.43)
2.07
(7.51)

-4.11
(4.16)
-2.68
(3.67)
-5.21
(7.26)
-2.52
(1.77)
-6.05
(4.37)
-0.56
(10.30)
6.20
(2.54)
-1.13
(2.07)
2.02
(1.89)
4.52
(2.41)
4.27
(5.18)

1.61
(3.35)
0.48
(4.57)
3.40
(2.69)
2.61
(2.68)
7.34
(2.34)
-3.59
(2.94)
2.04
(3.07)
0.80
(4.25)
-5.98
(9.84)
5.27
(4.30)
-1.42
(9.12)

-2.18
(3.24)
-1.88
(2.80)
-4.58
(6.31)
-2.68
(1.47)
-3.28
(3.54)
-1.82
(5.67)
1.53
(1.25)
-3.53
(0.86)
0.58
(1.52)
5.76
(1.95)
5.79
(4.05)

0.34
(2.15)
0.79
(3.10)
3.22
(5.08)
-3.55
(3.40)
3.77
(4.39)
-0.98
(2.06)
8.28
(3.03)
3.58
(2.66)
-6.00
(6.49)
-0.96
(5.05)
-2.98
(7.89)

Table C-3.

(Continued)

Covariate

Fair
Poor
Any Physical Limitation
Any Cognitive Limitation
Depressive Symptoms
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke

QPDC 10th
Whites Blacks
13.36
(6.18)
5.85
(8.26)
0.76
(4.51)
-5.59
(8.72)
-6.41
(8.14)
4.49
(2.59)
1.87
(4.07)
-1.95
(2.59)
2.57
(4.37)
4.58
(9.70)
0.88
(4.62)

-0.95
(10.68)
0.72
(21.52)
3.99
(3.79)
-10.51
(6.02)
-10.10
(7.59)
-7.29
(3.68)
-12.56
(5.94)
5.44
(3.39)
-1.46
(15.31)
1.65
(5.59)
9.99
(9.19)

QPDC 20th
QPDC 30th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
7.84
6.85
9.89
12.14
(6.68)
(4.29)
(6.54)
(5.54)
4.06
12.05
-0.99
10.36
(6.16)
(10.88)
(10.46) (10.59)
-3.51
1.65
-3.91
-4.46
(3.48)
(2.68)
(3.29)
(5.24)
-4.71
0.62
-4.88
6.51
(9.66)
(5.72)
(8.85)
(3.88)
-3.43
-2.52
-7.71
-15.53
(7.87)
(11.54) (6.77)
(7.35)
3.39
-5.58
6.19
8.31
(3.55)
(6.71)
(2.25)
(2.49)
1.24
-4.10
1.65
0.85
(2.51)
(6.15)
(1.59)
(6.87)
-1.30
7.44
2.35
4.65
(0.92)
(5.40)
(2.51)
(6.23)
4.82
-7.70
-0.53
0.96
(4.01)
(4.70)
(5.51)
(4.14)
1.76
0.21
-12.12
-11.21
(5.61)
(13.32) (2.10)†
(3.41)
-4.31
5.73
2.23
-4.67
(8.88)
(6.47)
(1.94) (12.39)
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QPDC 40th
Whites Blacks
7.54
(3.27)
-3.59
(5.88)
-1.94
(2.60)
-2.55
(7.16)
-3.77
(5.42)
5.06
(3.22)
1.06
(1.49)
1.29
(2.63)
-0.66
(4.46)
2.59
(9.29)
-4.16
(0.84)

3.76
(3.54)
8.13
(7.64)
4.43
(5.84)
6.99
(2.13)
-5.53
(8.00)
6.61
(2.46)
5.54
(6.64)
4.32
(9.91)
6.12
(10.02)
-6.52
(6.86)
-1.53
(16.26)

Table C-3.

(Continued)

Count of Comorbid
Conditions

0.05
(0.61)

1.60
(0.54)

QPDC 20th
QPDC 30th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
0.11
1.04
-0.31
0.30
(0.79)
(0.61)
(0.71)
(0.36)

Charlson Comorbidity
Score Q3

-2.13
(1.26)

1.61
(4.15)

-2.74
(1.33)

4.59
(1.89)

-0.70
(1.88)

Charlson Comorbidity
Score Q4

-3.04
(5.97)

-0.03
(5.14)

-2.63
(6.36)

5.10
(1.45)

More Likely to Take
Risks

1.76
(5.19)

4.33
(4.08)

-1.18
(4.45)

Can overcome illness
without medical care

0.60
(1.22)

-1.73
(12.84)

Does not need health
insurance

-9.41
(1.50)
-2.94
(1.56)
-0.93
(1.58)
-0.88
(1.02)
-1.73
(4.45)

-8.47
(19.76)
5.42
(2.18)
0.60
(5.57)
14.91
(3.58)
-5.58
(3.44)

Covariate

Current Smoker
Had Moderate /
Vigorous Exercise
Obese (BMI≥30)
Income:
Poor/Near-Poor

QPDC 10th
Whites Blacks

QPDC 40th
Whites Blacks
-0.18
(0.41)

0.14
(0.24)

6.72
(1.56)

-0.59
(2.03)

6.46
(3.15)

0.37
(3.29)

9.59
(3.32)

-0.63
(1.73)

12.38
(3.86)

8.14
(4.86)

-0.43
(4.45)

-1.45
(4.22)

-2.03
(1.49)

-6.52
(2.78)

2.40
(1.44)

-3.29
(18.23)

-0.30
(1.54)

-12.41
(9.17)

-0.76
(1.11)

-11.41
(10.92)

-9.79
(3.53)
-4.02
(2.02)
-3.88
(1.32)
1.46
(1.12)
-0.17
(1.32)

-9.66
(22.38)
0.60
(2.63)
-4.60
(5.61)
11.96
(2.41)
-13.74
(6.00)

-7.97
(2.08)
-3.77
(7.31)
-4.66
(0.93)
0.63
(0.88)
0.75
(5.01)

1.76
(16.68)
-1.08
(3.46)
-1.55
(6.81)
12.83
(3.92)
-2.32
(5.54)

-12.93
(1.81)
0.34
(4.31)
-3.21
(1.93)
1.67
(0.65)†
1.86
(2.80)

7.17
(15.42)
1.91
(2.95)
-1.31
(5.57)
9.26
(2.22)
-6.90
(2.25)
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Table C-3.

(Continued)

-0.21
(1.85)
4.16
(2.68)
-2.23
(2.71)
-0.68
(2.67)

-5.21
(3.51)
-4.11
(5.38)
-7.49
(8.38)
-14.44
(7.16)

QPDC 20th
QPDC 30th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
-0.50
-4.90
4.06
-11.83
(1.10)
(3.37)
(1.44)
(2.73)
-7.55
2.26
-3.24
4.71
(7.61)
(2.68)
(5.08)
(1.70)
-2.14
3.68
-0.25
0.62
(2.17)
(7.64)
(2.87)
(5.86)
-4.16
-0.87
-1.80
-2.80
(2.55)
(7.61)
(2.30)
(3.15)

1.49
(2.45)

26.03
(7.05)

2.47
(0.93)

15.07
(1.22)

2.07
(2.65)

1.95
(4.27)
-1.61
(1.97)

22.97
(6.57)
19.00
(4.33)

3.61
(1.42)
1.09
(0.98)

14.02
(3.80)
18.36
(3.02)

Auto Eligible for PD
Low-Income Subsidy

6.80
(4.96)

-12.98
(7.23)

1.42
(2.39)

Average Copay for CV
Drugs ($2010)

-0.07
(0.04)

0.17
(0.04)

-0.07
(0.04)

Covariate

Low-Income
Middle-Income
Education:
Less than High School
High School Diploma
Drug Coverage Plan:
Part D: PDPs
Part D: MA-PD
Employer/Other Private

QPDC 10th
Whites Blacks
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QPDC 40th
Whites Blacks
1.31
(0.84)
1.42
(2.41)
1.83
(2.79)
0.68
(2.78)

-10.77
(5.19)
-7.59
(3.21)
1.87
(4.31)
-2.12
(6.33)

8.27
(3.82)

-0.55
(1.58)

10.94
(4.48)

3.64
(1.88)
0.68
(1.50)

13.38
(5.46)
21.03
(7.83)

2.93
(2.00)
-1.83
(1.02)

14.43
(7.73)
27.54
(9.05)

-12.87
(5.46)

3.29
(3.87)

-12.29
(3.17)

-0.21
(2.63)

-4.34
(3.27)

-0.06
(0.07)

-0.04
(0.04)

-0.12
(0.08)

-0.05
(0.02)

-0.18
(0.09)

Table C-3.

(Continued)

Covariate

QPDC 10th
Whites Blacks

QPDC 20th
QPDC 30th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)

QPDC 40th
Whites Blacks

Concurrently taking:
2-3 CV Drugs

10.44
(5.65)

10.51
(3.41)

6.51
(5.25)

4.91
(1.12)

0.67
(3.01)

-1.05
(2.33)

-1.54
(1.94)

-9.49
(1.33)

≥4 CV Drugs

12.98
(15.12)

12.70
(2.93)

6.61
(9.14)

5.49
(3.68)

3.21
(9.93)

1.60
(3.18)

-2.40
(5.88)

-11.46
(4.31)

Quantiles of Ambulatory
Visits:
Q 3 (5-7)

-1.47
(1.59)

-3.11
(9.26)

3.16
(1.53)

-6.55
(5.78)

6.18
(2.44)

-7.05
(6.03)

5.00
(2.36)

-10.24
(2.69)

-2.22
(2.11)
-6.96
(5.36)
-11.41
(10.66)

-9.52
(11.90)
3.99
(7.44)
-13.49
(9.96)

-1.39
(4.61)
-1.31
(6.31)
3.64
(4.89)

-2.50
(7.37)
-0.37
(3.62)
-6.96
(12.11)

1.26
(2.78)
-1.40
(5.87)
2.01
(6.08)

-9.17
(7.16)
2.18
(3.13)
6.62
(4.59)

0.58
(1.88)
-2.76
(4.56)
-6.02
(4.40)

-11.63
(4.00)
-0.78
(3.84)
1.59
(7.35)

Any Emergency
Department VisitBaseline Year

3.78
(3.82)

-1.03
(3.89)

3.23
(4.04)

6.22
(2.78)

5.31
(2.58)

11.67
(5.08)

1.98
(1.12)

10.09
(5.46)

No. of Pharmacies Used

-2.92
(3.04)

1.17
(5.15)

-4.52
(1.67)

-4.62
(6.06)

-6.07
(2.71)

-4.23
(4.03)

-5.86
(2.69)

-4.51
(4.93)

Very Satisfied with
Received Healthcare

1.89
(2.07)

2.91
(6.35)

3.11
(1.74)

14.35
(5.47)

3.95
(0.77)

8.66
(6.26)

4.32
(1.50)

7.77
(4.04)

Q 4 (8-12)
Q 5 (≥13)
Had a Usual Source of
Care
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Table C-3.

(Continued)

Covariate
Provider Always
Explained
Provider Always
Listened
Provider Always
Respected
Constant (Base QPDC)

Sample Size

QPDC 10th
Whites Blacks
3.41
(2.69)
-1.84
(3.42)
-1.42
(1.18)
41.86
(13.73)
2,585

-1.83
(5.73)
-3.84
(3.72)
-3.16
(7.00)
31.83
(31.56)
703

QPDC 20th
QPDC 30th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
3.13
-3.21
-0.41
-3.71
(3.94)
(7.80)
(0.89)
(6.86)
-0.64
-6.17
-1.40
-2.23
(1.72)
(3.93)
(3.30)
(7.12)
-2.46
-8.88
0.56
-4.97
(2.76)
(7.79)
(3.32) (10.28)
48.09
40.80
65.63
31.49
(11.90) (12.60)
(9.32) (12.29)
2,585
703
2,585
703

QPDC 40th
Whites Blacks
1.16
(0.52)†
-3.16
(0.76)†
0.96
(1.82)
84.83
(8.00)
2,585

0.60
(5.93)
3.11
(6.11)
-7.12
(9.19)
48.12
(11.74)
703

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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Table C-4.

RIF unconditional quantile regressions for by race, Q50th-Q80th
Covariate

Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban Residence
Census Region:
Midwest
South
West
Health Status:
Very Good
Good

QPDC 50th
Whites Blacks
-2.06
(1.10)
-2.54
(2.25)
-5.80
(4.64)
0.68
(1.98)
-1.40
(3.19)
-1.57
(6.49)
4.07
(2.03)
-2.00
(0.62)
1.53
(1.29)
6.61
(1.90)
4.16
(3.94)

1.29
(7.79)
0.57
(6.27)
0.09
(9.02)
-6.02
(4.13)
1.01
(3.50)
0.79
(3.86)
15.25
(6.92)
7.76
(7.15)
-1.55
(7.69)
4.24
(1.85)
4.89
(3.27)

QPDC 60th
QPDC 70th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
-0.79
-1.49
-2.96
-3.67
(5.63)
(1.73)
(6.48)
(0.85)
1.23
3.59
-5.74
-4.45
(4.12)
(5.69)
(2.41)
(1.54)
0.15
-3.83
-0.49
-6.86
(5.76)
(3.03)
(4.28)
(2.71)
0.83
-0.42
0.21
-3.67
(1.15)
(1.51)
(0.96)
(2.42)
-0.89
-3.29
-1.26
-3.33
(1.65)
(3.11)
(0.83)
(2.67)
-0.61
-1.12
1.59
-1.41
(5.42)
(3.24)
(4.61)
(3.46)
1.78
9.13
0.91
7.39
(1.64)
(8.20)
(1.85)
(4.73)
-0.84
0.08
0.03
0.24
(1.49)
(7.53)
(0.94)
(3.88)
1.94
-5.45
1.05
0.67
(1.11)
(5.94)
(1.03)
(3.90)
5.37
2.99
4.19
3.11
(4.56)
(2.59)
(2.12)
(0.55)
1.96
6.49
1.16
6.01
(2.86)
(5.34)
(1.89)
(1.30)
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QPDC 80th
Whites Blacks
-0.89
(1.17)
-2.53
(0.65)
-1.50
(1.59)
-0.08
(0.84)
-0.71
(0.29)
1.32
(4.31)
0.09
(1.07)
0.02
(1.38)
1.16
(0.44)
1.23
(0.28)
0.67
(1.38)

-0.18
(3.92)
4.92
(3.46)
2.04
(3.60)
-2.91
(2.85)
-2.60
(2.33)
-0.07
(4.34)
2.96
(1.59)
0.52
(1.40)
-2.55
(2.52)
4.94
(2.94)
3.52
(2.18)

Table C-4.

(Continued)
Covariate

Fair
Poor
Any Physical
Limitation
Any Cognitive
Limitation
Depressive
Symptoms
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke

QPDC 50th
Whites Blacks
7.27
(3.73)
-2.18
(5.10)
-1.21
(1.43)
-4.16
(4.10)
1.93
(5.15)
3.08
(3.18)
1.90
(1.43)
1.22
(2.63)
3.60
(2.55)
2.10
(6.66)
-3.57
(2.20)

9.30
(7.28)
17.13
(4.83)
10.62
(2.91)
5.25
(1.85)
-6.19
(3.78)
9.44
(4.48)
1.05
(7.95)
4.49
(7.53)
-1.17
(7.12)
-7.88
(3.53)
3.72
(17.65)

QPDC 60th
QPDC 70th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
4.41
9.23
2.70
7.18
(2.46)
(6.89)
(1.47)
(6.02)
-1.80
0.29
17.20
14.05
(4.38)
(3.14)
(4.07)
(2.89)
-1.19
-0.55
1.37
6.99
(2.10)
(2.14)
(3.02)
(3.29)
-3.18
0.41
-2.32
-3.85
(6.20)
(3.21)
(2.21)
(1.42)
-1.98
-1.53
-2.57
2.88
(3.38)
(3.69)
(1.86)
(1.33)
4.07
1.39
7.81
14.64
(3.58)
(3.03)
(4.12)
(3.47)
1.53
2.49
1.13
1.90
(0.92)
(5.63)
(0.93)
(2.40)
1.22
2.91
1.90
0.36
(1.53)
(4.95)
(1.47)
(2.31)
5.25
-1.02
-0.17
4.11
(3.20)
(6.66)
(2.63)
(2.53)
0.58
-2.44
1.41
-2.02
(5.05)
(4.05)
(4.41)
(7.00)
0.95
2.21
-0.94
-4.20
(1.24) (12.54)
(1.89)
(3.35)
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QPDC 80th
Whites Blacks
1.83
(0.70)
1.43
(0.88)
-1.10
(1.40)
-3.03
(1.76)
-0.64
(0.97)
0.39
(1.89)
0.12
(0.79)
1.64
(1.47)
1.51
(4.55)
-1.00
(3.65)
0.74
(1.03)

7.45
(5.46)
12.10
(3.78)
-0.95
(1.66)
-4.67
(2.11)
4.60
(0.80)
8.02
(1.48)
1.38
(1.44)
-0.00
(1.95)
-2.53
(5.51)
-3.61
(2.05)
1.24
(2.44)

Table C-4.

(Continued)

Count of Comorbid
Conditions

-0.57
(0.29)

-0.24
(0.31)

QPDC 60th
QPDC 70th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
-0.53
-0.99
-0.08
-0.67
(0.40)
(0.55)
(0.18)
(0.43)

Charlson
Comorbidity Score
Q3

-1.15
(2.50)

8.15
(2.73)

-2.16
(1.78)

2.67
(3.60)

0.24
(0.74)

-0.56
(3.94)

0.56
(0.55)

-3.95
(0.88)

Charlson
Comorbidity Score
Q4

0.19
(0.88)

10.86
(2.38)

-2.21
(1.69)

4.06
(1.49)

-3.22
(1.64)

5.58
(4.10)

-1.89
(2.66)

-1.12
(1.58)

More Likely to Take
Risks

-2.50
(2.51)

-2.67
(1.61)

-2.07
(1.57)

-2.97
(2.83)

-2.28
(0.98)

0.12
(2.31)

-1.54
(1.58)

-1.63
(2.91)

Can overcome illness
without medical care

0.87
(1.31)

-2.98
(12.17)

0.98
(1.02)

2.65
(8.98)

1.71
(2.13)

3.26
(8.17)

0.87
(1.89)

5.04
(7.53)

Does not need health
insurance

-3.76
(4.09)
0.12
(1.88)
-3.21
(2.00)
1.49
(2.01)
-0.07
(1.97)

-3.57
(15.92)
-5.97
(5.46)
-1.08
(2.86)
4.10
(0.57)
-7.81
(3.08)

-4.85
(2.86)
-5.56
(1.92)
-2.33
(2.16)
2.00
(1.76)
0.32
(1.68)

-1.72
(10.83)
-3.79
(3.35)
3.20
(2.88)
0.66
(0.96)
-6.44
(4.44)

-1.07
(2.45)
-2.56
(2.02)
-1.09
(1.76)
0.12
(0.82)
-1.22
(1.37)

-2.34
(5.81)
-0.73
(3.48)
1.81
(4.37)
1.38
(1.03)
-3.41
(6.90)

-0.28
(2.58)
-0.43
(2.36)
0.00
(0.84)
0.89
(0.97)
-0.39
(0.82)

4.10
(4.64)
1.92
(1.80)
1.74
(2.51)
3.12
(0.64)
-5.48
(4.55)

Covariate

Current Smoker
Had Moderate /
Vigorous Exercise
Obese (BMI≥30)
Income:
Poor/Near-Poor

QPDC 50th
Whites Blacks
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QPDC 80th
Whites Blacks
0.10
(0.20)

-0.34
(0.45)

Table C-4.

(Continued)
Covariate

Low-Income
Middle-Income
Education:
Less than High
School
High School
Diploma
Drug Coverage
Plan:
Part D: PDPs
Part D: MA-PD
Employer/Other
Private
Auto Eligible for PD
Low-Income
Subsidy
Average Copay for
CV Drugs ($2010)

QPDC 50th
Whites Blacks
0.63
(1.62)
1.24
(0.61)

-9.15
(4.36)
-3.25
(3.70)

QPDC 60th
QPDC 70th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
1.09
-1.89
0.96
-1.85
(2.48)
(6.98)
(1.37)
(8.75)
0.29
-3.30
0.02
0.58
(1.01)
(6.58)
(0.99)
(8.34)

2.81
(1.40)

-2.38
(4.45)

1.85
(1.30)

-4.77
(4.08)

0.33
(0.69)

-4.49
(2.01)

0.84
(0.42)

0.05
(1.75)

0.77
(1.55)

-3.79
(3.60)

-0.03
(0.47)

-2.80
(3.20)

-1.29
(0.24)

-3.12
(2.17)

-0.76
(0.37)

0.50
(3.50)

-0.01
(1.23)

2.06
(4.59)

0.79
(1.61)

1.23
(4.28)

2.34
(0.93)

1.60
(8.76)

1.10
(0.97)

-2.76
(6.28)

3.78
(3.53)
-1.94
(2.01)

1.80
(8.80)
12.79
(3.33)

5.75
(1.08)
0.21
(1.76)

-3.36
(4.74)
8.87
(2.97)

4.12
(0.81)
1.18
(1.07)

-2.11
(6.43)
9.70
(2.43)

2.97
(0.70)
-0.18
(0.95)

-2.76
(3.42)
8.15
(2.34)

-2.22
(3.76)

1.29
(3.31)

-0.23
(2.24)

-0.18
(4.49)

-0.68
(0.93)

-0.12
(3.23)

-1.71
(0.99)

3.09
(2.49)

-0.05
(0.01)

-0.23
(0.05)

-0.05
(0.02)

-0.16
(0.05)

-0.04
(0.02)

-0.06
(0.06)

-0.01
(0.01)

-0.04
(0.05)
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QPDC 80th
Whites Blacks
-0.85
(0.85)
-0.32
(0.84)

-1.64
(4.85)
-1.36
(4.74)

Table C-4.

(Continued)
Covariate

QPDC 50th
Whites Blacks

QPDC 60th
QPDC 70th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)

QPDC 80th
Whites Blacks

Concurrently taking:
2-3 CV Drugs

-1.13
(1.30)

-12.82
(3.63)

-5.27
(1.14)

-11.34
(3.45)

-4.97
(1.86)

-10.41
(1.66)

-3.09
(0.58)

-9.61
(1.87)

≥4 CV Drugs

-2.00
(2.72)

-13.34
(2.76)

-6.36
(2.29)

-11.61
(4.09)

-7.77
(3.18)

-8.89
(3.23)

-6.59
(1.51)

-4.75
(2.13)

Quantiles of
Ambulatory Visits:
Q 3 (5-7)

3.89
(2.13)

-5.33
(2.49)

1.46
(2.42)

0.98
(4.24)

0.46
(1.49)

-1.08
(5.67)

0.47
(0.70)

-0.24
(2.66)

1.47
(0.98)
-1.08
(2.29)
-5.55
(3.43)

-15.69
(5.07)
2.45
(3.95)
-2.21
(10.25)

1.19
(1.54)
-0.92
(2.45)
-0.10
(2.92)

-0.74
(2.96)
6.62
(4.28)
-4.42
(10.52)

0.18
(1.00)
-2.60
(1.67)
3.20
(3.53)

0.60
(1.37)
4.12
(4.96)
-6.90
(7.89)

-0.67
(0.64)
-0.88
(1.23)
-0.08
(3.99)

0.77
(0.84)
-0.68
(3.34)
-7.85
(2.52)

1.45
(0.81)

2.57
(4.29)

2.76
(1.20)

2.27
(3.88)

1.73
(1.55)

2.43
(3.23)

1.42
(1.12)

4.18
(2.47)

-5.17
(1.46)

-6.76
(3.40)

-1.66
(2.07)

-6.44
(6.26)

-0.90
(1.02)

-6.81
(4.40)

-0.40
(0.80)

-5.30
(2.45)

4.99
(2.69)

7.85
(1.40

1.40
(2.44)

2.68
(2.58)

0.20
(1.10)

4.17
(0.96)

1.03
(0.50)

3.96
(2.30)

Q 4 (8-12)
Q 5 (≥13)
Had a Usual Source
of Care
Any Emergency
Department VisitBaseline Year
No. of Pharmacies
Used
Very Satisfied with
Received Healthcare
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Table C-4.

(Continued)
Covariate
Provider Always
Explained
Provider Always
Listened
Provider Always
Respected
Constant (Base QPDC)

Sample Size

QPDC 50th
Whites Blacks
1.95
(2.37)
-2.89
(1.27)
0.33
(1.21)
87.74
(8.13)
2,585

2.33
(3.96)
0.19
(4.97)
-6.10
(7.32)
70.03
(27.98)
703

QPDC 60th
QPDC 70th
Whites Blacks
Whites Blacks
Coefficient Estimate (Standard Error)
2.01
-0.16
2.02
-2.34
(1.92)
(1.79)
(1.09)
(3.32)
2.86
-0.95
1.84
-1.60
(3.47)
(0.57)
(2.41)
(0.48)
0.55
1.00
0.61
4.75
(1.25)
(7.13)
(1.01)
(3.70)
92.18
80.64
93.28
98.77
(6.40) (14.34)
(7.27) (15.40)
2,585
703
2,585
703

QPDC 80th
Whites Blacks
0.94
(0.98)
-1.57
(1.13)
0.83
(0.54)
100.45
(9.46)
2,585

-4.92
(1.79)
1.91
(1.78)
2.93
(2.41)
105.77
(6.75)
703

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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Table C-5.
Outcome

Oaxaca-Blinder decomposition using coefficients from pooled RIF models, Q10th-Q40th
QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Panel A: Fitted Adherence Levels and Differences
QPDC, Blacks
QPDC, Whites
Difference

26.63 (3.33)
34.28 (1.22)
-7.65 (3.77)

43.99 (2.52)
51.50 (1.11)
-7.51 (2.86)

50.65 (2.68)
60.10 (1.28)
-9.45 (3.06)

64.39 (2.37)
70.45 (1.14)
-6.05 (2.69)

Panel B: Portion of Adherence Difference Due to:
Characteristics

Aggregate
Contribution
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban
Residence
Census Region:
Midwest
South
West
Health Status:
Very Good
Good

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

1.68 (2.00)

-9.33 (3.80)

2.23 (1.74)

-9.73 (2.98)

3.77 (1.68)

-13.22 (3.20)

3.21 (1.37)

-9.26 (2.70)

-0.27 (0.30)
0.13 (0.17)
0.47 (0.35)
-0.02 (0.19)
0.05 (0.71)

-2.60 (2.47)
-1.83 (1.95)
0.84 (2.54)
2.67 (5.61)
0.36 (2.97)

-0.30 (0.28)
0.10 (0.14)
0.33 (0.23)
-0.05 (0.17)
1.05 (0.57)

0.39 (2.44)
0.87 (1.46)
1.46 (2.10)
4.47 (4.39)
3.82 (2.35)

-0.26 (0.25)
0.03 (0.07)
0.29 (0.23)
-0.16 (0.18)
1.35 (0.66)

2.38 (2.08)
0.27 (1.41)
1.69 (2.12)
0.73 (4.24)
3.14 (2.35)

-0.16 (0.22)
0.02 (0.07)
0.29 (0.21)
-0.21 (0.18)
0.90 (0.59)

0.90 (1.99)
0.47 (1.35)
1.01 (1.98)
-2.55 (3.85)
1.98 (2.13)

-0.01 (0.21)

0.64 (7.88)

0.00 (0.17)

-3.40 (7.03)

-0.03 (0.17)

-0.52 (7.13)

-0.10 (0.15)

2.44 (6.72)

-0.39 (0.34)

1.88 (1.84)

-0.37 (0.27)

1.02 (1.53)

-0.57 (0.37)

0.08 (1.76)

-0.32 (0.33)

1.66 (1.56)

-0.89 (0.72)
0.76 (0.50)

7.25 (6.42)
-0.43 (1.73)

-0.25 (0.60)
0.12 (0.42)

4.11 (4.59)
-0.11 (1.07)

-0.45 (0.72)
-0.09 (0.45)

2.13 (5.16)
-0.85 (1.03)

-0.55 (0.72)
-0.11 (0.38)

5.90 (4.52)
-0.41 (0.88)

-0.48 (0.33)

-0.60 (4.54)

-0.45 (0.26)

-1.48 (3.02)

-0.34 (0.28)

-0.41 (3.34)

-0.45 (0.29)

-0.88 (2.67)

0.04 (0.14)

1.18 (6.25)

0.07 (0.17)

-3.18 (3.95)

0.04 (0.13)

-1.70 (4.49)

0.07 (0.18)

-1.98 (3.49)
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Table C-5.
Characteristics

Fair
Poor
Any Physical
Limitation
Any Cognitive
Limitation
Depressive
Symptoms

(Continued)
QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.94 (0.50)
0.14 (0.21)

-1.25 (5.21)
0.83 (1.62)

1.02 (0.48)
0.12 (0.18)

-1.53 (3.35)
0.55 (1.24)

0.70 (0.50)
0.05 (0.17)

-0.17 (3.84)
0.90 (1.42)

0.87 (0.46)
0.01 (0.16)

-0.01 (2.94)
1.23 (1.11)

0.01 (0.10)

-0.54 (5.41)

-0.05 (0.11)

1.87 (4.35)

-0.04 (0.09)

5.66 (4.25)

-0.03 (0.08)

7.70 (3.72)

-0.47 (0.38)

-0.30 (1.83)

-0.20 (0.30)

0.77 (1.57)

-0.31 (0.33)

2.03 (1.46)

-0.15 (0.26)

1.15 (1.39)

-0.73 (0.41)

-1.88 (1.88)

-0.42 (0.33)

-0.77 (1.38)

-0.24 (0.31)

-0.43 (1.29)

-0.32 (0.26)

-0.68 (1.13)

-0.10 (0.20)
0.06 (0.15)
-0.01 (0.04)
-0.06 (0.10)
0.00 (0.07)

-11.53
(14.21)
-5.26 (4.49)
0.48 (1.70)
-0.03 (0.47)
-0.53 (1.15)
0.86 (0.86)

-0.17 (0.57)
-0.01 (0.28)

Hypertension

0.26 (0.35)

Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke
Count of
Comorbid
Conditions
Charlson
Comorbidity
Score Q3

0.59 (0.36)

0.29 (10.50)

0.61 (0.32)

-0.26 (9.42)

-0.00 (0.16)
0.00 (0.12)
-0.01 (0.04)
-0.02 (0.09)
-0.00 (0.06)

-2.36
(11.44)
0.13 (3.96)
1.42 (1.37)
-0.26 (0.46)
-0.72 (0.89)
0.39 (0.66)

-0.14 (0.19)
-0.13 (0.12)
0.00 (0.05)
0.01 (0.09)
-0.01 (0.07)

1.29 (3.77)
0.33 (1.22)
0.22 (0.47)
-0.56 (0.89)
0.11 (0.81)

-0.12 (0.19)
-0.07 (0.10)
0.00 (0.04)
-0.04 (0.09)
-0.01 (0.07)

2.43 (3.55)
0.43 (1.30)
0.05 (0.45)
-0.75 (0.75)
0.30 (0.80)

8.16 (6.58)

-0.11 (0.42)

3.04 (5.13)

0.41 (0.47)

1.31 (5.05)

0.23 (0.38)

-0.62 (4.32)

3.48 (3.36)

-0.13 (0.24)

3.25 (2.54)

0.01 (0.23)

2.97 (2.30)

0.05 (0.22)

2.99 (2.25)

0.01 (0.31)
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Table C-5.
Characteristics

Charlson
Comorbidity
Score Q4
More Likely to
Take Risks
Can overcome
illness without
medical care
Does not need
health
insurance
Current
Smoker
Had Moderate /
Vigorous
Exercise
Obese
(BMI≥30)
Income:
Poor/Near-Poor
Low-Income
Middle-Income

(Continued)
QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-0.04 (0.15)

0.92 (1.89)

-0.04 (0.13)

1.14 (1.58)

0.03 (0.11)

1.82 (1.62)

0.01 (0.10)

1.63 (1.41)

-0.04 (0.10)

0.97 (1.22)

-0.04 (0.08)

0.43 (1.20)

0.02 (0.08)

-0.91 (1.42)

0.05 (0.09)

-0.48 (1.20)

0.04 (0.22)

-1.01 (1.07)

-0.00 (0.19)

-0.50 (0.80)

0.00 (0.24)

-0.87 (0.82)

0.07 (0.18)

-0.23 (0.71)

-0.04 (0.10)

0.29 (0.77)

-0.06 (0.12)

0.51 (0.77)

-0.05 (0.11)

0.60 (0.82)

-0.10 (0.14)

0.87 (0.69)

-0.00 (0.12)

0.70 (1.11)

-0.10 (0.13)

0.61 (0.87)

-0.10 (0.15)

0.84 (0.87)

-0.01 (0.12)

-0.53 (0.82)

0.23 (0.25)

0.32 (3.29)

0.26 (0.21)

0.06 (2.39)

0.41 (0.25)

1.17 (2.82)

0.28 (0.22)

0.86 (2.40)

-0.00 (0.24)

7.09 (2.91)

0.16 (0.21)

4.05 (2.29)

0.14 (0.23)

3.83 (2.50)

0.15 (0.20)

1.14 (2.11)

-0.47 (0.64)

-4.53 (3.44)

-0.02 (0.59)

-3.39 (2.86)

0.11 (0.58)

-2.39 (3.21)

0.18 (0.55)

-1.41 (2.61)

-0.07 (0.22)
-0.01 (0.13)

-2.63 (2.12)
-4.04 (3.70)

0.18 (0.19)
-0.01 (0.14)

-3.15 (1.77)
-3.07 (3.28)

0.02 (0.23)
-0.00 (0.10)

-2.44 (2.05)
-3.69 (3.50)

0.03 (0.19)
-0.00 (0.08)

-1.26 (1.91)
-0.42 (2.97)
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Table C-5.
Characteristics

Education:
Less than High
School
High School
Diploma
Drug Coverage
Plan: Part D:
PDPs
Part D: MA-PD
Employer/Othe
r Private
Auto Eligible
for PD LowIncome
Subsidy
Average Copay
for CV Drugs
($2010)
Concurrently
taking:
2-3 CV Drugs
≥4 CV Drugs

(Continued)
QPDC 10th

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-0.98 (0.89)

-1.18 (3.78)

-0.42 (0.78)

3.58 (3.85)

-0.03 (0.86)

1.43 (3.86)

0.17 (0.76)

-1.67 (3.60)

0.24 (0.39)

-4.94 (3.79)

0.32 (0.34)

1.99 (3.84)

0.26 (0.40)

-0.21 (4.07)

0.10 (0.34)

-1.21 (3.68)

0.40 (0.36)

12.30 (6.27)

0.24 (0.25)

2.80 (4.86)

0.33 (0.29)

3.23 (4.58)

0.00 (0.24)

1.92 (3.62)

0.16 (0.28)

5.80 (4.36)

0.26 (0.23)

2.16 (3.08)

0.31 (0.27)

3.05 (3.08)

0.18 (0.22)

0.94 (2.48)

0.06 (0.34)

3.68 (2.23)

-0.21 (0.27)

2.15 (1.60)

-0.25 (0.30)

3.52 (1.43)

0.06 (0.26)

2.67 (1.19)

0.59 (0.96)

-4.90 (2.31)

-0.23 (0.85)

-4.08 (1.81)

0.42 (0.94)

-2.42 (1.88)

0.16 (0.80)

0.09 (1.65)

0.54 (0.35)

2.16 (2.77)

0.35 (0.28)

-0.18 (2.13)

0.42 (0.29)

-2.41 (2.11)

0.41 (0.24)

-2.50 (1.85)

-0.04 (0.23)

-0.28 (5.29)

-0.03 (0.15)

-4.06 (3.63)

-0.00 (0.07)

-6.22 (3.70)

0.01 (0.10)

-5.76 (3.28)

0.44 (0.30)

-0.01 (1.75)

0.31 (0.19)

-0.62 (1.35)

0.09 (0.16)

-1.62 (1.19)

-0.13 (0.16)

-1.49 (1.08)
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Table C-5.
Characteristics

(Continued)
QPDC 10th
Difference in
Characteristics

Ambulatory Visit Quantiles:
Q 3 (5-7)
-0.05 (0.15)
Q 4 (8-12)
0.21 (0.29)
Q 5 (≥13)
0.46 (0.34)
Had a Usual
0.18 (0.15)
Source of Care
Any ED Visit0.13 (0.15)
Baseline Year
No. of
0.48 (0.37)
Pharmacies
Very Satisfied
-0.01 (0.14)
with Healthcare
Provider
0.06 (0.14)
Explained
Provider
-0.03 (0.10)
Listened
Provider
-0.01 (0.09)
Respected
Constant
(Base QPDC)
Sample Size

QPDC 20th
QPDC 30th
Estimate (Standard Error)

QPDC 40th

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.28 (2.27)
-0.13 (1.77)
2.04 (1.76)
-7.53
(13.74)

0.02 (0.09)
0.21 (0.24)
0.18 (0.27)

-2.60 (1.77)
-0.71 (1.36)
1.00 (1.31)

0.07 (0.14)
-0.12 (0.25)
0.12 (0.28)

-2.94 (1.58)
-1.44 (1.35)
0.36 (1.47)

0.07 (0.14)
-0.03 (0.21)
0.18 (0.25)

-2.10 (1.26)
-1.25 (1.24)
0.37 (1.32)

-0.07 (0.13)

2.72 (15.34)

-0.05 (0.13)

-2.38 (14.92)

0.09 (0.13)

2.13 (13.42)

0.13 (1.57)

0.09 (0.12)

1.92 (1.43)

0.19 (0.15)

1.01 (1.29)

0.06 (0.10)

0.70 (1.03)

-1.10
(10.02)

0.62 (0.34)

-5.26 (7.86)

0.89 (0.38)

0.31 (8.33)

1.07 (0.32)

2.34 (7.17)

3.79 (4.92)

-0.17 (0.17)

5.21 (4.20)

-0.18 (0.18)

4.15 (3.88)

-0.24 (0.19)

1.38 (3.56)

-3.63 (6.47)

0.07 (0.14)

-5.14 (4.70)

-0.01 (0.10)

-1.62 (4.92)

0.00 (0.09)

-0.74 (4.40)

-3.77 (6.07)

-0.04 (0.11)

-1.61 (4.73)

-0.02 (0.10)

3.48 (5.69)

-0.04 (0.10)

5.32 (4.32)

-3.15 (5.55)

-0.05 (0.11)

-1.83 (5.18)

0.01 (0.09)

-5.65 (5.74)

0.00 (0.08)

-6.44 (5.20)

-8.80
(32.31)

-17.62
(25.77)

-25.75
(30.57)

-26.61
(26.37)

3,288

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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Table C-6.

Oaxaca-Blinder decomposition using coefficients from pooled RIF models, Q50th-Q80th

Outcome

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Panel A: Fitted Adherence Levels and Differences
QPDC, Blacks

73.83 (1.89)†

81.38 (1.60)†

89.54 (1.07)†

QPDC, Whites

77.86 (1.02)†

86.19 (0.95)†

93.22 (0.71)†

-4.03 (2.15)

-4.80 (1.88)†

-3.68 (1.37)†

Difference

96.98 (0.60)†
99.42
(0.41)†
-2.44 (0.76)†

Panel B: Portion of Adherence Difference Due to:
Characteristics

Aggregate
Contribution
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban
Residence
Census Region:
Midwest
South
West
Health Status:
Very Good

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

2.52 (1.30)

-6.55 (2.29)

1.64 (1.27)

-6.45 (2.16)

0.91 (0.88)

-4.59 (1.53)

0.20 (0.54)

-2.64 (0.87)

-0.18 (0.19)
0.04 (0.07)
0.37 (0.22)
0.06 (0.14)
0.37 (0.52)

0.82 (1.73)
0.86 (1.22)
1.42 (1.83)
-0.32 (3.19)
0.80 (1.85)

-0.26 (0.21)
0.07 (0.10)
0.39 (0.24)
0.03 (0.12)
0.25 (0.48)

0.38 (1.74)
1.80 (1.20)
2.01 (1.80)
-3.01 (2.93)
-0.79 (1.73)

-0.10 (0.14)
0.05 (0.08)
0.25 (0.16)
0.00 (0.11)
0.41 (0.34)

0.02 (1.14)
1.88 (0.82)
1.42 (1.20)
-1.76 (1.86)
-0.67 (1.10)

-0.06 (0.08)
0.03 (0.04)
0.08 (0.07)
-0.02 (0.06)
0.11 (0.20)

0.13 (0.61)
1.12 (0.49)
0.88 (0.72)
-0.46 (1.06)
0.26 (0.61)

-0.07 (0.15)

-0.65 (5.81)

-0.05 (0.15)

-0.13 (5.07)

0.05 (0.10)

-1.54 (3.66)

0.06 (0.07)

0.65 (1.99)

-0.48 (0.33)

1.79 (1.21)

-0.19 (0.26)

1.20 (1.11)

-0.11 (0.20)

0.34 (0.78)

0.01 (0.10)

0.46 (0.48)

-0.32 (0.57)
-0.14 (0.32)

3.85 (3.57)
-0.41 (0.79)

-0.31 (0.54)
-0.22 (0.31)

0.51 (3.10)
-0.26 (0.81)

-0.00 (0.41)
-0.14 (0.24)

-0.35 (2.41)
-0.38 (0.51)

-0.10 (0.25)
-0.07 (0.13)

0.55 (1.34)
0.03 (0.27)

-0.48 (0.27)

-1.06 (1.98)

-0.33 (0.24)

-0.10 (1.75)

-0.24 (0.18)

0.40 (1.27)

-0.11 (0.10)

-0.17 (0.75)
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Table C-6.

(Continued)

Characteristics

Good
Fair
Poor
Any Physical
Limitation
Any Cognitive
Limitation
Depressive
Symptoms
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke
Count of
Comorbid
Conditions
Charlson
Comorbidity
Score Q3

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.04 (0.13)
0.63 (0.38)
-0.02 (0.15)

-0.96 (2.81)
-1.31 (2.30)
1.03 (0.90)

0.03 (0.10)
0.55 (0.38)
0.02 (0.13)

1.35 (2.69)
0.86 (2.17)
1.30 (0.87)

0.02 (0.07)
0.29 (0.28)
0.05 (0.08)

1.00 (1.94)
1.00 (1.58)
1.03 (0.62)

0.01 (0.04)
0.15 (0.16)
0.05 (0.05)

-0.64 (1.14)
-0.36 (0.91)
0.06 (0.33)

-0.00 (0.06)

5.47 (3.11)

-0.02 (0.06)

2.48 (2.90)

-0.01 (0.05)

-0.10 (1.98)

-0.02 (0.04)

0.88 (1.22)

-0.13 (0.27)

0.99 (1.15)

-0.25 (0.26)

0.94 (1.07)

-0.24 (0.16)

-0.16 (0.65)

-0.19 (0.10)

0.21 (0.35)

0.10 (0.25)

-0.50 (1.01)

-0.04 (0.22)

0.04 (0.98)

-0.20 (0.16)

0.68 (0.57)

-0.07 (0.09)

0.14 (0.30)

0.41 (0.27)
-0.17 (0.16)
-0.08 (0.09)
-0.01 (0.04)
-0.02 (0.07)
-0.01 (0.07)

8.84 (8.11)
-0.42 (3.24)
0.13 (1.00)
-0.23 (0.42)
-0.43 (0.62)
0.52 (0.59)

0.41 (0.27)
-0.11 (0.14)
-0.08 (0.10)
-0.02 (0.05)
0.01 (0.07)
0.00 (0.05)

7.33 (8.34)
-0.23 (2.82)
-0.14 (0.88)
-0.11 (0.35)
-0.13 (0.66)
-0.73 (0.59)

0.20 (0.18)
-0.09 (0.10)
-0.10 (0.08)
-0.01 (0.03)
-0.02 (0.05)
-0.00 (0.03)

4.43 (6.25)
0.31 (1.97)
-0.16 (0.58)
-0.18 (0.27)
-0.20 (0.44)
0.06 (0.35)

0.09 (0.12)
-0.03 (0.06)
-0.08 (0.05)
-0.00 (0.02)
0.02 (0.03)
0.00 (0.02)

4.67 (2.71)
0.11 (1.12)
-0.04 (0.39)
-0.08 (0.16)
-0.05 (0.24)
-0.02 (0.20)

0.64 (0.31)

0.10 (4.10)

0.42 (0.31)

-0.00 (4.36)

0.11 (0.23)

-2.87 (2.56)

-0.08 (0.15)

-0.59 (1.49)

-0.05 (0.20)

2.24 (2.01)

-0.18 (0.18)

0.53 (1.97)

-0.04 (0.12)

-1.25 (1.16)

0.06 (0.07)

-0.61 (0.66)
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Table C-6.

(Continued)

Characteristics

Charlson
Comorbidity
Score Q4
More Likely to
Take Risks
Can overcome
illness without
medical care
Does not need
health
insurance
Current
Smoker
Had Moderate /
Vigorous
Exercise
Obese
(BMI≥30)
Income:
Poor/Near-Poor
Low-Income
Middle-Income

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.00 (0.08)

0.78 (1.31)

-0.03 (0.08)

0.75 (1.28)

-0.07 (0.08)

0.61 (0.66)

-0.03 (0.04)

0.33 (0.37)

0.04 (0.08)

-0.05 (1.08)

0.04 (0.08)

0.46 (0.93)

0.06 (0.07)

0.42 (0.59)

0.03 (0.04)

0.20 (0.34)

-0.03 (0.15)

-0.02 (0.64)

-0.04 (0.13)

0.01 (0.68)

-0.11 (0.11)

-0.01 (0.47)

-0.06 (0.07)

-0.11 (0.24)

-0.02 (0.06)

0.17 (0.61)

-0.04 (0.07)

-0.03 (0.53)

-0.01 (0.04)

0.19 (0.35)

-0.00 (0.02)

0.16 (0.22)

0.01 (0.11)

-0.29 (0.71)

-0.17 (0.14)

0.08 (0.66)

-0.08 (0.08)

0.27 (0.46)

-0.00 (0.04)

0.27 (0.30)

0.25 (0.20)

1.17 (2.19)

0.18 (0.19)

1.03 (2.07)

0.06 (0.13)

1.35 (1.26)

0.02 (0.07)

-0.17 (0.70)

0.18 (0.19)

0.29 (1.91)

0.19 (0.19)

-0.18 (1.76)

0.06 (0.12)

0.87 (1.19)

0.09 (0.08)

0.08 (0.73)

-0.09 (0.44)

-3.02 (2.39)

-0.01 (0.42)

-1.49 (2.48)

-0.27 (0.28)

-0.54 (1.71)

-0.12 (0.17)

-0.78 (0.92)

0.01 (0.17)
-0.00 (0.07)

-1.75 (1.73)
-2.06 (2.68)

0.07 (0.16)
-0.00 (0.06)

-0.81 (1.80)
-0.45 (2.51)

0.07 (0.11)
-0.00 (0.04)

-0.43 (1.15)
0.44 (1.53)

-0.05 (0.06)
0.00 (0.03)

0.24 (0.64)
-0.54 (0.89)
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Table C-6.

(Continued)

Characteristics

Education:
Less than High
School
High School
Diploma
Drug Coverage
Plan:
Part D: PDPs
Part D: MA-PD
Employer/Othe
r Private
Auto Eligible
for PD LowIncome
Subsidy
Average Copay
for CV Drugs
($2010)
Concurrently
taking:
2-3 CV Drugs
≥4 CV Drugs

QPDC 50th

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.56 (0.67)

-1.73 (2.91)

0.39 (0.72)

-3.68 (2.71)

-0.01 (0.52)

-1.42 (2.02)

0.09 (0.32)

-1.24 (1.14)

-0.05 (0.27)

-0.65 (2.88)

-0.02 (0.25)

-2.68 (2.87)

0.18 (0.18)

-0.47 (1.77)

0.11 (0.12)

0.07 (0.96)

0.03 (0.21)

0.28 (3.37)

0.13 (0.19)

0.34 (3.20)

0.24 (0.15)

-1.27 (2.29)

0.10 (0.09)

-0.32 (0.95)

0.22 (0.20)

-1.14 (2.37)

0.33 (0.21)

-2.49 (2.15)

0.25 (0.17)

-1.56 (1.53)

0.17 (0.11)

-0.59 (0.77)

0.13 (0.22)

1.43 (1.04)

-0.07 (0.23)

1.32 (1.02)

-0.14 (0.18)

1.10 (0.72)

-0.00 (0.11)

0.70 (0.41)

-0.11 (0.73)

1.06 (1.41)

-0.08 (0.63)

-0.33 (1.40)

0.11 (0.42)

0.89 (0.89)

-0.06 (0.23)

0.89 (0.52)

0.43 (0.22)

-2.25 (1.41)

0.39 (0.20)

-1.20 (1.31)

0.35 (0.13)

0.15 (0.87)

0.08 (0.08)

0.17 (0.53)

0.01 (0.07)

-3.14 (2.91)

0.02 (0.14)

-2.74 (3.13)

0.03 (0.16)

-2.58 (1.96)

0.02 (0.09)

-2.15 (1.20)

-0.10 (0.16)

-0.64 (0.98)

-0.24 (0.18)

-0.27 (1.07)

-0.30 (0.15)

0.26 (0.65)

-0.24 (0.11)

0.42 (0.39)
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Table C-6.
Characteristics

(Continued)
QPDC 50th
Difference in
Characteristics

Ambulatory Visits Quantiles
Q 3 (5-7)
0.06 (0.12)
Q 4 (8-12)
-0.13 (0.21)
Q 5 (≥13)
0.01 (0.19)
Had a Usual
0.08 (0.11)
Source of Care
Any ED Visit0.05 (0.09)
Baseline Year
No. of
0.74 (0.28)
Pharmacies
Very Satisfied
-0.24 (0.19)
with Healthcare
Provider
0.02 (0.08)
Explained
Provider
-0.04 (0.09)
Listened
Provider
0.01 (0.06)
Respected
Constant
(Base QPDC)
Sample Size

QPDC 60th
QPDC 70th
Estimate (Standard Error)

QPDC 80th

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-1.15 (1.27)
-1.23 (1.01)
1.19 (1.10)

0.02 (0.08)
-0.03 (0.21)
0.10 (0.20)

0.00 (0.05)
0.02 (0.14)
0.16 (0.15)

-0.30 (0.46)
0.26 (0.42)
-0.19 (0.42)

0.02 (0.09)

-0.08 (0.80)
0.31 (0.61)
0.76 (0.76)
-12.36
(8.94)

0.00 (0.03)
0.03 (0.09)
0.07 (0.09)

2.51 (12.50)

-0.20 (1.18)
-0.33 (0.95)
0.81 (1.06)
-4.97
(13.03)

0.01 (0.04)

-6.35 (5.24)

0.08 (1.07)

0.08 (0.09)

0.13 (1.01)

0.05 (0.06)

0.27 (0.63)

0.05 (0.05)

0.15 (0.41)

-2.52 (5.76)

0.39 (0.26)

-4.20 (5.60)

0.16 (0.17)

-5.65 (3.64)

0.07 (0.12)

-1.80 (2.36)

0.02 (2.91)

-0.10 (0.14)

1.69 (2.78)

-0.04 (0.09)

1.25 (1.79)

-0.04 (0.06)

0.26 (1.02)

-0.69 (3.95)

0.02 (0.08)

-3.24 (3.85)

0.03 (0.06)

-3.33 (2.48)

0.01 (0.03)

-0.71 (1.33)

3.21 (3.90)

-0.02 (0.08)

2.58 (3.82)

-0.01 (0.06)

2.24 (2.35)

-0.03 (0.04)

2.09 (1.66)

-3.42 (5.63)

0.01 (0.07)

1.82 (4.01)

0.01 (0.05)

2.13 (2.88)

0.02 (0.04)

-0.27 (1.54)

-15.53
(22.44)

-0.03 (0.06)

-3.28
(21.40)

8.68 (14.98)

-0.53 (8.67)

3,288

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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Table C-7.
PDC≥80%

Oaxaca-Blinder decomposition of mean differences in continuous PDC and in the probability of having

Outcome

Linear Probability Model
(PDC≥80%)

Logistic Model
(PDC≥80%)
Estimate (Standard Error)

Ordinary Least Squares
(Continuous PDC)

Panel A: Fitted Adherence Levels and Difference
Blacks
Whites
Difference

Characteristics
Aggregate
Contribution
Age 70-75
Age 75-80
Age ≥ 80
Female
Married
Urban Residence
Census Region:
Midwest
South
West

Average Probability of Adherence (PDC≥80%)
0.41 (0.02)
0.41 (0.02)
0.47 (0.01)
0.47 (0.01)
-0.06 (0.03)
-0.06 (0.03)

Mean PDC
68.05 (1.42)
73.09 (0.67)
-5.04 (1.62)

Panel B: Portion of adherence difference due to
Difference in
Difference in
Difference in
Difference in
Difference in
Characteristics
Returns to
Characteristics
Returns to
Characteristics
Characteristics
Characteristics

Difference in
Returns to
Characteristics

0.03 (0.03)

-0.09 (0.04)

0.03 (0.03)

-0.09 (0.04)

0.95 (2.58)

-5.99 (3.09)

-0.00 (0.00)
-0.00 (0.00)
-0.00 (0.00)
-0.00 (0.00)
0.01 (0.01)
0.00 (0.00)

0.00 (0.02)
0.01 (0.02)
0.03 (0.03)
-0.01 (0.03)
-0.01 (0.04)
0.01 (0.06)

-0.00 (0.00)
-0.00 (0.00)
-0.00 (0.00)
-0.00 (0.00)
0.01 (0.01)
0.00 (0.00)

0.00 (0.02)
0.01 (0.01)
0.03 (0.03)
-0.01 (0.03)
-0.01 (0.03)
0.01 (0.06)

-0.08 (0.21)
0.01 (0.11)
0.02 (0.25)
-0.05 (0.26)
0.03 (1.01)
-0.02 (0.23)

0.30 (0.93)
0.56 (0.89)
1.21 (1.38)
-0.19 (2.06)
1.07 (2.37)
0.09 (3.57)

-0.01 (0.01)

0.03 (0.02)

-0.01 (0.01)

0.03 (0.02)

-0.68 (0.50)

1.23 (1.29)

0.01 (0.02)
0.01 (0.01)

0.02 (0.03)
-0.02 (0.02)

0.01 (0.01)
0.01 (0.01)

0.02 (0.03)
-0.01 (0.02)

0.60 (0.99)
0.52 (1.02)

1.45 (1.53)
-0.90 (1.64)
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Table C-7.

(Continued)

Characteristics

Health Status:
Very Good
Good
Fair
Poor
Any Physical
Limitation
Any Cognitive
Limitation
Depressive
Symptoms
Hypertension
Hyperlipidemia
Angina/CHD
CHF
AMI
Stroke
Comorbid
Conditions Count
Charlson
Comorbidity Score
Q3

Linear Probability Model
(PDC≥80%)

Logistic Model
(PDC≥80%)
Estimate (Standard Error)
Difference in
Difference in
Characteristics
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-0.00 (0.01)

-0.00 (0.03)

-0.00 (0.01)

0.00 (0.00)
0.01 (0.01)
0.01 (0.00)

0.01 (0.03)
0.00 (0.02)
0.01 (0.01)

0.00 (0.00)

Ordinary Least Squares
(Continuous PDC)
Difference in
Characteristics

Difference in
Returns to
Characteristics

0.00 (0.03)

-0.29 (0.50)

0.05 (2.04)

0.00 (0.00)
0.01 (0.01)
0.01 (0.00)

0.01 (0.03)
0.00 (0.02)
0.01 (0.01)

0.03 (0.20)
0.57 (0.65)
0.31 (0.26)

-0.11 (2.13)
0.11 (1.22)
0.53 (0.44)

0.07 (0.04)

0.00 (0.00)

0.06 (0.03)

0.03 (0.12)

1.77 (2.21)

0.00 (0.01)

0.01 (0.01)

0.00 (0.00)

0.01 (0.01)

-0.02 (0.33)

0.29 (0.46)

-0.00 (0.01)

-0.01 (0.01)

-0.00 (0.01)

-0.01 (0.01)

-0.34 (0.37)

-0.15 (0.39)

0.02 (0.01)
-0.00 (0.00)
-0.00 (0.00)
0.00 (0.00)
0.00 (0.00)
0.00 (0.00)

0.12 (0.09)
0.00 (0.04)
-0.00 (0.01)
-0.00 (0.01)
-0.01 (0.01)
0.00 (0.01)

0.02 (0.01)
-0.00 (0.00)
-0.00 (0.00)
0.00 (0.00)
0.00 (0.00)
0.00 (0.00)

0.12 (0.09)
0.00 (0.04)
0.00 (0.01)
-0.00 (0.00)
-0.00 (0.01)
0.00 (0.01)

0.46 (0.63)
0.04 (0.21)
-0.12 (0.15)
0.00 (0.06)
0.08 (0.16)
0.00 (0.09)

1.57 (5.02)
-1.01 (2.20)
0.50 (0.80)
-0.09 (0.29)
-0.49 (0.57)
0.19 (0.40)

0.01 (0.01)

-0.03 (0.07)

0.01 (0.01)

-0.03 (0.06)

-0.06 (0.53)

1.18 (3.29)

0.00 (0.01)

0.02 (0.02)

0.00 (0.00)

0.02 (0.02)

0.24 (0.28)

1.13 (1.04)

170

Table C-7.

(Continued)

Characteristics

Linear Probability Model
(PDC≥80%)

Logistic Model
(PDC≥80%)
Estimate (Standard Error)
Difference in
Difference in
Returns to
Characteristics
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

0.00 (0.01)

0.02 (0.02)

0.00 (0.00)

0.00 (0.00)

0.01 (0.01)

Ordinary Least Squares
(Continuous PDC)
Difference in
Characteristics

Difference in
Returns to
Characteristics

0.02 (0.02)

0.24 (0.28)

1.13 (1.04)

0.00 (0.00)

0.01 (0.01)

0.10 (0.15)

0.76 (0.78)

Charlson
Comorbidity Score
Q3
Charlson
Comorbidity Score
Q4
More Likely to
Take Risks
Can overcome
illness without
medical care
Does not need
health insurance
Current Smoker
Had Moderate /
Vigorous Exercise
Obese (BMI≥30)
Income:
Poor/Near-Poor

0.00 (0.00)

-0.00 (0.01)

0.00 (0.00)

-0.00 (0.01)

0.01 (0.10)

0.12 (0.74)

-0.00 (0.01)

-0.00 (0.01)

-0.00 (0.00)

-0.00 (0.01)

0.10 (0.40)

-0.32 (0.79)

-0.00 (0.00)

0.00 (0.01)

-0.00 (0.00)

0.00 (0.01)

-0.01 (0.09)

0.17 (0.37)

-0.00 (0.00)

-0.00 (0.01)

-0.00 (0.00)

-0.00 (0.01)

-0.02 (0.13)

0.13 (0.34)

-0.00 (0.01)

0.04 (0.03)

-0.00 (0.00)

0.03 (0.03)

0.05 (0.35)

0.66 (1.77)

0.00 (0.00)

-0.00 (0.02)

0.00 (0.00)

-0.00 (0.02)

0.54 (0.32)

1.49 (1.02)

-0.02 (0.01)

-0.01 (0.01)

-0.01 (0.01)

-0.01 (0.01)

-1.06 (0.84)

-0.95 (0.80)

Low-Income

-0.00 (0.00)

-0.01 (0.02)

-0.00 (0.00)

-0.01 (0.02)

-0.28 (0.28)

-0.97 (0.82)
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Table C-7.

(Continued)

Characteristics

Linear Probability Model
(PDC≥80%)
Difference in
Characteristics

Middle-Income
Education:
Less than High
School
High School
Diploma
Drug Coverage
Plan:
Part D: PDPs
Part D: MA-PD
Employer/Other
Private
Auto Eligible for
PD Low-Income
Subsidy
Average Copay for
CV Drugs ($2010)
Concurrently taking:
2-3 CV Drugs
≥4 CV Drugs

Logistic Model
(PDC≥80%)
Estimate (Standard Error)
Difference in
Difference in
Returns to
Characteristics
Characteristics
0.00 (0.00)
-0.02 (0.03)

0.00 (0.00)

Difference in
Returns to
Characteristics
-0.02 (0.03)

-0.01 (0.02)

-0.01 (0.02)

-0.01 (0.02)

0.00 (0.01)

-0.02 (0.04)

0.00 (0.01)

Ordinary Least Squares
(Continuous PDC)

0.01 (0.15)

Difference in
Returns to
Characteristics
-1.59 (1.81)

-0.01 (0.01)

-0.41 (1.09)

-0.27 (0.82)

0.00 (0.01)

-0.02 (0.04)

0.43 (0.60)

-1.19 (2.72)

0.00 (0.03)

0.00 (0.01)

0.00 (0.03)

0.60 (0.61)

1.94 (2.11)

-0.00 (0.01)

-0.02 (0.02)

-0.00 (0.00)

-0.02 (0.02)

0.35 (0.37)

0.60 (1.39)

-0.01 (0.01)

0.02 (0.02)

-0.01 (0.01)

0.02 (0.02)

-1.10 (0.54)

2.78 (1.30)

-0.00 (0.01)

0.00 (0.00)

-0.00 (0.01)

0.00 (0.00)

-0.68 (0.85)

-0.21 (0.22)

0.02 (0.01)

-0.03 (0.02)

0.02 (0.01)

-0.04 (0.03)

0.47 (0.43)

-0.57 (1.47)

0.00 (0.00)
-0.01 (0.00)

-0.05 (0.03)
-0.01 (0.01)

0.00 (0.00)
-0.01 (0.00)

-0.05 (0.03)
-0.01 (0.01)

0.02 (0.15)
-0.11 (0.19)

-2.74 (2.12)
-0.26 (0.52)
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Difference in
Characteristics

Table C-7.

(Continued)

Characteristics

Linear Probability Model
(PDC≥80%)
Difference in
Characteristics

Ambulatory Visits Quantiles
Q 3 (5-7)
-0.00 (0.00)
Q 4 (8-12)
0.00 (0.01)
Q 5 (≥13)
-0.00 (0.00)
Had a Usual
0.00 (0.00)
Source of Care
Any ED Visit0.00 (0.00)
Baseline Year
No. of Pharmacies
0.01 (0.01)
Very Satisfied
-0.00 (0.00)
with Healthcare
Provider
0.00 (0.00)
Explained
Provider Listened
0.00 (0.00)
Provider
-0.00 (0.00)
Respected
Constant
Sample Size

Logistic Model
(PDC≥80%)
Estimate (Standard Error)

Ordinary Least Squares
(Continuous PDC)

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

Difference in
Characteristics

Difference in
Returns to
Characteristics

-0.01 (0.02)
-0.01 (0.02)
0.02 (0.02)

-0.00 (0.00)
0.00 (0.01)
-0.00 (0.00)

-0.01 (0.01)
-0.01 (0.02)
0.02 (0.02)

-0.05 (0.14)
0.37 (0.46)
-0.13 (0.32)

-0.96 (0.83)
-1.00 (1.17)
0.85 (1.06)

0.03 (0.15)

0.00 (0.00)

0.02 (0.14)

0.06 (0.16)

-2.65 (8.52)

0.00 (0.01)

0.00 (0.00)

0.00 (0.01)

0.13 (0.14)

0.32 (0.59)

-0.03 (0.08)

0.01 (0.01)

-0.04 (0.08)

0.63 (0.56)

-1.58 (4.90)

0.01 (0.03)

-0.00 (0.00)

0.01 (0.03)

-0.27 (0.25)

2.39 (2.26)

-0.02 (0.05)

0.00 (0.00)

-0.02 (0.04)

-0.03 (0.16)

-2.10 (2.64)

0.02 (0.05)

0.00 (0.00)

0.02 (0.05)

-0.00 (0.10)

0.59 (2.45)

-0.01 (0.06)

-0.00 (0.00)

-0.01 (0.06)

-0.03 (0.14)

-1.58 (2.76)

-0.23 (0.28)

-0.21 (0.26)

-10.18 (15.41)

3288

Boldface estimates have P values <0.05. Standard errors were estimated by balanced repeated replications using MEPS-provided
survey weights and half-sample identifiers.
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